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Abstract 
 
The Drug Discovery project is centred on the design, synthesis and characterisation of novel 
positive allosteric modulators (PAMs) for α7 nicotinic receptors (nAChR). These receptors 
are widely found in the central and peripheral nervous systems and are involved in a range 
of physiological processes. They are active targets for the treatment of pain as well as 
psychiatric and neurodegenerative disorders. Nicotinic receptors are ion channels which 
open and allow ions to flow in or out of the neuron upon binding of an agonist. Positive 
allosteric modulators (PAM) enhance the receptor’s response to the binding of the 
endogenous agonist, giving greater ion flow than the effect for binding of the agonist alone. 
A number of novel heterocycles were designed and synthesised and their effect on the α7 
nAChR evaluated. The nitrogen heterocycles gave varied pharmacological effects on the 
receptor and small changes in structure led to large changes in pharmacological activity.  
 
During the course of this project we have discovered Au-catalysed and non-catalysed 
processes for the dihalohydration of alkynols to form diiodoketoalcohols, 
dichloroketoalcohols and dichlorolactols. 
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Chapter 1 Introduction 
1.1 The Nervous System 
The nervous system is an organ system which conducts signals to and from different parts 
of the body. The way that animals act and react depends on this complex, organised and 
discrete neuronal processing.  
The nervous system can be split into two main systems: the central nervous system (CNS) 
and the peripheral nervous system (PNS). The CNS includes the brain and the spinal cord 
whilst the PNS has nerves which connect the CNS to the extremities of the body. Both 
nervous systems are mainly comprised of neurons and their supporting cells. Neurons are 
specialised cells which are able to conduct electrical signals to other neurons (up to 
15,000). The three functional classes of neuron are: interneurons, efferent neurons and 
afferent neurons. Around 99% of the neurons in the nervous system are interneurons and 
lie entirely within the CNS. It is believed that humans have > 1×1011 interneurons.  
Neurons have a cell body (soma) which contains the nucleus and have dendrites to connect 
to other cells. Neurons also have an axon which is insulated in a myelin sheath which leads 
to other neurons. Dendrites can receive a signal which travels through the axon to the 
terminal where there is a synapse with the next neuron, the signal causes vesicles 
containing neurotransmitters in the cells to be released into the synaptic cleft. The 
neurotransmitters diffuse to receptor sites on the post-synaptic membrane; initiating 
electrical signal in this neuron, relaying the original signal. This process is known as 
neurotransmission.  
 
1.2 Neuron receptors 
1.2.1 Cys-loop ion channel receptors 
The neurotransmitters interact with the receptors on the surface of post-synaptic 
membranes. The receptors on the phospholipid bilayer are membrane-bound proteins that 
have a neurotransmitter receptor site and a central pore that allows ions to flow through 
once activated. These receptors on neurons are known as Cys-loop receptors. The name is 
derived from the characteristic loop formed by a disulfide bond between two cysteine 
residues in the N-terminal extracellular domain. Cys-loop receptors are ligand-gated ion 
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channels which include GABAA, GABAA-ρ (GABAC), serotonin (5-HT3), glycine and 
acetylcholine (ACh) receptors. 5-HT3 is structurally the most similar to nicotinic receptors. 
 
Figure 1.1: Endogenous neurotransmitters for Cys-Loop receptors 
GABAA and GABAC receptors are inhibitory and upon activation become permeable to Cl
-. 
The GABAA-ρ receptors contain only rho-subunits and are highly expressed in the retina. 5-
HT3 receptors upon activation become permeable to Na
+, K+ and Ca2+. Glycine receptors are 
also inhibitory and upon activation become permeable to Cl-. They can be activated by β-
alanine and taurine. Nicotinic acetylcholine receptors, upon activation by acetylcholine 
(ACh) allow the flow of Na+, K+ and Ca2+ ions and this receptor will be explained further in 
this section.  
The function of the Cys-loop receptors is the direct conversion of a chemical 
(neurotransmitter) signal from the pre-synaptic neuron to an action potential in the post-
synaptic neuron. This group are characterised by the presence of two domains: the 
intracellular domain including the ion pore and the extracellular domain which includes the 
binding site for ligands. Upon neurotransmitter binding, there is a conformational change 
in the protein allowing ions to flow.  
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1.2.2 Nicotinic acetylcholine receptors (nAChR) in vertebrates 
Nicotinic receptors are the most intensively studied type of neurotransmitter-gated ion 
channel. The α7 nicotinic acetylcholine receptor (nAChR), with 5 identical α7 subunits was 
the first ligand-gated ion channel to be discovered and is part of the superfamily of Cys-
loop receptors.2 In mammals nicotinic receptors are found on the post-synaptic membrane 
of neuronal cells, as well as non-neuronal cells such as lymphocytes, macrophages, 
epithelial and endothelial cells.3  
The nAChR is comprised of 5 homomeric or heteromeric protein subunits, symmetrically 
arranged around a central pore to form a receptor subtype. Each subunit comprises a large 
extracellular amino-terminal domain, 4 transmembrane helices (TM1-TM4) and a long 
cytoplasmic loop between TM3 and TM4 and the C-termini located extracellularly.4 Each 
subunit comprises of: amino-terminal extracellular domain, transmembrane domain and a 
variable cytoplasmic domain.  
 
Figure 1.2: Topology of a single receptor subunit showing the 4 transmembrane domains 
(TM) 
The subunits may all be identical such as in the α7 nAChR or be different such as in the case 
of α4β2 subtype (3 × β2 units and 2 × α4 subunits). Neuronal nAChR subtypes expressed in 
mammalian brain and ganglia are assembled in combinations of α2-9 and β2-4 and are 
pharmacologically classified into two branches based on their sensitivity to α-Bungarotoxin 
(α-BGT). α-BGT is a component of the venom of the Taiwanese snake Bungarus 
multicinctus. The peptide consists of 74 amino acids and weighs 8 kD. There are many 
entropically viable forms of this peptide which retains its structure after boiling or addition 
of strong acid. 
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Figure 1.3: α-Bungarotoxin  
It is a neurotoxin that is known to bind irreversibly and competitively to the nAChR. The α-
BGT insensitive branch is made up of subtypes with combinations of α2-6 and β2-4 
subunits. The α7-9 subunits are involved in the α-BGT sensitive subtypes in brain and 
ganglia, and the amount of α7-containing receptor is comparable to that of the α4β2 
subtype in brain.5  
 
Figure 1.4: Topology of α4β2 and α7 nicotinic receptors 
The α7 and α4β2 nAChR subtypes are the prominent subtypes expressed in the mammalian 
brain.6 The α7 nAChR was discovered in the early 1990s and since then has received 
considerable attention.7,8   
The different subunits vary in their primary amino acid structure which allows changes in 
the interaction between the subunits, providing structural variation in the protein giving 
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the proteins their unique characteristics. The many different subtypes are distributed 
throughout the nervous system dependent on their function. The α7 nAChR is also highly 
expressed in the hippocampus, a region that is known to be involved in memory formation. 
Gene knockout studies have also shown that α7 nAChRs have a role in learning, attention 
and memory. Genetic and pharmacological studies have shown that the nAChRs are 
implicated in a number of neurodegenerative diseases leading to decreased cognitive 
function, learning and memory, motor control and immune function.9 Due to their 
fundamental role in the CNS, targeting α7 nAChRs is a viable strategy for the treatment of a 
variety of disorders, particularly those involving attention deficits and cognition. It is 
proposed that enhancing nAChR function by activation makes the receptor an attractive 
drug target due to the potential to ameliorate pathophysiological deficits in certain disease 
states.9 These receptors are currently active targets for the treatment of pain, psychiatric 
and neurodegenerative disorders.10  
 
1.2.3 Nicotinic acetylcholine receptors (nAChR) in insects  
The introduction thus far has focused on vertebrate nAChRs, however, the invertebrates 
also have a nervous system. It was found that invertebrate nAChRs are the site of action for 
neuroactive pesticides known as neonicotinoids. Once nicotine itself was characterised as 
an agonist of nAChRs, researchers found that it could act as an insecticide by activating and 
blocking insect nAChRs causing convulsions, then paralysis and eventually death. Nicotine is 
still in use as an insecticide today, however, the use of neonicotinoids is much more 
prevalent. Their advantage over nicotine is their selectivity for insect nAChRs and low 
vertebrate toxicity.  
 
Figure 1.5: Top-selling neonicotinoid pesticides 
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The best-selling neonicotinoids are shown in Figure 1.5 and note that these molecules have 
either nitramide or cyanamide moieties. Imidacloprid is the best-selling insecticide in the 
world and was developed by Bayer Cropscience in 1986. Neonicotinoids act as irreversible 
agonists of the nicotinic receptor, this leads to blocking of receptors and accumulation of 
acetylcholine. Insect nAChRs are poorly understood compared to vertebrate nAChRs in 
terms of diversity and functional architecture. The pharmacological characterisation of 
many insect nAChRs has been hindered due to the difficulty of achieving recombinant 
nAChR expression to give functional receptors.11 Researchers have created functional 
hybrid receptors by co-expession of Drosophila α-subunits and vertebrate β-subunits in 
Xenopus oocytes. These receptors are more sensitive to imidacloprid than the equivalent 
vertebrate receptors. The rationale for the selectivity of imidacloprid (and the other 
neonicotinoids) for insect receptors is that they are not ionised at physiological pH and do 
not interact strongly with vertebrate nAChR receptor sites. In insect nAChRs at 
physiological pH, one of the amines on the pesticides is charged and can interact with 
amino-acid sidechains of the receptor. It is believed by many that the reason of decline of 
bee population may be due to neonicotinoids causing colony collapse disorder.12 
 
1.3 Alzheimer’s Disease (AD) and other neurodegenerative disorders 
Alzheimer’s Disease (AD) is the most common form of dementia and is the most common 
neurodegenerative disorder. It was first described by Alois Alzheimer, a German 
neurologist. Currently the condition can only be confirmed by autopsy by finding the 
characteristic brain lesions associated with the disease.  These brain lesions are neuritic 
plaques and neurofibrilliary tangles that are dispersed in the cerebral cortex and the 
hippocampus. The neuritic plaques have a central core of extracellular, waxy, fibrous 
protein known as β-amyloid surrounded by degenerating dendritic and axonal nerve 
endings. The neurofibrilliary tangles are closed bundles of abnormal filaments that 
accumulate in the cell bodies of affected neurons. The formation of these lesions damage 
the acetylcholine (ACh), releasing axons, leading to the loss of these neurons and results in 
the reduced ACh in these areas. AD is characterised by cognitive decline, a loss of neurons 
and synapses, as well as a reduction in nAChR expression. One of the key stages of AD 
proliferation in terms of memory loss is the decrease in the production of ACh.13,14 AD 
affects millions of people worldwide and with only limited treatments currently available, 
much effort is devoted towards new therapies. The current approved drugs for AD are 
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acetylcholine esterase (AChE) inhibitors.15 Donezepil hydrochloride, rivastigmine and 
galantamine are recommended for patients with mild to moderate symptoms of AD in the 
UK. 
 
Figure 1.6: Acetylcholine esterase inhibitors 
These molecules block the breakdown of ACh by inhibition of the enzyme that degrades 
ACh in the synaptic cleft which help to maintain the existing supplies of ACh. Another cause 
of the proliferation of AD is the excess of the neurotransmitter glutamate, causing 
excitotoxicity leading to cell death.  
 
Figure 1.7: An antagonist of NMDA receptors 
Memantine is an uncompetitive antagonist of glutamatergic N-methyl-D-aspartate (NMDA) 
receptors, which limits the overstimulation by glutamate. In the cerebral cortex, 
neurodegeneration is mainly associated with the α4β2 subtype, whereas in the 
hippocampus the decline is predominately in the α7 subtype (with strong correlation with 
loss of cognitive function). Molecules that selectively affect the α7 nAChR result in 
improvement in the cognitive deficits associated with AD.13 
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1.4 Activation of nicotinic receptors  
Acetylcholine (ACh) is the endogenous ligand for nAChRs and is found as a 
neurotransmitter in both the peripheral and central nervous systems. 2 ACh is the ester of 
acetic acid and choline and was the first neurotransmitter to be discovered. ACh is 
biosynthesised by the enzyme choline acetyl transferase with choline and acetyl-CoA. 
  
Figure 1.8: Acetylcholine (ACh) 
Upon binding of ACh, the nAChR ion channel is stabilised in the open conformation for 
several milliseconds. The channel then closes to a resting state or a desensitised state that 
is unresponsive to ACh or other agonists.  Whilst open, nAChRs conduct cations, which can 
cause a local depolarisation of the membrane and produce an intracellular ionic signal.16 
Activation of nAChRs in the brain results in increased release of other key 
neurotransmitters, many of them activate Cys-loop receptors and include dopamine, γ-
aminobutyric acid (GABA), glutamate and serotonin. Nicotine is a plant alkaloid from the 
nightshade family (Solanaceae) which is synthesised in the roots and accumulates in the 
leaves of the plants.  
 
Figure 1.9: Nicotine 
Nicotine has strong affinity for nAChRs and gives a strong agonist effect.16,17 Long term 
effects of nicotine exposure are the desensitisation and upregulation of the receptors. ACh 
and nicotine have varying potency dependent on the receptor subtype. Research has 
shown that chronic exposure to ACh or nicotinic drugs causes a decrease in the rate of the 
ionic response causing desensitisation of the receptor. Long term exposure to nicotinic 
drugs can cause significant changes in receptor properties and numbers. The α7 nAChR has 
been implicated in the memory-enhancing potential of nicotine. The number of binding 
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sites, as well as the affinities for agonists and antagonists is highly dependent on the 
receptor subtypes, creating challenges for drug design.  
 
1.4.1 Agonists of α7 nAChRs 
In this section we will focus on subtype-selective agonists for nicotinic receptors. In the 
absences of an agonist, the receptor is predominantly in the closed state, with the integral 
ion channel closed. This ‘resting’ state is responsive to the application of an agonist 
allowing flux across the membrane. Agonists either stabilise the open channel 
conformation or destabilise the closed channel conformation, allowing the conduction of 
cations, which cause a local depolarisation of the membrane and produce an intracellular 
ionic signal. The ‘active’ state can be short-lived, such that the receptor undergoes a series 
of transitions to a ‘desensitised state’ with the agonist bound in high affinity while the 
channel is closed. Loss of the agonist would lead to the receptor returning to the resting 
state.  
 
Figure 1.10: Representation of Receptor opening and closing  
The speed of activation, the intensity of membrane depolarisation, the size of ionic signal 
and the types of cation conducted will all depend on the nAChR subunit composition.16  
Below are some examples of agonists that are selective for α7 nicotinic receptors.  
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Figure 1.11: Agonists of α7 nicotinic receptors 
WAY-317538 is a potent small molecule agonist of α7 nAChRs with excellent in vitro and in 
vivo profiles, excellent brain penetration and oral bioavailability.18 AR-R17779 is a small 
molecule which was, at the time (2004), the first potent subtype-selective α7 nAChR 
agonist.19 PHA-543613 has been identified as a potential treatment of cognitive deficits in 
schizophrenia.20 Tropisetron is a 5-HT3 antagonist which was found to display a potent and 
selective partial agonism of the α7 nAChR.21 This drug has been used in clinical trials as an 
antiemetic, but since the discovery of this dual effect on ion channels, it is not understood 
whether this effect is due to the nicotinic receptor agonism or serotonin receptor 
antagonism.22 RG3487 like tropistron acts a partial agonist on the α7 nAChR and an 
antagonist of the 5-HT3R. In a rat model, this molecule leads to the exhibition of improved 
spatial learning and object recognition memory.23 PNU-282987 is the most potent of a set 
of benzamides discovered through a high-throughput assay. This molecule is a potential 
treatment for some of the symptoms of schizophrenia.24 Four of these molecules contain a 
quinuclidine moiety, as well as amides, carbamates or esters. There is a clear structure-
activity (SAR) that provides selectivity and potency for the α7 nicotinic receptor. Nicotinic 
receptor agonists are currently in clinical trials for Alzheimers Disease, schizophrenia and 
cognitive dysfunctions.25–27 
The benefits of subtype selective agonists of nAChRs are limited due to the uncertainty in 
whether chronic treatment with agonists might provide suboptimal benefit due to 
sustained activation and desensitisation of the nAChR.8 One of the disadvantages of using 
small molecules for stimulation of receptors is that there can be poor selectivity for a 
specific receptor subtype. 
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1.4.2 Antagonists of α7 nAChRs 
Antagonists act as inhibitors and decrease (or completely block) the peak response in the 
presence of an agonist. This effect can occur by competitive inhibition or by blocking of the 
ion channel. Nicotinic receptor antagonists have been used in the clinic for the blocking of 
the receptors for treatment of illnesses such as drug addiction. Below are some examples 
of antagonists of nicotinic receptors (Figure 1.12).  
 
Figure 1.12: Antagonists of α7 nicotinic receptors 
Dihydro-β-erythroidine is one of 70+ alkaloids isolated from the Erythrina genus.28  The 
family of compounds are known for their hypotensive, sedative and CNS activity. The 
hydrobromide salt of this compound is an α4 selective antagonist. Mecamylamine is a 
synthetic antihypertensive which is a non-competitive antagonist of nAChRs and used as a 
treatment for nicotine addiction.29 Methyllycaconitine is a plant alkaloid which is a potent 
selective antagonist of α7 containing nAChRs, often used in studies as a selective blocker of 
α7 homomeric nicotinic receptors.30  
 
1.4.3 Allosteric Modulation of Ion Channels 
Allosteric modulation is the change in peak response with an agonist due to binding of a 
molecule at an allosteric site. An allosteric site is any site on the receptor where the 
endogenous ligand does not bind (there is no competition between allosteric or orthosteric 
ligands). An increase of the peak response relative to the agonist alone is termed positive 
allosteric modulation (PAM) and a decrease of the response relative to the agonist alone is 
termed negative allosteric modulation (NAM). A therapeutic example of allosteric binding is 
the benzodiazepine drugs. Benzodiazepines are positive allosteric modulators or 
potentiators of the GABAA receptor by facilitating opening of the receptor integral Cl
- 
channel.31 This effect is the underlying principle of anxioltic (reduction of anxiety) action of 
benzodiazepines.32 
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Figure 1.13: General structure of Benzodiazepines 
The advantage of using positive allosteric modulators (PAM) over agonists is that 
modulation is only revealed in the presence of the endogenous ligand and the modulator 
has no action alone. They exhibit their function upon binding of the protein at an allosteric 
site, affecting the conformational stability of the protein to give an inhibiting or activating 
effect. There are many advantages for targeting allosteric sites, the most significant is that 
the drugs have a decreased potential for toxic effects by preservation of temporal and 
spatial stability of the receptor. Due to their co-operativity they have little or no effect 
alone irrespective of the dose.   
Enhancing the effects of the endogenous transmitter acetylcholine via positive allosteric 
modulation and utilising the existing cholinergic neurotransmission for activation of the 
receptor provides an excellent opportunity for drug discovery for many CNS centred 
illnesses.8  
In some cases, the in vitro properties and physiochemical properties remain to be further 
optimised but the molecules currently available are limited by low potency, low solubility, 
low metabolic stability and poor CNS penetration. For these reasons, identification of 
selective, potent and pharmacologically suitable PAMs for nAChRs is an active area of 
research. A key part of achieving this goal will be the identification of allosteric sites and 
assessing clarification of in vitro functional profiles.8  
Relying on the endogenous transmitter is a potential disadvantage of the PAM approach, 
with reduced neurotransmitter efficacy, such as in the advanced stages of 
neurodegeneration.8 However, this strategy can give an improvement to current available 
therapies. Modulation of nAChRs can be potentially used to treat brain disorders, such as 
Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), depression, 
schizophrenia and many addictions. 
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1.5 Positive Allosteric modulation of α7 nAChRs 
Positive allosteric modulators (PAMs) give an enhanced response when binding of ACh 
takes place and negative allosteric modulators (NAMs) give an inhibitory effect upon 
binding of ACh (compared to binding of ACh alone). There has been evidence that allosteric 
ligands bind in the transmembrane domain and cytoplasmic domains of nAChRs. Allosteric 
modulators often have no or little intrinsic activity, allowing greater physiological selectivity 
than agonists that act on receptors selectively, but indiscriminately with regard to ongoing 
physiological activity. This area of neuropharmacology has been extensively reviewed in the 
literature and the receptor subtype most investigated is the α7 nicotinic receptor. 9,33,34 
Some early examples of allosteric modulators of the nicotinic receptor are outlined in 
Figure 1.14. 
 
Figure 1.14: 5-Hydroxyindole and Genistein 
5-Hydroxyindole causes a significant increase in subsequent ACh-evoked current. The 
receptor interaction with 5-hydroxyindole is weak and non-selective, requiring high 
concentrations for potentiation of the receptor. Genistein is a tyrosine kinase inhibitor 
which was found to act as a PAM in a very similar way to 5-hydroxyindole. These molecules 
are not selective and act on the other Cys-loop receptors. After these molecules were 
characterised, research was conducted to discover molecules that give selective Type 1 or 
Type 2 positive allosteric modulation for α7 nicotinic receptors.  
 
1.5.1 Type 1 positive allosteric modulators (PAMs) 
Type 1 PAMs facilitate the transition from ‘resting’ to ‘open’ channel state upon binding of 
ACh, increasing the agonist response amplitude without significant effect on the response 
decay rate (no effect on desensitisation).8 Type 1 PAMs affect the apparent peak current, 
agonist sensitivity and Hill coefficient. The Hill coefficient quantifies the cooperative 
binding effect, where the binding of the PAM facilitates the binding of ACh, with higher 
cooperative binding the higher the Hill coefficient. PAMs that increase peak current 
response in the presence of an agonist are designated as Type 1 PAMs (Figure 1.15). 
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Figure 1.15: Profile of Type 1 PAMs9 
In the presence of ACh alone there is a relatively small peak current response, but with ACh 
in the presence of a Type 1 PAM the peak response is much greater. This potentiation is 
attained by decreasing the energy between the ‘closed’ and ‘open’ states upon binding of 
an allosteric ligand. Below are examples of recent molecules that show Type 1 PAM activity 
and are selective for the α7 nAChR.  
 
Figure 1.16: Type 1 PAMs: NS-1738, CCMI, SB-206553 
NS-1738 was first reported in 2007 as a Type 1 PAM. It also improved performance in the 
rat social recognition test to the same extent as  nicotine, demonstrating that NS-1738 is 
capable of producing cognitive enhancement in vivo.35 CCMI evokes robust positive 
modulation of agonist-induced currents at α7 nAChRs. CCMI was discovered from a library 
of GABAA receptor agonists but has little to no efficacy at other ligand-gated ion channels.
36 
SB-206553 was discovered as a mixed antagonist of serotonin receptors, but was later 
found to be a PAM for the α7 nicotinic receptor.37  
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1.5.2 Type 2 positive allosteric modulators (PAMs) 
PAMs that upon ligand binding stabilise the open channel state to an extent that there is 
not only an increase in amplitude, but also a reduction of the receptor desensitisation are 
described as Type 2 PAMs.8  
 
Figure 1.17: Profile of Type 2 PAMs9 
As before, Type 2 positive allosteric modulators increase the peak current response 
compared to the agonist alone. The transition from the ‘open’ state to the ‘desensitised’ 
state can occur quickly (Type 1 PAM) or slowly (Type 2 PAM). Type 2 positive allosteric 
modulators slow the desensitisation kinetics, by binding the receptor in such a way that 
stabilises the open conformation with respect to the desensitised state, causing slower 
receptor closing. Some examples of Type 2 PAMs of α7 nAChRs are below (Figure 1.18).  
 
Figure 1.18: Type 2 PAMs: PNU-120596, TQS, A867744 and RO512946 
PNU-120596 is one of the better characterised PAMs and is structurally similar to NS-1738. 
One interesting characteristic of this compound is its ability to restore activity to the 
agonist-desensitised channel.38 TQS was discovered to be a Type 2 allosteric modulator by 
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our collaborators, this molecule will be discussed further later in this section.39 A867744 is 
also a well characterised Type 2 PAM reported by Abbott in 2009 with good potency and 
selectivity.34 RO5126946 is an aminocyclopropane which is a potent Type 2 PAM selective 
for the α7 nAChR which was found to have cognitive enhancing properties.40 
 
1.6 Recent Research in the Sheppard Group  
As shown in the previous section, the Millar group has previously identified a Type 2 
positive allosteric modulator selective for α7 nAChRs through a high throughput screen.  
These molecules were discovered after TQS, which was found to be an early example of an 
allosteric agonist for nicotinic receptors.39 
 
Figure 1.19: Tetrahydroquinoline based molecules that affect nAChRs 
4BPTQS was found to be a very potent allosteric agonist (does not bind in the orthosteric 
site, where ACh binds, but binds elsewhere on the receptor and gives an agonist response). 
With this interesting result, analogues of these molecules were synthesised in the 
Sheppard Group. A plethora of tetrahydroquinoline-based products were synthesised and 
characterised. These compounds were synthesised through a 3-component reaction with 
InCl3 catalyst.
41 
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Scheme 1.1: An Indium chloride catalysed multicomponent reaction 
This multicomponent reaction with an aldehyde, cyclopentadiene and sulfanilamide has a 
wide substrate scope and provided compounds that were analysed by our collaborators at 
UCL Pharmacology. The compounds above exhibit an allosteric agonism and PAM effects 
on the receptor. A selection of compounds is shown in Figures 1.20 and 1.21.   
 
Figure 1.20: TQS-based allosteric agonists 
Compounds 1, 2 and 3 have a strong allosteric agonist effect on the receptor. Many other 
TQS compounds exhibit positive allosteric modulation on the receptor. 
 
Figure 1.21: TQS-based positive allosteric moduators 
Compounds 4, 5 and TQS were found to be PAMs for the α7 nAChR. A clear result from this 
study is that small structural changes of the molecule can give different pharmacology.  
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The understanding that small changes in the chemistry can lead to distinct changes in 
pharmacology led to further work in this area. The synthesis of a number of new 
tetrahydroquinoline compounds with different methyl groups on one of the aromatic rings 
was completed.  
As predicted the different molecules gave different effects on the receptor. Changes in the 
methyl-substitution of one of the phenyl rings were characterised as eliciting 5 different 
pharmacological responses.  
Table 1.1: Pharmacological effect of structurally related TQS compounds 
Pharmacological 
Effect 
 
allosteric  
agonism  
Type1 PAM 
 
Type2 PAM 
 
Silent allosteric 
modulation (SAM) 
 
negative allosteric 
modulation (NAM)  
 
Allosteric agonisms and positive allosteric modulation have been discussed previously in 
this section. Silent allosteric modulators (SAMs) are molecules which do not affect the peak 
response with ACh, however, they must bind in the allosteric site as they block the effect of 
other allosteric agonists and PAMs. Negative allosteric modulators (NAMs), also known as 
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non-competitive antagonists bind in such a way that reduces the peak response compared 
to ACh alone. Although these molecules give a diverse array of pharmacological effects 
their chemical properties are lacking for further drug development.  
There are limitations for the use of TQS-based molecules for the exploration of these 
receptors. The molecules are synthesised as a mixture of diasteromers with potentially only 
one active isomer. The molecules are quite lipophilic with poor aqueous solubility and 
potentially low bioavailability. These molecules are covered by patents, therefore there is 
no privilege in pursuing molecules covered by another organisations intellectual property. 
The molecules are also not particularly drug-like,42 following the Lipinski’s Rules of five: <5 
H-bond donors, <10 H bond acceptors, molecular mass <500 and octanol/water partition 
coefficient, log P <5. Several criteria were felt to be important for any potential modulators 
to meet based on the current limitations of TQS-based allosteric modulators:  
 Select for α7 nAChRs (over any other heteromeric nAChRs) 
 Good aqueous solubility  
 Structurally novel  
The aim of this drug discovery project is to synthesise novel allosteric modulators of the α7 
nicotinic acetylcholine receptor. We believe that there is potential for the synthesis of new 
molecules with a new molecular framework. These molecules will help to expand the 
understanding of the receptor, its allosteric site, its mechanism of receptor opening and its 
desensitisation.  
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Chapter 2 Novel Allosteric Modulators for Nicotinic Receptors 
2.1 Aim  
The aim of this Drug Discovery project is the synthesis of novel allosteric modulators for α7 
nicotinic receptors. This work would expand the success in the Sheppard group in the 
synthesis of a series of novel tetrahydroquinoline based allosteric agonists and positive 
allosteric modulators (PAMs).41  We approached this project by using the basic structures of 
4BPTQS (an allosteric agonist) and a literature molecule which displays Type 1 positive 
allosteric modulation on the same receptor  A867744.34  
 
Scheme 2.1: A867744 and 4BPTQS and a representation of the proposed effectors of the 
receptor 
By the union of these two frameworks, we have the potential to synthesise molecules with 
pharmacological activity on the α7 nAChR. A pharmacophore approach was enlisted to 
describe the molecular ‘features’ that give pharmacological effects with the receptor. The 
primary aryl sulfonamide (red), a heterocyclic core (blue) and groups attached to the core 
(black) were the features selected.  
We want to overcome the limitations of TQS by the synthesis of novel molecules that are 
not covered by patents and that are drug-like (adhering to the Lipinski Rules) with good 
aqueous solubility. 
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2.2 Pyrroles 
2.2.1 Synthesis of Pyrroles (First Generation molecules) 
We started the project with the synthesis of a biaryl pyrrole. This would have the primary 
aryl sulfonamide and a heterocycle with only one aromatic group attached to it. This was 
proposed to ascertain whether the two other groups attached to the heterocycle are 
actually required for pharmacological activity.   
We began the project with the synthesis of a set of pyrroles 10. The approach used well 
established chemistry and a relatively short route that would allow us to isolate sufficient 
material for pharmacological testing. The forward synthesis is outlined in Scheme 2.2.  
 
Scheme 2.2: Synthetic plan for pyrroles 
The synthesis begins with a reduction and hydrolysis of 7 to give dicarbonyl 8. After the 
Paal-Knorr reaction with sulfanilamide 9 and intermediate 8 gives the pyrrole 10.  
The first step was a nucleophilic displacement of a bromide 11 with nitriles 12a-b to set up 
cyanoacetals 13a-b in acceptable yields. The cyanoacetals acts as ‘masked’ 1,4-dicarbonyls 
which, after reduction of the nitrile and hydrolysis give the desired Paal-Knorr precursor.  
 
Scheme 2.3: Nucleophilic substitution of a bromide 11  
The next step was to reduce the nitriles to imines with diisobutylaluminum hydride (DIBAL) 
in toluene. The crude imines were treated with 2M HCl to form the aldehyde-acetals 14a-b. 
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Scheme 2.4: Reduction and hydrolysis to give cyclisation precursors 
This step was designed to hydrolyse the acetal as well as the imine, however, after a 
number of hours the acetal was still present. It was thought that the acetal would be 
hydrolysed in the subsequent step, cleaved during the temperature and acidic conditions of 
the Paal-Knorr reaction.43,44 
  
Scheme 2.5: Paal-Knorr pyrrole synthesis  
The Paal-Knorr reaction between the aldehyde 14a-b and sulfanilamide 9 under microwave 
heating gave the disubstituted pyrroles 15a-b in poor yield. This poor yield was later 
attributed to the self-condensation of the aldehyde under the conditions to the furan, as 
well as other impurities in the reaction mixture. Once the desired products were isolated, 
they were both characterised. This was the first opportunity to assess molecules that could 
affect the nAChR and they were submitted for testing.  
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2.2.2 Pyrroles (First Generation molecules) – Pharmacological results by AC at UCL 
Pharmacology 
The pharmacological activity of the compounds synthesised were tested by our 
collaborators in the Millar group at UCL Pharmacology. 
Their properties were examined on α7 nAChRs expressed from Xenopus oocytes.45 Oocytes 
were placed in a recording chamber and continuously perfused with a saline solution (115 
mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2, and 10 mM HEPES, pH 7.3) with a flow rate of 
approximately 15 ml/min. Two electrode voltage-clamp recordings were performed (with 
the oocyte membrane potential held at -60 mV).41 There is a change in membrane 
resistance due to the effect of various stimuli, which is measured in the change in the 
membrane potential which is constantly measured.  
It was found that the molecules 15a and 15b did not give an agonist response when applied 
to the α7 nAChR alone, this result indicates that these molecules are not agonists. It was 
also found that when the compounds were co-applied with acetylcholine there was no 
potentiation of the response. This result shows us that the molecules were not acting as a 
positive allosteric modulators (PAM). When the compound was co-applied with 4BrTQS 
(allosteric agonist) the compounds were showing a small amount of inhibition of the 
response. This result gives us evidence that the molecules bind at the same site but have 
no pharmacological response, these are silent allosteric modulators (SAMs). 
 
Figure 2.1: 1st generation pyrroles with no effect on the receptor   
The lack of response was attributed to a weak interaction between the receptor and the 
compound, leading to binding but no pharmacological effect. It was proposed that 2 groups 
connected to the pyrrole in addition to the aryl sulfonamide would give a greater 
interaction with the receptor and potential allosteric agonism/modulation. We then 
synthesised a number of larger more substituted pyrroles.  
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2.2.3 Synthesis of Pyrroles (Second Generation molecules) 
From the pharmacological testing, it was found that the molecules did bind. Therefore, we 
understand that our first target (with 2 groups on the pyrrole ring) would be more likely to 
give satisfactory effects.  
 
Figure 2.2: A new target – triaryl pyrroles 
Although there was a small change in structure, the change requires new disconnections 
for the 1,4-dicarbonyl compound for heterocycle formation. The 1,4 dicarbonyl 17 is the 
precursor for the Paal-Knorr synthesis, which was derived from a Stetter reaction between 
acetaldehyde and chalcone 18. The chalcones were produced through a Claisen-Schmidt 
condensation.  
 
Scheme 2.6: Synthetic plan for triaryl pyrroles 
A straightforward aldol condensation between halo-substituted benzaldehydes 20a-c and 
benzophenone 21 cleanly formed α,β-unsaturated ketones 22. These were purified by flash 
chromatography to give the (E)-enones. 
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Scheme 2.7: Claisen-Schmidt condensation to give chalcones 
With these products in hand we subjected these substrates to an intermolecular Stetter 
reaction with a N-heterocyclic carbene catalyst 23. This would set up a 1,4-dicarbonyl 
suitable for Paal-Knorr pyrrole synthesis.  
 
Scheme 2.8: Intermolecular Stetter reaction 
We followed a procedure by Kim co-workers46 (using a different N-heterocyclic carbene  
(NHC) catalyst). From repetition of this reaction it was found that it was important that the 
acetaldehyde was freshly distilled and added in great excess. The reaction appears to halt 
after 24 h and the reaction was not reinitiated by addition of base, thiazole salt or 
acetaldehyde. Fortunately, it was possible to separate the products from the starting 
materials to give diketones 24a-e in good yields.  
The last step was the Paal-Knorr pyrrole synthesis. When this reaction was attempted in 
the microwave with AcOH only the furan 25 was formed (See Scheme 2.9). Slow initial 
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imine formation allowed the acid-catalysed intramolecular cyclisation and dehydration to 
give the furan. 
  
Scheme 2.9: Formation of furan 25  
The reaction was then performed thermally at 100 °C, this reaction did exhibit some 
formation of the pyrrole alongside the furan. However, after a number of days the starting 
material remained. The reaction conditions were changed, using MeOH as the solvent and 
an excess of the sulfanilamide 9 in the microwave at 120 °C. After 15 min, the starting 
material remained but after 1 h all the starting material had been consumed. The reaction 
went cleanly to the desired product with trace amounts of the furan as a side product. It 
was found that using an excess of sulfanilamide 9 was the most important factor. In 
addition, microwave heating was not required and the reaction could be heated thermally 
at reflux overnight. With these conditions we synthesised a number of pyrroles with 
different halogens on one of the aromatic rings.  
 
 Scheme 2.10: Paal-Knorr pyrrole synthesis of triaryl pyrroles 
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The pyrrole synthesis gave the desired products in generally good yields. After the 
completion of the halogen series of the pyrroles 26a-e, we found that the molecules had 
quite low solubility in DMSO, which led to problems in the assay with compounds 
precipitating out of solution under high concentrations. Therefore we decided to synthesise 
new analogues, replacing the phenyl ring with heteroaromatic rings in view to increase the 
solubility in DMSO.  
 
Scheme 2.11: Synthesis of pyridine containing pyrroles 
The Stetter reactions were challenging for these heteroaromatic substrates and gave the 
diketones 28a-b in poor yield. The crude products contained many different substances 
that made purification by flash chromatography challenging. The poor conversion was 
attributed to electron donation into the chalcone from the heteroatoms, causing the 
chalcone to be electron rich and less accepting of the electron density from the 
nucleophile. We also synthesised a furan derivative (32) using the same method.  
 
Scheme 2.12: Synthesis of pyridine containing pyrroles 
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As with the 2-pyridyl example 31, the crude product was a complex mixture. This 1,4 
diketone 31 could not be isolated cleanly and the semi-purified product was used in the 
next step to obtain the pyrrole 32. None of the products gave a significant increase in 
solubility in DMSO for the assay. However, we were keen to assess the effect of these 
molecules on the α7 nicotinic receptor.   
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2.2.4 Pyrroles (Second Generation molecules) – Pharmacological results by AC at UCL 
Pharmacology 
We synthesised a number of substituted pyrroles and these were, as before, tested at UCL 
Pharmacology. The products were co-applied with ACh and the measurement of the 
change of the peak response relative to ACh alone was made.  
 
Figure 2.3: Novel pyrrole Type 1 positive allosteric modulators of the α7 nAChR 
The values under the molecules represent the n-fold peak potential increase compared to 
acetylcholine alone. Therefore a value of 1.0 would show no improvement over 
acetylcholine alone and a value of 2.0 would be twice as effective as acetylcholine alone.  
We were very pleased to find that these molecules gave some positive allosteric 
modulation of the α7 nAChr. From the halogen series we found that the 26c derivative had 
the greatest allosteric modulation effect of × 3.6, which is only slightly higher than 
derivative 26b with a value of × 3.4. Its was found that compound 26a only had a tiny effect 
and derivative 26e only increased the peak response by 2.  
With these positive results we looked to examine the range of molecules of a similar 
structure that would give a pharmacological response. This was done for 2 reasons:  
 These molecules are sparingly soluble in DMSO (the solvent used in the assay) and 
therefore dose-response curves at higher concentrations can not be constructed 
and the poor solubility of the products may limit their efficacy 
 There is possible overlap between the structures and the Abbott patent structures, 
which could cause possible patent protection problems in the future 
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Note that the rings at the 1 and 3 positions are in the same plane and the phenyl ring lies 
orthogonal to this plane. This conformation minimises the steric clash between the 
aromatic rings of the 1 and 2 positions.   
We believe that the planar nature of this molecule leads to the poor solubility but also 
leads to the good pharmacological action. Therefore it was hoped that by incorporating 
heteroaromatics in the molecule it would allow more hydrogen bonding and keep the 
molecule in solution during the assay. These more polar products have the same geometry 
as previous products analysed. A new set of pyrroles were synthesised using the same 
methodology used previously to form furan and pyridine derivatives. 
 
Figure 2.4: Novel pyrrole Type 1 positive allosteric modulators of the α7 nAChR 
There was significant improvement in the activity with the furan derivative 32 with × 8.2 on 
the pyrrole and little change with using the pyridyl ring compared the phenyl ring. This 
small change must affect the way the molecule 32 interacts with the receptor to reduce the 
energy between the ‘open’ and ‘closed’ state compared to molecule 26a. 
With these encouraging results we decided to expand our set of molecules to pyrazoles. 
Pyrazole derivatives of these molecules contain 2 nitrogen atoms as the heteraromatic 
core. It was hoped that these molecules would give similar effects on the receptor but with 
greater aqueous solubility.  
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2.3 Pyrazolines and Pyrazoles 
2.3.1 Synthesis of Pyrazolines and Pyrazoles 
After the success of the finding that pyrroles 26a-e, 29a-b, 32 are novel Type 1 PAMs for 
nicotinic receptors, it was proposed that structurally related pyrazoles would behave in a 
similar fashion, with increased pharmacokinetics in new patent space. The initial plan was 
similar to the pyrrole formation. We began the synthesis with enone formation, this enone 
would be oxidised to the epoxide, followed by reaction with sulfanilhydrazine to form the 
desired pyrazole.  
 
Scheme 2.13: Route towards novel pyrazoles 
The first reaction completed was the large scale synthesis of the hydrazine reagent, as this 
was a key intermediate for the synthesis of pyrazoles with the N-N bond of the ring 
obtained from a preformed hydrazine derivative. Sulfanilamide 9 was converted to the 
diazo salt with conc. HCl and NaNO2 followed by reduction with SnCl2 to give the hydrazide 
salt 33 in excellent yield. 
  
Scheme 2.14: Synthesis of hydrazine salt 33  
The next step was the synthesis of the chalcone 34a, which as before, was simple and gave 
good yields for most of the reactions. The next step was the oxidation of the enone.  
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Scheme 2.15: Attempted of oxidation of an enone 
The oxidation reaction was complete after 2 h, however, no epoxide was seen in the crude 
product mixture. The crude product contained mostly unidentifiable degradation products 
and therefore we decided to explore alternative routes for formation of pyrazoles.  
The new route employed used the chalcone 34 directly with the hydrazine salt 33 to form a 
pyrazoline 37. This pyrazoline is an interesting intermediate itself which would oxidise 
under the reaction conditions to the desired pyrazole 35. 
 
Scheme 2.16: Revised route towards novel pyrazoles 
The enone 34a was reacted directly overnight with the hydrazine in AcOH and NaOAc to 
form the desired pyrazoline 37a. In the crude product there were some degradation 
products, which could be attributed to the long reaction times and relatively acidic 
conditions. This reaction was optimised first by using sub-stoichiometic quantities of p-
tolulenesulfonic acid (PTSA) in EtOH, which led to less by-products. It was also found that 
the reaction completed within 4 h and that the reaction works without the presence of 
PTSA to form the pyrazoline 37a in good yield. 
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Scheme 2.17: Pyrazoline formation 
The pyrazoline 37a is of a similar structure to the pyrrole 26a previously seen. The 
pyrazoline is chiral and the orientation of the phenyl ring can be either in or outside the 
plane of the remainder of the molecule giving it an unique interaction with the receptor.  
The pyrazoline 37a, although not a target molecule, was believed to have slightly different 
interactions with the receptor. Therefore a number of pyrazolines were synthesised using 
the conditions outlined previously from the enones.  
 
Scheme 2.18: Synthesis of pyrazolines 37a-h 
The reactions gave pyrazolines 37a-h in varied yields from poor to good. The phenol 
derivative 37d formed in very poor yields, this was attributed to the delocalisation of the 
phenol lone pair leading to deactivation of the enone to nucleophilic attack of the 
hydrazine. The pyrazoline 37h was produced along with a small quantity of the pyrazole 
35h (produced through auto-oxidation).  After the successful isolation and characterisation 
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of these novel pyrazolines, they were oxidised to the pyrazoles as they did not oxidise 
spontaneously as predicted.   
A method using bromine water was attempted which led to unidentified brominated 
products and a method using MnO2 was also attempted with no success.  
 
Scheme 2.19: Attempted oxidation of pyrazoline 37a 
Pyrazole formation was accomplished with DDQ (2,3-dichloro-5,6-dicyano-1,4-
benzoquinone) in toluene over 2 h, after a quick purification step the pyrazole was isolated 
in good yield.  
 
Scheme 2.20: Successful oxidation of pyrazoline 37a to pyrazole 35a 
Using this protocol we oxidised the remainder of the pyrazolines 37b-h also in good yields 
(in most cases).  
The oxidation is successful with most substrates, however, the highly electron-rich 
aromatics cause problems with the DDQ oxidation of 35h. 
 
Chapter 2 Pyrazolines and Pyrazoles 
35 
 
 
Scheme 2.21: Oxidation of pyrazolines to pyrazoles 35a-g 
Fortunately, there was some oxidation in the previous pyrazoline formation step which was 
conducted on a large enough scale to give enough of the pyrazole 35h for pharmacological 
testing.   
 
Scheme 2.22: Unsuccessful oxidation of pyrazoline 37h to pyrazole 35h 
We decided to synthesise a pyrazole with 2 phenol rings, therefore we started with the 
aldol condensation, which proved unsuccessful and so we tried an alternative approach.47 
The use of a Lewis acid in dioxane allowed the formation of the desired chalcone in good 
yield.  
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Scheme 2.23: Successful phenolic chalcone formation  
The conditions for pyrazoline formation were satisfactory for this substrate and gave the 
pyrazoline 41 in good yield.  
 
Scheme 2.24: Successful pyrazoline formation 
With the product in hand and the difficulty in oxidation with DDQ, we used an alternative 
approach to the DDQ oxidation. We used palladium on carbon under an oxygen 
atmosphere, which successfully oxidised the pyrazoline 41 to pyrazole 42.  
 
Scheme 2.25: Successful oxidation of pyrazoline 41 to a bis-phenol pyrazole 42  
The reaction went cleanly to give the pyrazole in good yield. With a wide set of pyrazolines 
and pyrazoles, the compounds were evaluated by our collaborators at UCL Pharmacology. 
These compounds have been synthesised from the α,β-unsaturated ketones or enones. We 
wanted to synthesise more molecules, however, the synthesis is only suitable for biaryl 
enones. To explore the pharmacology of potentially new molecules, a new synthesis of 
pyrazoles in one-pot from the enones derived from propargylic alcohols was initiated. This 
research is outlined and discussed in Chapter 3.  
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2.3.2 Pyrazolines – Pharmacological results by AC at UCL Pharmacology 
We synthesised a number of pyrazoles and their intermediate pyrazolines and these were 
assessed at UCL Pharmacology. 
 
Figure 2.5: Pyrazolines with little or no PAM activity 
We found that many of the derivatives do not display any PAM activity on the receptor. The 
molecules that do elicit a response seem to show only very small effects. It is surprising 
that there is little difference between pharmacology of these dissimilar structures. The 
furan derivative (37b) had no effect, which is interesting because these compounds gave 
the greatest fold potentiation effects as the pyrrole derivatives.  
The orientation of the aromatic rings of the 1 and 3 positions of pyrazolines are in the same 
plane and this is different to the pyrrole. The aromatic ring at the 5 position of the 
pyrazoline is positioned out of the plane and backwards. These differences may account for 
the reduced pharmacological effect.   
One positive result from this set of compounds was that they were markedly more soluble 
in DMSO than the pyrrole derivatives. Although disappointed with the poor 
pharmacological effect, these molecules were merely intermediates to the pyrazoles. 
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2.3.3. Pyrazoles – Pharmacological results by AC at UCL Pharmacology 
We synthesised a number of pyrazoles and these were assessed at UCL Pharmacology. 
 
Figure 2.6: Pyrazoles with Type 1 PAM activity 
All the synthesised pyrazoles 35a-h exhibited PAM activity with all giving enhanced 
response compared to the corresponding pyrazoline. The most effective PAM was found to 
be the para-OH analogue 35d with 12 times more depolarisation than ACh alone. The bis-
phenol derivative 42 quenched the effect of ACh and acted as a negative allosteric 
modulator (NAM). This change could be attributed to the free OH interacting strongly in 
the allosteric site. Interestingly, replacement of Br in this molecule for an OH, causes a 
change from PAM activity to NAM activity, which is surprising for such a small change. The 
difference in pharmacology must be due to the difference on how the OH interacts with 
the receptor. 
The bis-phenol 42 must increase the energy barrier between the ‘open’ and ‘closed’ state; 
by stabilising the ‘closed’ state or by destabilising the ‘open’ state. Pyrazole 35a must 
decrease the energy barrier between the ‘open’ and ‘closed’ states so that when ACh is 
introduced there is an enhanced effect.  
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The furan derivative 35d only gave a mild improvement relative to the analogous pyrrole 
26a. Surprisingly, the para-NO2 analogue 35c had very good activity whereas the pyrazoline 
37c gave none. In comparison to the pyrroles, the shape of these molecules are shaped 
differently with the aromatic rings at the 1 and 3 positions of the pyrazole almost in the 
same plane (orthogonal in the pyrrole) and the aromatic in the 5-position orthogonal to the 
heteroaromatic ring (same as the pyrrole).  
Following the success of forming the pyrazoles (2 nitrogen atoms in the core), we 
envisaged that triazoles (3 nitrogen atoms in the core) would allow synthesis of molecules 
with similar molecular shape with increased solubility. The next section will discuss the 
synthesis of 1,2,4-triazoles and their effect on the receptor. 
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2.4 Triazoles 
2.4.1 Synthesis of 1,2,4-Triazoles 
From the research conducted on the pyrroles and pyrazoles, it was natural to progress to 
triazoles. The proposed plan involves a significantly different approach to what has been 
explored thus far. The triazole 43 is derived from a condensation reaction between the 
imide 44 and a hydrazine. The imide is obtained through an oxidation of amide 45, formed 
through  an amidation reaction. 
  
Scheme 2.26: Proposed synthetic route to triazoles 
The first step, an amidation reaction, was completed with benzylamine, the acid chloride 
and base to give the product 47 in good yield.  The next step, oxidation with a catalytic 
quantity of CrO3 was a more challenging reaction.
48  
 
Scheme 2.27: Successful amidation reaction 
The reaction was slower than the literature procedure leading to the addition of more of 
the catalyst and longer reaction times. The crude product was purified by flash 
chromatography to give the imide as a colourless oil for the triazole formation.  
 
Scheme 2.28: Successful oxidation to form imide 
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Unfortunately, the condensation-cyclisation step did not occur with any of the conditions 
attempted. The hydrazine remained, but the imide seemed to degrade. We expected that 
1,3,5-triaryl substituted triazole 49 to be the sole product from this reaction, but found that 
there was the possibility that triazole 48 could also be a product of this reaction.  
 
Scheme 2.29: Unsuccessful triazole formation 
Although there was the potential to form two products in this reaction, no products were 
seen. Therefore, we decide to pursue an alternative route for a regioselective triazole 
formation. 
This new route to the triazole involved the formation of an intermediate hydrazonamide 
51. The forward synthesis begins with a hydrazone formation from hydrazine 33 and 
aldehyde 50. The hydrazone 51 is then chlorinated to the hydrazonyl chloride 52 which is 
then reacted with a primary amine to give the 1,2,4-triazole 54 after oxidation.  
 
Scheme 2.30: Revised synthetic route to triazoles 
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This route has the advantage that it will not form regioisomeric products and also that the 
substituent at position 5 of the triazole is added in the final reaction. This meant that with a 
stock of hydrazonyl chloride 52, it would be possible to synthesise a number of analogues 
with different R groups on 54. This route provides greater diversity than the syntheses for 
the pyrroles and pyrazoles.  
We started with the large scale synthesis of the hydrazone from a condensation of 
sulfanilhydrazine 33 and 4-bromobenzaldehyde 50. The reaction to form the hydrazone 
went cleanly in good yield.  
 
Scheme 2.31: Hydrazone formation 
The formation of the hydrazonyl chloride was a more challenging reaction. In this reaction 
there was no starting material after 4 h and after workup and flash chromatography, the 
desired product was isolated in only 20% yield.   
 
Scheme 2.32: Hydrazonyl chloride formation 
There were difficulties in this reaction from the start, the hydrazone only sparingly 
dissolves in the reaction solvent at room temperature. Also, the hydrazonyl chloride is 
likely to be unstable to the acidic nature of silica, thus flash chromatography is not a 
desirable purification technique. The proposed mechanism for the reaction is outlined 
below.  
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Scheme 2.33: Hydrazonyl chloride formation mechnanism 
In our attempts to find a solution we used other solvents and mixtures of solvents that 
would allow the formation of the dimethylsulfonium chloride with good dissolution. 
Unfortunately, none of these changes led to an improvement in the yield of the reaction. 
Because the yield for this step was low and with the possibility of alternative routes it was 
decided to abandon this route. 
 A small amount of hydrazonyl chloride was obtained and a reaction to form the triazole 
was attempted. The hydrazonamide intermediate was not isolated; the crude product from 
the first reaction was used in the next step with the addition of tetrapropylammonium 
perruthenate (TPAP) and N-methyl morpholine oxide (NMO). After removing the solvent 
from the reaction and purification by flash chromatography, the triazole was isolated in 
very good yield.  
 
Scheme 2.34: Triazole formation from a hydrazonyl chloride 
With this success, we found that this synthetic route was viable for the synthesis of 
triazoles. The problem was the formation of the hydrazone with a leaving group. After 
exploration of the literature we found a potential solution by using a nitrohydrazone (NO2 
as leaving group).  
 A new route was proposed with a similar reterosynthetic path, this route has the 
hydrazonamide intermediate derived from a nitrohydrazone 58. This nitrohydrazone 58 
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was synthesised from the diazo salt of sulfanilamide 55 and an appropriate nitro compound 
57. The nitro compound was formed from the nucleophilic displacement.   
 
Scheme 2.35: Proposed route to nitrohydrazone 58 
The synthesis began with the nucleophilic displacement of bromobenzyl bromide 56 with 
AgNO2 to give the nitromethyl benzene product 57. The formation of the nitro compound 
occurred in good yield, following a literature procedure.49 
 
Scheme 2.36: Nitromethylbenzene formation 
The formation of the nitrohydrazone was achieved by adding the diazo salt 55 to an ice-
cold solution of deprotonated nitro compound 57, which quickly precipitates the 
nitrohydrazone product 58.  
 
Scheme 2.37: Nitrohydrazone formation 
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With this product in hand, we repeated the triazole formation reaction replacing the 
hydrazonyl chloride 52 with the nitrohydrazone 58. The reaction provides the 1,2,4-triazole 
product in good yield.  
Scheme 2.38: Triazole formation from a nitrohydrazone 
There was a similar reaction profile between both the hydrazones 52 and 58, with the 
hydrazonyl chloride giving a higher yield over the last steps. Due to the difficulties in the 
formation of the hydrazonyl chloride, the overall efficiency of using the nitrohydrazone 
route is much greater. With the ease of formation of this novel triazole we explored a 
number of different primary amines as potential substrates for triazole formation.  
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Scheme 2.39: Formation of a number of triazoles  
A range of triazoles 54a-j were synthesised in relatively low yields over the two steps, but 
this method allowed the formation of triazoles with non-aromatic R-groups in the 5-
position. The next step was the deprotection of the alcohol 54h and amine 54j, this was 
completed using TBAF and HCl respectively, to give the alcohol and the free amine salt.  
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Scheme 2.40: Deprotections of 54h and 54j 
These reactions were successful and gave the products in good to excellent yields. We felt 
that we produced a wide range of triazole molecules that would have diverse 
pharmacological effects on the nicotinic receptor. The triazoles were tested at UCL 
Pharmacology.  
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2.4.2 Triazoles – Pharmacological results by AC at UCL Pharmacology 
We synthesised a number of triazoles and these were assessed at UCL Pharmacology. The 
first set synthesised were 3 nitrogen analogues of some previously active pyrazoles.  
 
Figure 2.7: Triazoles 
Interestingly, triazole 54a shows a small amount of Type 2 PAM activity whilst the other 
triazoles 54b and 54c are just Type 1 PAMs. Type 2 PAMs not only facilitate the opening of 
the receptor upon the addition of ACh but also slow the desensitisation kinetics. The 
justification for intermediate PAM activity is due to the broad classification of PAM types, 
they are based on functional profiles and not on molecular mechanisms or binding sites. 
Therefore, more complex and intermediate effects can be observed with PAMs. All of the 
pyrroles, pyrazolines and pyrazoles synthesised exhibit only Type 1 PAM, NAM or no 
activity at all. The differences between the triazole 54a and the pyrazole 35a are only small 
in terms of molecular shape. The triazole 54a does show a small amount of Type 2 PAM 
activity whilst the pyrazole 35a shows solely Type 1 PAM activity.  
We now have the opportunity to compare pyrrole 26a, pyrazole 35a and triazole 54a; these 
molecules only vary in their heteroaromatic core.  
 
Figure 2.8: Comparison of pyrrole 26a, pyrazole 35a and triazole 54a 
A general trend for the heterocycles is that they show greater n-fold peak potentials with 
the increase of nitrogens in the heterocyclic core.   
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The triazole synthesis that we have developed allowed the formation of a number of 
different R groups other than aromatic groups at the 5 position of the triazole. This allows 
us to synthesise more flexible and 3D triazoles that could not be done with the pyrazole 
synthesis. We were happy to find that the triazoles synthesised exhibited positive allosteric 
modulation and negative allosteric modulation, generally with good solubility.    
 
Figure 2.9: Triazoles with varied pharmacological activity 
Changes at the 5 position of the triazoles gave changes in the pharmacological response. 
Hydrophobic groups at this 5 position (54a-b, 54d-g and 54i) gave good PAM activity. In 
addition to the enhancement in the peak response when co-applied with ACh, there is a 
degree of desensitisation of the receptor. The example where the group at the 5-position 
of the triazole is benzyl (54e) was found to have very interesting receptor kinetics. The 
benzyl derivative 54e has fast initial response to the same magnitude to the ACh alone, 
followed by the increase in the n-fold peak potential along with increased desensitisation 
kinetics, that makes it a Type 2 PAM. There is little difference in terms of molecular shape 
between 54e and 54b which displays solely Type 1 activity.  
The difference may be due (in part) to the fact the methylene unit between the phenyl ring 
and the heteroaromatic core conveys greater flexibility. This molecule must reduce the 
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energy between receptor opening A and closing. This effect can be attributed to the 
molecule stabilising the ‘active’ state and also binds in such a way that slows the transition 
B from the ‘active’ state to the ‘desensitised state’ by destabilising the ‘desensitised’ state 
(See Figure 2.10).  
 
Figure 2.10: Representation of receptor opening and closing with a PAM 
More polar groups (54c, 54h and 59h) give only slight PAM activity and as the polarity is 
increased to the amine salt 59j, PAM activity is lost and this molecule acts as a NAM. The 
amine salt acting as a NAM may be due to the polar group causing electrostatic repulsion of 
the ions in the channel. This restriction of channel opening would stabilise the ‘resting’ 
state which will cause a reduced response to the addition of the agonist. 
 
Figure 2.11: Representation of receptor opening and closing with a NAM 
For some of the triazoles (54a-b, 54d-f), our collaborators conducted a more in-depth study 
of the effect of the molecules on native α7 nAChRs and mutant receptors. This is because 
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the molecules display Type 1 and Type 2 positive allosteric modulation, as well as 
intermediates of these effects. Type 1 PAMs show little to no desensitisation of the 
receptor upon activation whereas Type 2 PAMs show dramatic slowing of the 
desensitisation.  
 
Figure 2.12: α7 receptors with a selection of molecules (co-applied with ACh) 
They found that these triazoles were selective for human and rat α7 nicotinic receptors 
over α4β2 nAChRs, Mouse 5-HT3A (serotonin receptor), and rat α7/5-HT3A (Chimeric 
receptor), see Table 2.1.  
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There are potential individual point mutations in nAChRs that can have significant effects 
on the pharmacological response of receptors, increasing or decreasing their selectivity and 
pharmacological responses to ligands. There is growing evidence that indicates that Type 1, 
Type 2 PAMs and allosteric agonists can act via a transmembrane site in α7 nAChRs. 
Therefore, point mutations provide a valuable insight into receptor binding of these 
molecules, receptor opening and the allosteric binding site. The mutation L247T is a 
replacement of a leucine residue as the 247th amino acid in the α7 subunit is replaced by a 
threonine residue. This mutation lies towards the middle of the second transmembrane 
domain (TM2) of the subunit, this change can cause a dramatic slowing of receptor 
desensitisation.  
 
Figure 2.13: L247T mutated α7 receptors with a selection of molecules 
In the α7 nAChRs displaying the L247T mutation all five compounds showed agonist 
activity, regardless of whether they were Type 1 or Type 2 PAMs on human α7 nAChRs. This 
is different to other PAMs, for example, they showed NS-1738 does not exhibit any activity 
on this receptor. These molecules stabilise the ‘open’ state upon binding of the agonist in 
the native receptor. With this mutation, these molecules are able to stabilise the ‘open’ 
state to allow the ions to flow. The mutation must in some way lower the energy between 
the ‘resting’ and ‘open’ states.  
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In contrast to the L247T mutation, the M260L mutation (replacement of methionine for 
leucine), located higher in TM2 usually shows little to no effect on the rate of receptor 
desensitisation.  
 
Figure 2.14: M260L mutated α7 receptors with a selection of molecules 
For the α7 nAChRs containing the M260L mutation, strong agonist activity was only seen 
with 2 molecules (54e and 54f) the other molecules had little to no effect on the receptor. 
Coincidentally, these molecules exhibited the greatest reduction in desensitisation in the 
wild-type α7 receptors. These molecules must interact with the receptor in such a way that 
stabilise the ‘open’ or destabilise the ‘resting’ states of the receptor. The molecules 54e 
and 54f are Type 2 PAMs on the native α7 nAChR and act as agonists on the M260L 
mutated receptors. This is interesting because the intermediate and Type 1 PAMs on the 
native α7 nAChR do not have any effect on the mutated M260L receptor.  
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2.5 Conclusion  
We have designed and developed routes for the synthesis of novel substituted heterocycles that 
exhibit allosteric modulation effects on the α7 nicotinic acetylcholine receptor. We began the 
project with the synthesis of novel pyrroles that were found to act as Type 1 positive allosteric 
modulators for the receptors, before the synthesis of more complex molecules.  
 
Pyrazolines were produced as intermediates, which were discovered to be also novel (but weak) 
allosteric modulators for nicotinic receptor. Pyrazoles showed strong Types 1 PAM effects on the 
receptor.   
 
After the exploration of the core containing 2 N-atoms (pyrazoles) we then explored the 3 N-atoms 
(triazoles) derivatives and found a mixture of pharmacological effects.  
 
Dependent on the R group the molecules exhibit effects including: Type 1 PAM, Type 2 PAM and 
negative allosteric modulation. We also found that with site-selective mutagenesis we can see 
changes in pharmacological response with small differences in the molecular structure.  
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2.6 Future Work 
Future work in this project would be to explore more molecules that will display a 
pharmacological response on nicotinic receptors.  
Maleimides 
One promising area of progress is with maleimide reagents. As these molecules contain a 
Micheal acceptor, it could be possible for reaction with the amino acid residues on the 
protein which would give further evidence for the location of the allosteric binding site.  
 
The dehydration reaction between maleic anhydride and sulfanilamide in AcOH with acetic 
acid led to a maleimide product, however, some monoacylation of the amine also occurred 
during this reaction. An alternative route, using P2O5 as the dehydrating agent, led to the 
desired maleimide product. The maleimide 62 was reacted with thiophenol to give 
succinimide 63. This molecule was tested and was found to have no effect on nicotinic 
receptors. No further work was completed.  
1,2,3-Triazoles 
With the diverse structures that gave activity on the receptor, it is possible that novel 1,2,3-
triazoles would acts as modulators on the receptor. The benefits of this approach would be 
a very facile synthesis of a number of analogues through a well understood and established 
method with readily available starting materials. 
Chapter 2  Conclusion and Future Work 
57 
 
 
Molecules that act on non-α7 nAChRs 
In this project we have focused on synthesis of molecules that act as modulators of the α7 
nicotinic receptor. Many of the molecules synthesised have been subtype selective, 
however, synthesis of α4β2 or other subtypes of receptors would be very interesting in the 
project moving forward. Another possible extension would be the synthesis of agonist or 
modulators that are selective for insect nAChRs.  
Synthesis of aminocyclopropane that affect nicotinic receptors 
During my PhD I have been able to work on the synthesis of aminocyclopropanes.50 
Selective α7 nAChR Type 2 PAM RO5126946 is an aminocyclopropane and we believe that 
we could potentially synthesise analogues through this route.  
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Chapter 3 Gold-catalysed reactions 
3.1 Pyrazole formation using gold-catalysis 
3.1.1. Introduction 
In Chapter 2, the conversion of enones into pyrazoles was discussed (Scheme 3.1). The 
reaction is a two-step process, first the hydrazine addition to form the pyrazoline 65 
followed by oxidation to give the pyrazole 66. 
 
 Scheme 3.1: Two-step pyrazole formation from the enone 64 
The limitation of this reaction is derived from the formation of the enone 64. The enones 
used primarily in the nicotinic project are produced by a Claisen-Schmit condensation from 
an aldehyde and a ketone.  
 
Scheme 3.2: Claisen-Schmidt condensation 
These reactions are very efficient when R and R’ are aromatic rings, however, where R and 
R’ are alkyl groups there are more α-protons giving unselective deprotonation, which lead 
to by-product forming reactions and polymerisation pathways.  
Scheme 3.3: Potential products from Claisen-Schmit formation 
There are many reviews on the gold activation of alkynes.51–55 In particular, the Meyer-
Schuster rearrangement56 would be a more controlled approach to this class of enones 
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starting from readily synthesised propargylic alcohols. Our plan was to synthesise pyrazoles 
from propargylic alcohols through enone intermediates. Previous work in the Sheppard 
group has shown the utility of propargylic alcohols by their clean transformation into 
enones with the use of a gold catalyst and a protic additive. This protocol for the Meyer-
Schuster rearrangement is mild and convenient (Scheme 3.4). 57,58 Alternative conditions 
can also be used for Meyer-Schuster rearrangement.59,60  
 
Scheme 3.4: Gold-catalysed Meyer-Schuster rearrangement 
Gagosz’s catalyst, [Bis(trifluoromethanesulfonyl)imidate] (triphenylphosphine)Au(I) (2:1) 
toluene adduct is commercially available and is a highly effective catalyst for this 
transformation. The reaction is tolerant of a variety of functional groups and enones that 
are inaccessible using the Claisen-Schmidt procedure can now be produced.  
Another limitation of the pyrazole formation discussed in Chapter 2 is that the reaction is 
broken into two steps, first the pyrazoline formation, then the oxidation to the pyrazole. An 
intuitive approach to the pyrazole would be the formation of an oxidised enone in the form 
of a α-haloenone (Scheme 3.5).  
 
Scheme 3.5: Haloenones to Pyrazoles 
The advantage of this approach is that there will be no requirement for a separate 
oxidation step. In 1991, McNelis and co-workers first reported the formation of a α-
haloenones from propargylic alcohols. 61 Both protocols use N-halosuccinimides (NXS) as 
the electrophilic halogen source. The reactions give good yield but a limitation is the poor 
substrate scope.  
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Scheme 3.6: Meyer-Schuster rearrangement halogenation61 
In 2013, Gault and co-workers reported an α-iodoenone from a propargylic alcohol as a 
unwanted product. 62 The reaction requires gold-catalysis in the presence of NIS and gives 
the enone with good yield and E/Z selectivity.  
 
Scheme 3.7: Gold-catalysed Meyer-Schuster rearrangement iodination62 
The most prominent work in this field has been competed by Zhang and co-workers in 
2009.63 The reaction has a wide substrate scope to give iodoenones and bromoenones in 
generally good to excellent yields.  
 
Scheme 3.8: Gold-catalysed Meyer-Schuster rearrangement halogenation63 
The aim of this project is the synthesis of pyrazoles either from enones (with an oxidant) or 
iodoenones, both of which are derived from propargylic alcohols.  
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Scheme 3.9: Aim of Chapter 3- Pyrazole synthesis  
 
3.1.2. Synthesis of a pyrazole from a propargylic alcohol 
The propargylic alcohols in this project were produced using a preparation previously used 
in the group with n-BuLi, a carbonyl compound and a terminal alkyne.   
 
Scheme 3.10: Propargylic alcohol formation 
The reactions to synthesise propargylic alcohols are generally efficient with isolated yields 
of 45 – 96%. These substrates are suitable for the Meyer-Schuster rearrangement. As the 
product from the Meyer-Schuster rearrangement is clean, we envisaged that the product 
could be telescoped in the subsequent reaction to form pyrazoles directly from the 
reaction mixture in one-pot. The first reaction attempted was enone formation with 
Gagosz’s Au catalyst and MeOH in toluene.  
 
Scheme 3.11: Pyrazole formation from the enone 
Propargylic alcohol 70a was converted to the pyrazole 72 via the enone 71, however, the 
efficiency of the overall reaction was rather low. The presence of hydrazine and iodine, we 
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believe, led to diazene and ultimately nitrogen formation. At the same time there is 
degradation of I2 giving a fairly low conversion to the pyrazole. The hydrazine addition and 
oxidation in separate steps may decrease the amount of side-product formation. 
Therefore, we used a preparation from the literature to synthesise the iodoenone 73a.64 
 
Scheme 3.12: Iodoenone formation 
In our hands the yield was 54% for the iodoenone 73a. We believed the preparation did not 
require the co-catalysts (MoO2(acac)2 and Ph3PO) and thus we attempted a synthesis 
closely related to the Meyer-Schuster rearrangement conditions used previously in our 
group. Addition of NIS to the reaction mixture allowed the successful isolation of the 
iodoenone 73a in 71% yield. This result is particularly impressive as the reaction conditions 
were not optimised. We then submitted the propargylic alcohol to the iodoenone 
formation until complete conversion of SM. This was then followed by the addition of 
hydrazine.  
 
Scheme 3.13: Pyrazole formation from the iodoenone 
The first attempt for the synthesis of a pyrazole via the iodoenone was successful but 
provided pyrazole 72 in disappointing 45% yield. We predict that upon hydrazine addition 
we would expect hydrazone formation, followed by attack of the pendant amine to give a 
iodopyrazoline 75, with loss of HI gives the pyrazole. The poor yield may be attributed to 
the instability of the hydrazone 74.  
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Scheme 3.14: Proposed mechanism for pyrazole formation from an iodoenone 
With the repetition of the iodoenone synthesis we see the formation of a new by-product. 
This product appeared to be derived from the addition of 2 atoms of iodine and water to 
the propargylic alcohol to give an α,α-diiodo-β-hydroxyketone 76a. The structure was 
confirmed by isolation of this product by adding water to the reaction mixture.  
 
Scheme 3.15: First isolation of a diiodoketoalcohol 76a 
This unprecedented reaction is the diiodohydration of a propargylic alcohol which has not 
been previously reported. In addition, this is the first example of a gold-catalysed 
diiodohydration reaction.  
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3.2 Literature Review of Dihalohydration Reactions  
The addition of water and halogens to an alkyne to give a dihaloketone was first discovered 
in the 19th century. The addition of water and halogens across a carbon-carbon triple bond 
is termed dihalohydration. Dihalohydration of alkynes has existed for a long time with the 
earliest report in 1895 with the dichlorohydration of 2-butyne to give 3,3-dichlorobutan-2-
one by Faworksi.65 The details of this transformation are not available other than 
hypochlorous acid as the reagent.  
 
Scheme 3.16: First report of a dihalohydration of an alkyne65 
Later in 1910, a report of dichlorohydration of alkynylethers was completed also using 
hypochlorous acid by Jozitsch.66 The procedure was the same used by Faworski, but with a 
slightly wider substrate scope.  
 
Scheme 3.17: Another early report of dihalohydration66 
The next significant report was in 1967, with the first report of dibromohydration of 
alkynes by Jovtscheff and co-workers.67 The electrophilic bromine source is N-
bromosuccinimide (NBS).  
 
Scheme 3.18: First report of dibromohydration of alkynes67 
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In 1995, the first procedure of difluorohydration of an alkyne was reported by Stavber and 
co-workers.68 The procedure involves Selectfluor as an electrophilic fluorine source, the 
yields of this transformation are only moderate.  
 
Scheme 3.19: First report of difluorohydration of alkynes68 
In 1998, the dibromohydration and diiodohydration of conjugated alkynes was reported by 
Eden.69 There are only 4 examples of the reaction, therefore the reaction scope has not 
been fully explored. The diiodides can be produced in excellent yields from an operationally 
simple procedure.  
 
Scheme 3.20: Dihalohydration of conjugated alkynes 69 
In 2003, a report was published of a operationally facile approach for the synthesis of 
dichloroketones from alkynes.70 The substrate scope of this transformation is not 
particularly wide. The general efficiency of the transformation is good.   
 
Scheme 3.21: Dichlorohydration of alkynes70 
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The facile aerobic photo-oxidative dibromohydration of terminal alkynes to 
dibromoacetophenones was reported in 2010 by Itoh and co-workers. The reaction works 
excellently where R is aromatic, whereas where R is alkyl the yield is only 17%.71 
 
Scheme 3.22: Light-activated dibromohydration of terminal alkynes71 
The dihalohydration of a number of alkynes with wide reaction scope was reported by Li72 
and co-workers in 2010. The reaction requires a readily available iron catalyst and N-
halosuccinimides. Terminal aromatic alkynes could be converted to dihaloacetophenones 
in water alone in good to excellent yields. 
 
Scheme 3.23: Dihalohydration using a iron catalyst72 
Vangipuram and co-workers reported the synthesis of dihaloacetophenones in 2013.73 The 
dichlorides and dibromides are produced in generally good to excellent yields. However, 
the diiodides are can only be isolated in poor to moderate yields.  
 
Scheme 3.24:Dihalohydration of terminal alkynes73 
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Also in 2013, there was a report of dibromohydration of alkynes using N,N-dibromo-
toluenesulfonamide (TsNBr2). This route to dibromoketones is rapid with good yields with 
no catalysts required.74 
 
Scheme 3.25:Dibromohydration using TsNBr2
74 
In 2014, Moran and co-workers reported the conversion of propargylic alcohols to 
dibromoketoalcohols and dichloroketoalcohols.75 The reaction conditions are similar to the 
conditions used by Vangipuram, however, this propargylic alcohol system is more 
complicated than the terminal alkyne system. The researchers were unsuccessful in their 
attempts to synthesise diiodoketoalcohols using NaI as the salt.  
 
Scheme 3.26: Dihalohydration using oxone and sodium salts 75 
In the literature there are many examples of dihalohydrations of alkynes. In the past five 
years there has been resurgence in this area of research. The limitations of the 
diiodohydration reactions in the literature are that they suffer from poor yields and poor 
substrate scope. The use of a gold-catalyst and NIS for the conversion of propargylic 
alcohols to give diiodoketoalcohols would be a valuable and significant addition to the 
dihalohydrations in the literature.  
 
Chapter 3 Diiodohydration  
68 
 
3.3 Synthesis of Diiodoketoalcohols 
During the investigation of a gold-catalysed iodoenone synthesis from propargylic alcohols 
we found that in addition to the iodoenone, a new ketone product was being formed in 
very small quantities (which we could not isolate). This product was found to be an α,α-
diiodo-β-hydroxyketone. This class of compounds, to the best of our knowledge, has not 
been reported previously. This transformation would be a useful addition to previously 
developed Au-catalysed reactions in the Sheppard group.76 This diiodoketoalcohol product 
also has the benefit of geminal iodine atoms which will allow potential exploration of new 
reactions based on the ketone, alcohol and the diiodide all placed in close proximity. At this 
time, we sought to optimise the reaction conditions in favour of the diiodoketoalcohol over 
the iodoenone.  
Table 3.1: Optimisation of the diiodohydration reaction  
 
Entry Solvent NIS (eq.) Time Yield 73a Yield 76a 
1 PhMe 1.2 2 h 71%  trace 
2 PhMe:H2O 20:1 1.2 18 h major 18% 
3 PhMe:H2O 20:1 2.4 5 h n.d.
[a] 49% 
4 Et2O:H2O 20:1 2.2 45 min n.d. 50% 
5 THF:H2O 20:1 2.2 45 min n.d. 38% 
6 MeCN:H2O 20:1 2.2 30 min n.d. 64% 
7 MeCN:H2O 10:1 2.1 1 h n.d. 71% 
8 MeCN:H2O 10:1 2.1 18 h 0%
[b] 0% [b] 
 [a] n.d. = not detected. [b] The gold catalyst was omitted. 
Water was required for the hydration of the alkyne, therefore, we added water to the 
reaction mixture enabling diiodide 76a to be isolated. The ketoalcohol 76 was the major 
product of this reaction but the isolated yield was low (Entry 2, 18%). Two atoms of iodine 
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are incorporated into the molecule and so an experiment with excess NIS was conducted to 
give the product 76a in acceptable yield (Entry 3, 49%). The lower yield was attributed to 
the poor solubility of water in PhMe, therefore, we conducted the experiment with some 
alternative solvents: Et2O, THF and MeCN (Entries 4-6). Et2O and THF gave no significant 
improvement, but acetonitrile gave a slight improvement in yield (Entry 6). A further 
increase in yield was achieved through the scale up of the reaction (more accurate 
measurement of the quantities), a greater quantity of water in the solvent mixture and a 
reduction in the excess of NIS (Entry 7). These changes in the conditions also led to none of 
the undesired iodoenone 73a being detected.  
We next set out to determine the scope of this diiodohydration reaction by applying these 
optimised conditions to various propargylic alcohols.   
 
Scheme 3.27: Successful diiodoketoalcohol formation 
Pleasingly, a selection of α,α-diiodo-β-hydroxyketones 76a–h could be obtained and 
isolated in acceptable to excellent yield. Secondary alcohols 76a, 76b, 76d–i can be 
produced as well as primary alcohol 76c derived from commercially available propargylic 
alcohol 76c. Diiodohydroxyester (76i) could be produced in excellent yield from the 
corresponding alkynyl ether. The reaction generally requires an electron-releasing 
substituent (tolyl, PMP and OEt) on the alkyne and other groups do not give the desired 
products.  
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Scheme 3.28: Unsuccessful diiodoketoalcohol formation 
Tertiary propargylic alcohols (70j and 70s) led to a mixture of unidentified products as did 
propargylic alcohols with aryl groups on the alcohol (70k, 70l, 70p and 70s). This could be 
attributed to the electron-releasing nature of the aromatic group along with the steric 
strain on forming the geminal diiodide. Failure of propargylic alcohol 70m was surprising, 
however, this could also be attributed to steric clash in the formation of the diiodide. 
Aliphatic propargylic alcohols 70n, 70p and 70q led to side-reactions and the desired 
diiodides could not be detected. Terminal propargylic alcohol (70o) was not a suitable 
substrate as little reaction occurred, and after 24 h only SM and unidentified products were 
seen. In the reaction with the pendant alkene (70r) there is potential for reaction on the 
alkene, as well as the alkyne. However, the reaction appeared clean but after column 
chromatography the major fraction was a mixture of two unidentified products produced in 
a low yield.   
We have explored the substrate scope and the limitations of this diiodohydration reaction. 
To justify and understand the reasons for these limitations we conducted experiments to 
gain an understanding of the potential mechanism(s) of this transformation. Firstly, we 
carried out the reaction under ‘water-free’ conditions. 
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Scheme 3.29: Diiodohydration reaction under water-free conditions 
The reaction yields mostly the iodoenone 73a as seen previously, but also present was a 
new product 77, which was apparently being hydrolysed to this iodoenone 73a. This 
product was assigned to be iodoacetamide 77 which was formed as a single geometrical 
isomer. The finding that the product was formed as a single geometrical isomer was 
completed in collaboration with Dr Abil Aliev, who conducted nuclear Overhauser effect 
spectroscopy (nOesy) experiments.  
 
Figure 3.1: nOesy experiments confirming (E)-geometry of 77 
There is nOe between the acetamide methyl group and the enone CH. This result suggests 
that the acetonitrile solvent is incorporated into the molecule to form 77 which is then 
hydrolysed to give the iodoenone 73a. We conducted experiments to determine whether 
the iodoenone 73a is an intermediate towards diiodide formation or that the diiodide 76a 
is an intermediate towards the iodoenone 73a formation.   
 
Scheme 3.30: Re-exposure to reaction conditions 
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These experiments suggest that the two products are produced by divergent mechanisms. 
Another method to discover whether the iodoenone is an intermediate for the 
diiodohydration is to synthesise an enantioenriched propargylic alcohol.  
 
Scheme 3.31: Diiodohydration of enantioenriched propargylic alcohol 
If there is no racemisation of the alcohol (R-76) in the diiodohydration reaction, this would 
suggest that an intermediate iodoenone is unlikely. If the product is racemic (rac-76) this 
would suggest that there would be an achiral intermediate. The synthesis of 
enantioenriched propargylic alcohol R-70d is outlined in Scheme 3.32.  
 
Scheme 3.32: Synthesis of an enantioenriched propargylic alcohol 
The reaction of tolylacetylene with DMF led to the formation of propargylic aldehyde 78 in 
good yield. Ethyl diazoacetate was added to the aldehyde in a nucleophilic addition 
reaction to give the diazocompound 79, which was treated with Rh2(OAc)4 for 1 h to give 
the ketone 80 in good yield over the 2 steps. The transfer hydrogenation of the ketone77 80 
with (R,R)-Teth-TsDPEN-RuCl catalyst gave clean conversion to the enantioenriched 
propargylic alcohol R-70d. The enantiopurity was determined by Moshers esters analysis.  
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Scheme 3.33: Moshers Ester determination of enantiopurity 
The NMR analysis of the crude reaction mixture gives a measure of enantiopurity of the 
alcohol from the diastereomers. This enantioenriched propargylic alcohol was then 
subjected to the diiodohydration conditions.   
 
Scheme 3.34: Diiodohydration with an enantioenriched propargylic alcohol 
No racemisation of the alcohol had occurred. This demonstrates that the mechanism of the 
reaction does not involve an achiral iodoenone intermediate. It is likely that the iodoenone 
and diiodoketoalcohol are being formed through a divergent mechanism. The omission of 
the Au-catalyst from the optimised reaction conditions led to no reaction being seen with 
SM remaining after a number of hours. With the omission of NIS, we could expect the 
Meyer-Schuster rearrangement products, however, we do not see any reaction after a 
number of hours.  
 
Scheme 3.35: Unsuccessful transformation of propargylic alcohols  
These results show us that without gold, there is no activation for any reaction to occur and 
that without NIS there is no electrophile to give the hydration. These results gives us a 
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valuable insight into the reaction mechanism, the reaction requires both gold catalyst and 
NIS. NIS is not only an iodine source but also a strong oxidant. It is possible that the AuI 
catalyst is oxidised by the NIS to form AuIII as a reactive species which catalyses the 
hydration.78–80 To test this hypothesis we conducted a catalyst screen NMR study (Table 
3.2).   
Table 3.2: Diiodohydration reaction with different gold catalysts 
 
Entry Catalyst Yield 3a[a] 
1  
 
72% 
2 
 
86% 
3  86% 
4 
 
74% 
5  86% 
6  99% (75%
[b]) 
7 AuCl3 60% (76a) 16% (73a) 
8 AuBr3 99%  
[a]
Yield calculated by crude NMR with trimethoxybenzene as an internal standard. [b]1 eq of 2,6-di-tert-
butylpyridine was added; yield measured after 24 h. 
 
We found that a number of gold catalysts were competent for the conversion to the 
diiodoketoalcohol including both AuI and AuIII catalysts.  This included catalysts with 
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phosphine ligands (Entries 1 (Echavarren’s catalyst), 4 - 6), N-heterocyclic carbene ligand 
(Entry 2), thiol ligand (Entry 3) and AuIII catalysts (Entries 7 an 8).  It can be predicted that 
the ligand is not important because the majority of the catalysts give the desired product 
regardless of the counter ion or the ligand. A gold(I) – gold(III) catalytic cycle is possible 
where the gold is oxidised by NIS.78–80 Another possibility is that gold catalyst could be 
acting as a Lewis acid, activating the NIS for the addition to the alkyne. With these 
observations, we have proposed a mechanism for this diiodohydration reaction. The 
reaction begins with the activation of the alkyne by IAuY2 (where Y = NTf2, I, PPh3 or a 
mixture thereof) which induces nucleophilic attack by acetonitrile to give an intermediate 
83, which undergoes cyclisation to give oxazine 84. Reductive elimination gives us iodo-
oxazine 85 and AuI which is oxidised by NIS to the active AuIII species and completes the 
catalytic cycle. With the addition of another equivalent of NIS, it iodinates the oxazine and 
H2O opens the oxazine and gives us N-acylimine 86. After hydrolysis, we can observe the 
diiodoketoalcohol 76. From iodo-oxazine 85, a [3,3]-sigmatropic rearrangement (potentially 
Au catalysed) gives the iodoacetamide 87, which accounts for the product 77 as a single 
geometrical isomer. This iodoacetamide 87 intermediate is hydrolysed to give the 
iodoenone 73, this product is only seen when no water is present in the reaction mixture.  
 
Scheme 3.37: Plausible AuI - AuIII mechanism with MeCN as solvent for diiodohydration 
It is worth noting that MeCN is not required for diiodohydration reaction. Therefore this is 
not the only possible mechanism, it must be possible for H2O to attack the activated alkyne 
directly, but this must be a less efficient process (giving lower yields for the reaction) 
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Scheme 3.38: Plausible AuI – AuIII mechanism with a non-nitrile solvent for diiodohydration 
The gold catalyst activates the alkyne as in the acetonitrile solvent, however, water must 
attack and form the vinyl-gold intermediate 87. Reductive elimination of the Au-
intermediate 87 gives the iodoenol 88. Loss of water from 88 gives the iodoenone 73. The 
iodoenol 88 can also react with another equivalent of NIS to give the diiodoketoalcohol 76.  
Another plausible mechanism involves the gold catalyst behaving as a Lewis acid (Scheme 
3.39)  
 
Scheme 3.39: Plausible Lewis acid mechanism with MeCN as solvent for diiodohydration 
The gold is able to activate the NIS for nucleophilic attack from the alkyne, which forms a 
vinyl cation intermediate 89. This intermediate can undergo nucleophilic attack from the 
MeCN followed by formation of an iodo-oxazine 85. This intermediate 85 can perform the 
same pathways seen in the gold(I)-gold(III) mechanism to give the iodoenone and the 
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diiodoketoalcohol. We proceeded to explore what transformations were possible with 
these usual products containing a ketone, an alcohol and a diiodide.  
 
3.3.1 The reactions of the Diiodoketoalcohol Products  
We explored the reactivity of these novel products by completing some test reactions. A 
sodium borohydride reduction of the ketone 76a was attempted. The reaction gave a 
complex mixture of products including the iodoenone 73a. There was a similar result upon 
the addition of base (NaOH) to give the iodoenone as the only identified product. 
 
Scheme 3.40: Unsuccessful reactions of diiodohydration products 
It is possible that reactions of these molecules with nucleophiles and bases are governed by 
the ability for the formation of a stabilised anion/enolate which can eliminate -OH to give 
the enone (Scheme 3.41).  
 
Scheme 3.41: Proposed mechanism of the iodoenone formation 
In the literature, a common use of gem-diiodides in the form of diiodomethane is the 
Simmons-Smith reaction.81,82 This reaction coverts the diiodide into an active organozinc 
carbenoid, which can react with an appropriate alkene to form a cyclopropane. We 
attempted to synthesise a cyclopropane using this methodology. 
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Scheme 3.42: Unsuccessful Simmons-Smith reaction  
After 18 h, none of the starting material remained and after purification by 
chromatography it was unclear what the main product of the reaction was. One fraction 
was found to contain a mixture of the iodoenone 73a, what appears to be enone 82 and 
another unidentified product. Success was achieved in terms of breaking C-I bonds, 
however there was no evidence of new C-C bond formation. This system is much more 
complex than diiodomethane (substrate used in most Simmons-Smith reactions) and may 
lead to breakdown of the carbenoid prior to any reaction with the alkene. Some successful 
experiments are shown below (Scheme 3.43) for the conversion of the diiodide to a β-
hydroxyketone 92 and diketone 93.  
 
Scheme 3.43: Successful reactions of diiodoketoalcohol 76a 
The oxidation of the diiodide with sodium methoxide gave only poor conversions to the 
diketone 93. An alternate method using DMSO at 80 °C also gave to diketone 93, however 
the reaction could not be repeated and just gave degradation products. Although both of 
these transformations are not particularly high yielding, it was important to explore the 
potential reactions of these products.  
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3.3.2 Alternative electrophilic iodine sources for diiodoketoalcohols 
In the exploration of alternative electrophilic iodine sources that would allow 
diiodohydration of propargylic alcohols, we found TMADCI (tetramethylammonium 
dichloroiodide). This reagent dissociates into tetramethylammonium chloride and iodine 
monochloride. It was believed that this reagent would be a more stable, easy to handle 
form of iodine monochloride. The expectation was that this reagent in the diiodohydration 
reaction replacing NIS would give the diiodide 76a. However, the diiodide 76a was not 
detected and the major product was dichloroketoalcohol 94a, isolated in good yield.  
 
Scheme 3.44: Unsuccessful diiodoketoalcohol formation 
We were excited to find that we could synthesise this product and we intended to 
determine the substrate scope to produce this interesting product. However, it was quickly 
discovered that the reaction was sometimes irreproducible or unreliable when repeated 
with a mixture of products produced, none of which was the dichloroketoalcohol 94a. One 
product appeared to show signals consistent with chloroiodoalkene 95.83,84 
 
Scheme 3.45: Unsuccessful dichloroketoalcohol formation 
This result led to a change in the focus of the research from diiodohydration towards 
dichlorohydration. 
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3.4 Synthesis of Dichloroketoalcohols 
With the successful synthesis of a number of diiodohydration products from a number of 
substrates, a natural expansion of this work would be other dihalohydrations. These 
products would be of interest due to the synthesis of chlorolipid natural products isolated 
from Mediterranean mussels Mytilus galloprovincialis, such as mytilipin B.85  
 
Fig 3.2: Sulfochlorolipid natural product 
We took the opportunity to explore whether we could synthesise α,α-dichloro-β-
hydroxyketones using the same method as the diiodohydration. This was due to the 
interest in the geminal dichlorides in natural products and the dichlorohydration reactions 
in the literature. To this end, we examined a number of electrophilic Cl+ sources in order to 
synthesise novel dichloroketoalcohols. We used 70a as our substrate and initially N-
chlorosuccinimide (NCS) as electrophilic chlorine source.  
 
Scheme 3.46: Unsuccessful dichloroketoalcohol formation 
Unfortunately, there was no reaction with NCS after long reaction times, this may be 
attributed to the relatively weak oxidising power compared to NIS. We then examined an 
alternative chlorinating agent, trichloroisocyanuric acid (TCA) under the gold-catalysed 
dihalohydration conditions.   
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Scheme 3.47: Successful dichloroketoalcohol formation 
The reaction with TCA and propargylic alcohol was surprisingly fast (<5 min) and very clean 
by TLC to give the desired dichlorohydration product 94a. The reaction mixture gets very 
warm from this quick exothermic reaction, therefore we decided to cool the reaction 
mixture before the addition of TCA to reduce the formation of by-products. The rate of 
reaction was so quick that we questioned whether gold was actually catalysing the 
reaction. We repeated the reaction without the Au-catalyst and found similar yield and 
reaction time was achieved. This indicates that the gold catalyst is not required and thus 
this reaction must have a different mechanism to the diiodohydration previously seen. 
Pleasingly, the reaction was higher yielding and more reproducible than the TMADCI 
protocol. We then explored the scope of this TCA induced dichlorohydration reaction.  
 
Scheme 3.48: Successful dichloroketoalcohol formation reactions  
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Pleasingly, a variety of dichloroketoalcohols (94a–h, 4j, 94n, and 94u) and dichloroesters 
(94i and 94t) could be produced from the corresponding propargylic alcohols in good to 
excellent yields. The reaction was applicable for primary (94c and 94n), secondary (94a–b, 
94d–i, 94k–m and 94t) and tertiary alcohols (94j) (not suitable for diiodohydration) in 
generally good yield. The synthesis of dichloroketoalcohols 94k–m is generally poor, but 
these substrates do not give the respective diiodohydration products at all.  Low molecular 
weight alcohol (94n) could be synthesised but isolated in poor yield. The symmetric 
dialkynol 70u was an acceptable substrate for the synthesis of a tetrachlorodiketoalcohol 
94u.  
In this dichlorohydration reaction the propargylic alcohols give the dichloroketoalcohol as 
the only isolable product. However, in the reaction with the alkynylether 70t we observed 
two distinct products forming: the major dihalohydration product 94t and a minor product 
96.  
 
Scheme 3.49: Successful dichloroketoalcohol formation 
The minor product is N-acyl imidate ester 96, which gives a combined isolated yield of 97%. 
The imidate ester 96 is formed as a single (E) geometrical isomer and hydrolyses slowly to 
the ester 94t. The finding that the product was formed as a single geometrical isomer was 
completed in collaboration with Dr Abil Aliev, who conducted nuclear Overhauser effect 
spectroscopy (nOesy) experiments.  
 
Figure 3.3: nOesy experiments confirming (E)-geometry 
We found a weak nOe between the methyl group of the acetamide and the proton next to 
the dichloride. In order to ascertain whether this dichlorohydration reaction follows a 
similar mechanism to the diiodohydration reaction we conducted further experiments. We 
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used our dichlorohydration conditions with our enantioenriched propargylic alcohol R-70d 
as a substrate.  
 
Scheme 3.50: Dichlorohydration with an enantioenriched propargylic alcohol 
This reaction produced the desired product in the same yield as the racemic variant. There 
was a small reduction in the enantiopurity of the product but this could be possibly 
attributed to inaccuracies in the measurement of the enantiopurity. This result suggests 
that the reaction mechanism does not go through an enone intermediate. We then decided 
to investigate whether the alcohol was required for the reaction to occur. We synthesised 
propargylic ether 97 and subjected it to our dichlorohydration procedure (Scheme 3.51). 
 
Scheme 3.51: Propargylic ether formation 
The methylation of the alcohol worked well giving good yield of ether 97. The 
dichlorohydration procedure led not to our desired product, but chloroenone 98 in poor 
yield. This reaction gives further evidence that the free alcohol is involved in the 
mechanism of this reaction. With this substrate the chloro-oxazine 102 intermediate is not 
able to be formed.  
 
Scheme 3.52: Possible mechanism for dichlorohydration of ether 97 
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 Synthesis of propargyl ketone 103 was completed by oxidation of the respective alcohol 
70f. We then exposed this ketone 103 to our dichlorohydration conditions, the reaction 
was slow (2 h) but successful to the dichlorodiketone 104 in good yield.  
 
Scheme 3.53: Propargylic alcohol oxidation  
This reaction shows that the alcohol does not need to be present for the dichlorohydration 
reaction to occur and ketone 103 can still participate to form the dichlorodiketone 104. 
This product is novel and further work could be done to explore the scope and limitations 
of this reaction.   
We propose a mechanism for the dichlorohydration reaction in Scheme 3.54. Nucleophilic 
attack of the alkyne to TCA gives the vinyl cation 105. Nucleophilic attack of the nitrogen 
atom of MeCN to the cation 105 and cyclisation gives the chloro-oxazine 106. The chloro-
oxazine can be chlorinated again and water added to open the oxazine into the imine 107, 
which is hydrolysed to the product 94.  
 
Scheme 3.54: Proposed mechanism for the dichlorohydration of propargylic alcohols 
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3.4.1 Dichlorohydration of Alkynols  
Encouraged by the simplicity and utility of this protocol with the wider range of substrates 
we decided to investigate whether alkynols could be acceptable substrates for the 
dichlorohydration reaction. Some homopropargylic alcohols and alkynols are commercially 
available (108a-c), however some require synthesis (108d-h).  
 
Scheme 3.55: Homopropargylic alcohol and alkynol formation 
Homopropargylic alcohols 108d-e were synthesised by a ring opening of an epoxide. 
Alkynols 108f-h were synthesised by a Sonogashira coupling of the commercially available 
alkynols and tolyliodide to give the products in excellent yields. These homopropargylic 
alcohols and alkynols were suitable substrates for the dichlorohydration procedure.  
 
Scheme 3.56: Dichlorohydration of alkynols 
We were delighted to find that a number of dichlorolactols were produced in generally 
good to excellent yields. We can produce both five-membered (109a–b, 109d–f) and six-
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membered (109c and 109g) lactols via both endo (109a, 109d–g) and exo (109b–c) 
cyclisation reactions. The 5-membered ring formation is generally more efficient than the 
6-membered ring formation. Looking at the dichlorohydration mechanism, the most 
stabilised vinyl carbocation is formed making the product regioselectively. With alkynol 
109h as the substrate there is no cyclisation to the seven-membered ring, but this example 
shows that a free OH is tolerated in the reaction.  
We wanted to assess the effect of having more than one free alcohol to determine whether 
the 5-membered ring was faster forming or more stable than the 6-membered ring.  
 
Scheme 3.57: Potential synthesis of dichlorobicycle 113 
To test whether the formation of these cyclic-complexes were possible we needed to 
synthesise some alkynyldiols 115a-c. The eneyne 114a was produced from the Sonogashira 
coupling of tolylacetylene with vinyl bromide in good yield. The same reaction was 
attempted with allyl bromide to give the enyne 114b, however no reaction occurred, 
therefore we used a procedure using a CuI source in an aprotic polar solvent (DMF) to give 
the enyne in moderate yield.  The alkenes 114a-b were dihydroxylated with K2OsO4 to give 
the diols 115a-b in adequate yields.  
 
Scheme 3.58: Synthesis of alkynyldiols 
The alkynediol 115c was produced from the reduction of 70d in excellent yield. We 
subjected these alkyndiols to our dichlorohydration conditions.  
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Scheme 3.59: Dichlorohydration of alkynyldiols 
We were happy to synthesise these complex lactols in moderate to excellent yields albeit 
as mixtures of the diastereoisomers.  
We then turned our attention to the possible reactions of the dichlorinated products (94 
and 109) as they appear more stable than the corresponding diiodohydration products.  
 
3.4.2 Reactions of the Dichlorohydration Products  
The dichlorohydration products appear more stable than the related diiodohydration 
products and it was hoped that we could manipulate/derivatise them in a useful way.   
 
Scheme 3.60: Reduction of some of the dichlorohydration products 
Happily, we were able to isolate the diols 117c and 117j from these reductions in excellent 
yields. The dichlorolactol 109f could also be reduced with NaBH4 to the linear diol 118 in 
excellent yield and with triethylsilane (Et3SiH) and BF3.OEt2 we can isolate the 
dichlorotetrahydropyran 119 in very good yield.  
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Scheme 3.61: Reduction of dichlorohydration product 109f 
In addition, a diastereoselective reduction of alcohol 94e with tetramethylammonium 
triacetoxyborohydride gives diol anti-120. 
 
Scheme 3.62: Diasteroselective reduction of dichloride 94e 
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3.5 Conclusion 
We have developed an unprecedented, mild, gold-catalysed reaction for the 
diiodohydration of propargylic alcohols to α,α-diiodo-β-hydroxyketones. This reaction gives 
good to excellent yields on a range of substrates and we have found that enantioenriched 
alcohols retain their enantiopurity. We have proposed plausible mechanisms based on the 
observations seen and intermediates that we have identified and believe the solvent is 
involved in the mechanism via formation of a halo-oxazine intermediate.  
 
We have also developed a non-catalysed dichlorohydration reaction of propargylic alcohols 
to α,α-dichloro-β-hydroxyketones. This reaction occurs without the use of a gold catalyst 
and this is because a more electrophilic halogen source was employed.  
 
This reaction has a wider substrate scope than the diiodohydration reaction and includes 
homoproparglyic alcohols and other alkynols for the synthesis of 5 and 6-membered ring 
dichlorolactols. 
 
We believe that these reactions are of interest to the scientific community due to wide 
substrate scope, facile reaction conditions, and relatively cheap readily available or easy 
synthesised starting materials. The products could be building blocks for pharmaceuticals 
and agrochemicals. 
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3.6 Future Work  
Haloenone formation 
The synthesis of haloenones from propargylic alcohols has been explored in the literature, 
however the use of this protocol only gave adequate yields in our hands (54%). With 
modified Meyer-Schuster conditions with no optimisation we were able to achieve a good 
yield of 71%.  
 
We believe that the Mo-catalyst and Ph3PO are not required for the synthesis of 
iodoenones and it would be interesting to investigate further and optimise the conditions 
to produce other α-haloenones. These products could be useful for Pd cross coupling 
reactions. 
 
Difluorohydration 
After the exploration of the diiodohydrations and dichlorohydrations a natural progression 
was to examine difluorohydrations and dibromohydrations.  
A mild Au-catalysed method to induce a difluorohydration of a propargylic alcohol would 
be of particular importance to the scientific community. This is because late-stage 
fluorination in pharmaceuticals can confer some stability to metabolism and give tunable 
interaction kinetics with proteins. There is one example from the literature with a 
propargylic acetate as the starting material and an IPr ligand (N-heterocyclic carbene) on 
the Au catalyst with excess Selectfluor.86  
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This reaction would be particularly useful in our manipulation of propargylic alcohols. The 
literature reaction conditions were mimicked with the difference being the starting 
material propargylic alcohol 70a was used and the omission of NaHCO3. Unfortunately, no 
reaction was seen under these conditions. Test reactions showed that using the 
electrophilic halogen source Selectfluor or many other F+ sources in place of NIS in our 
diiodohydration conditions does not lead to the formation of the desired difluorohydration 
product.  
 
Entry Reagent (2.1 eq) Result after 24 h 
1 Selectfluor   No reaction 
2 (PhSO2)NF No reaction 
3 XeF2 No reaction 
4 N-Fluoropyridinium triflate No reaction 
5 N-Fluoro-2,4,6-trimethylpyridinium triflate No reaction 
 
In these reactions, no products were seen with just the SM remaining. The reaction is 
potentially possible, however it may require more forcing conditions and optimisation.  
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Dibromohydration 
For a procedure for dibromohydration we began with NBS as an electrophilic bromine 
source in the place of NIS in our gold catalysed diiodohydration procedure. We found that 
we saw no reaction under these conditions (as with NCS).  
 
Using a more potent electrophilic bromine source allows the dibromohydration reaction to 
occur. We found that dibromoisocyanuric acid (DBA) is commercially available and 
explored whether this reagent could induce reaction.  
 
Early results suggest that this protocol can be used for the dibromohydration of propargylic 
alcohols to form α,α-dibromo-β-hydroxyketones. Further results show that alkynols can be 
used to form dibromolactols.  
 
These products give similar NMR spectra to the -chloro and -iodo analogues but the yield 
for these transformations is lower than the other analogues. These reduced yields may be 
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due to reduced reactivity of the halogen source or due to the steric requirements for the 
installation of a gem-dibromide. Further work on the mechanism and limitations of this 
reaction would be useful.  
Diiodides into difluorides 
We are still interested in the potential reactions of these unusual α,α-diiodo-β-
hydroxyketones. With our lack of success in the difluorohydration products, it may be 
possible to convert the diiodides to difluorides using AgBF4. Simple diiodides have been 
coverted into difluorides reported by Mitchell and co-workers in 1987.87 
 
We used these conditions on our diiodide 76c to ascertain whether this more complex 
substrate could be converted into the difluoride 123. This reaction was unsuccessful.  
 
There was an immediate colour change upon the addition of the AgBF4 to the solution 
containing the diiodide from brown to yellow and a yellow precipitate was formed 
(indicating AgI formation). Although the crude reaction mixture did not contain the starting 
material after 1 h, there were no identifiable products seen.  
Iodopyrazoles 
In previous work, we wanted to achieve the synthesis of pyrazoles from propargylic 
alcohols. It could be possible to synthesise iodopyrazoles and these could be interesting 
products in their own right.  
 
The iodopyrazoles could be used in Pd cross-coupling for the synthesis of tetra-substituted 
pyrazoles.   
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Use of dihaloketoalcohols in C-C bond formations 
Forming new C-C bonds is an increasingly important challenge in modern synthetic organic 
chemistry. Fu has reported Kumada-type coupling of a Grignard reagent and a α-
bromoketone in the presence of a transition metal catalyst.88,89 The particular utility of this 
process is that the addition of a ligand can covert a racemic bromide to create a new C-C 
bond regioselectively. 
 
It could be envisaged that the dihalohydration products can be used for the synthesis of 
new products.  
 
Synthesis of geminal dihalide natural products 
A potential use of dihalohydrations is to synthesise natural products: Citreochlorol is a 
metabolite isolated from the mycelia of the Penicillium species.90 
 
Synthesis of aminals and thiolactols 
In this project we have found that alkynols can be used to form dichlorolactols. A natural 
progression would be to examine whether alkynthiols or alkynamines could form 
dichlorinated thiolactols and aminals respectively.  
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The synthesis of substituted pyrrolidines and tetrahydrothiophenes from linear, easily 
synthesised starting materials would be a new route to these structures.91 The benefit of 
this chemistry is the tetrafunctionalisation of an alkyne in one step to give synthetically 
useful products and building blocks. 
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Chapter 4: Experimental 
All reactions were carried out in oven-dried glassware under a nitrogen atmosphere unless 
otherwise indicated. Diethyl ether (Et2O), tetrahydrofuran (THF), toluene (PhMe) and 
dichloromethane (DCM) were used following purification from an anhydrous engineering 
zeolite drying apparatus. All other chemicals were used as supplied unless otherwise 
indicated. Column chromatography was carried out using BDH (40-60 µm) silica gel and 
analytical thin layer chromatography was carried out using Merck Kieselgel aluminium-
backed plates coated with silica gel. Components were visualised using combinations of 
ultra-violet lights and potassium permanganate. Melting points were determined using a 
Reichert hot-stage apparatus and are uncorrected. Optical rotations were measured using a 
Perkin-Elmer 241 or Perkin-Elmer 343 polarimeter (sodium D-line, 529 nm) and [α]
D
 values 
are given in 10-1 deg cm2 g-1, concentration (c) in g per 100 mL. Infrared (IR) spectra were 
recorded on a Perkin-Elmer 1605 Fourier transform spectrometer or a Perkin-Elmer 
spectrum 100 FT-IR spectrometer as thin films. 1H NMR spectra were recorded at 500 MHz 
on a Bruker Avance 500 spectrometer or at 600 MHz on a Bruker Avance 600 spectrometer 
in the stated solvent using residual protic solvent CHCl3 ( = 7.26 ppm, s), as the internal 
standard. Chemical shifts are quoted in ppm using the following abbreviations: s, singlet; d, 
doublet; t, triplet; q, quartet; qn, quintet; sx, sextet; m, multiplet; br, broad or a 
combination of these. The coupling constants (J) are measured in Hertz. 13C NMR spectra 
were recorded at 125 MHz on a Bruker Avance 500 spectrometer or at 150 MHz on a 
Bruker Avance 600 spectrometer in the stated solvent using the central reference of CHCl3 
( = 77.0 ppm, t) as the internal standard. Chemical shifts are reported to the nearest 0.1 
ppm and 0.01 ppm for 13C and 1H respectively. Mass spectra were obtained using either a 
VG70-SE or MAT 900XP spectrometer at the Department of Chemistry, University College 
London.  
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2-(4-Bromophenyl)-4,4-diethoxybutanenitrile (13a) 
 
Potassium t-butoxide (0.63 g, 5.11 mmol) was added to a stirring solution of 4-
bromophenylacetonitrile (1.00 g, 5.10 mmol) and bromoacetaldehyde diethyl acetal (0.77 
mL, 5.10 mmol) in THF (20 mL) at RT. After 48 h, the solution was cooled to 0 °C and ice-
water (15 mL) added. The product was extracted with ether (2 x 15 mL), the solution was 
dried (MgSO4) and filtered before the solution was concentrated under reduced pressure. 
The crude product was purified by flash chromatography (7% EtOAc/petrol) to give the 
acetal 13a. 
Yellow oil, 754 mg, 2.42 mmol, 47%; νmax (film/cm
-1) 3058 (C-H), 2880 (C-H), 2220 (C≡N), 
1683 (C=C), 1583 (C=C), 1488 (C=C), 1394 (C=C); 1H NMR (500 MHz, CDCl3) δ 7.46 (2H, d, J = 
8.4, 2 × ArH), 7.19 (2H, d, J = 8.4, 2 × ArH), 4.54 (1H, dd, J = 6.7, 4.9, OCHO), 3.90 (1H, dd, J = 
9.3, 6.6, CHCN), 3.58 – 3.71 (2H, m, OCH2), 3.41 – 3.58 (2H, m, OCH2), 2.18 (1H, ddd,  J = 
13.8, 9.3, 4.9, CHHCHO2), 2.04 (1H, dt, J = 13.8, 6.6, CHHCHO2), 1.20 (3H, dt, J = 6.9, CH3), 
1.17 (3H, t, J = 7.1, CH3);  
13C NMR (125MHz, CDCl3) δ 134.6, 132.4, 129.1, 122.3, 120.1, 
100.0, 62.7, 62.0, 39.5, 32.8, 15.33, 15.28; LRMS: (CI): 312 ([M+H]+, 10), 267 (90), 238 (50), 
196 (55), 103 (100); HRMS: Found (CI): [M+H]+ 312.06045, C14H19O2NBr requires 312.05991 
 
2-(3-Bromophenyl)-4,4-diethoxybutanenitrile (13b) 
 
Potassium t-butoxide (0.63 g, 5.11 mmol) was added to a stirring solution of 3-
bromophenylacetonitrile (1.00 g, 5.10 mmol) and bromoacetaldehyde diethyl acetal (0.77 
mL, 5.10 mmol) in THF (20 mL) at RT. After 48 h, the solution was cooled to 0 °C and ice-
water (15 mL) added. The product was extracted with ether (2 x 15 mL), the solution was 
dried (MgSO4) and filtered before the solution was concentrated under reduced pressure. 
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The crude product was purified by flash chromatography (7% EtOAc/petrol) to give acetal 
13b.  
Yellow oil, 639 mg, 2.05 mmol, 40%; νmax (film/cm
-1) 2976 (C-H), 2881 (C-H), 2244 (C≡N), 
1596 (C=C), 1571 (C=C), 1475 (C=C), 1429 (C=C); 1H NMR (600 MHz, CDCl3) δ 7.50 (1H, t, J = 
1.7, ArH), 7.46 (1H, br. d, J = 7.9, ArH), 7.29 (1H, br. d,  J = 7.9, ArH) 7.25 (1H, m, ArH), 4.58 
(1H, dd, J =  6.9, 4.7, OCHO), 3.93 (1H, dd, J = 9.4, 6.4, CHCN), 3.63 – 3.74 (2H, m, OCH2), 
3.47 – 3.63 (2H, m, OCH2), 2.22 (1H, ddd,  J = 13.8, 9.4, 4.7, CHH2CHO2), 2.09 (1H, dt, J = 
13.8, 6.8, CHH2CHO2), 1.24 (3H, dt, J = 7.2, CH3), 1.20 (3H, t, J = 7.2, CH3); 
13C NMR (150 
MHz, CDCl3) δ 137.7, 131.5, 130.8, 130.6, 126.2, 123.2, 120.1, 100.1, 62.8, 62.2, 39.6, 33.0, 
15.39, 15.33; LRMS: (CI): 312 ([M+H]+, 20), 268 (65), 103 (100); HRMS: Found (CI): [M+H]+ 
312.06045, C14H19O2NBr requires 312.06018 
 
4-(3-(4-Bromophenyl)-1H-pyrrol-1-yl)benzenesulfonamide (15a) 
 
A solution of 1M diisobutylaluminium hydride in THF (0.86 mL, 0.86 mmol) was added 
dropwise to a solution of 13a (180 mg, 0.57 mmol) in toluene (10 mL) at -78 °C. The 
solution was then allowed to stir for 2 h. MeOH (1 mL) was added and the solution was 
allowed to warm to RT and 2M HCl (10 mL) was added and the solution was stirred for 1 h. 
The product was extracted with ether (3 x 25 mL), organic layers combined and washed 
with brine before being dried (MgSO4), filtered and concentrated under reduced pressure. 
The residue was dissolved in EtOH (5 mL) and TsOH (11 mg, 0.06 mmol) and sulfanilamide 
(98 mg, 0.57 mmol) were added and reacted in the mW at 100 °C for 15 min.  The residue 
was purified by flash chromatography (40% EtOAc/petrol) to give pyrrole 15a. 
Pale yellow solid, 65 mg, 0.24 mmol, 30%; Mp 245 – 247 °C; νmax (film/cm
-1) 3378 (N-H), 
3362 (N-H), 2922 (C-H), 1599 (C=C), 1320 (S=O), 1153 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 
8.11 (1H, t, J = 1.9, NCHC), 7.91 (2H, d, J = 9.0, 2 × ArH), 7.88 (2H, d, J = 9.0, 2 × ArH), 7.64 
(2H, d, J = 8.8, 2 × ArH), 7.59 (1H, d, J = 2.7, NCHCH), 7.54 (2H, d, J = 8.8, 2 × ArH), 7.42 (2H, 
s, NH2), 6.80 (1H, dd, J = 2.7, 1.9, NCHCH); 
13C NMR (150 MHz, DMSO-d6) δ 141.8, 140.6, 
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134.0, 131.6, 127.4, 126.8, 125.5, 120.6, 118.8, 118.6, 116.4, 109.5; LRMS: (ES): 375 ([M-
H]+, 100); HRMS: Found (ES): [M-H]+ 374.9812, C16H12N2O2SBr requires 374.9803 
 
4-(3-(3-Bromophenyl)-1H-pyrrol-1-yl)benzenesulfonamide (15b) 
 
A solution of 1M diisobutylaluminium hydride in THF (0.86 mL, 0.86 mmol) was added 
dropwise to a solution of 13b (180 mg, 0.57 mmol) in toluene (10 mL) at -78 °C. The 
solution was then allowed to stir for 2 h. MeOH (1 mL) was added and the solution was 
allowed to warm to RT and 2M HCl (10 mL) was added and solution was stirred for 1 h. The 
product was extracted with ether (3 x 25 mL), organic layers combined and washed with 
brine before being dried (MgSO4), filtered and concentrated under reduced pressure. The 
residue was dissolved in EtOH (5 mL) and TsOH (11 mg, 0.06 mmol) and sulfanilamide (98 
mg, 0.57 mmol) were added and reacted in the mW at 100 °C for 15 min. The residue was 
purified by flash chromatography (40% EtOAc/petrol) to give pyrrole 15b. 
Pale yellow solid, 56 mg, 0.15 mmol, 26%; Mp 173 – 175 °C; νmax (film/cm
-1) 3370 (N-H), 
3360 (N-H), 2925 (C-H), 1594 (C=C), 1511 (C=C), 1321 (C=C), 1157 (S=O); 1H NMR (600 MHz, 
DMSO-d6) δ 8.18 (1H, t, J 1.8, NCHC), 7.91 (1H, s, ArH), 7.90 (4H, m, 4 × ArH), 7.68 (1H, d, J = 
7.9, ArH), 7.60 (1H, d, J = 2.7, NCHCH), 7.41 (2H, s, NH2), 7.37 (1H, d, J = 8.7, ArH), 7.32 (1H, 
t, J = 7.5, ArH), 6.84 (1H, dd, J = 2.7, 1.8, NCHCH); 13C NMR (150 MHz, DMSO-d6) δ 141.7, 
140.6, 137.2, 130.8, 128.5, 127.4, 127.2, 125.2, 123.7, 122.4, 120.6, 118.8, 116.9, 109.5; 
LRMS: (ES): 377 ([M+H]+, 100); HRMS: Found (ES):  [M+H]+  376.9948, C16H14N2O2SBr 
requires 376.9959  
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(E)-3-(4-Bromophenyl)-1-phenylprop-2-en-1-one (22a) 
 
KOH (505 mg, 9.00 mmol) in water (10 mL) was added to a stirring mixture of 4-
Bromobenzaldehyde (555 mg, 3.00 mmol) and acetophenone (360 mg, 3.00 mmol) in EtOH 
(10 mL) at 0 °C and the reaction stirred for 1 h at RT. A precipitate formed and this was 
filtered and washed with water (2 x 10 mL) and dried under reduced pressure to give 
alkene 22a.  
Yellow powder, 749 mg, 2.61 mmol, 87%; Mp 115-118 °C [126-129 °C]92; νmax (film/cm
-1) 
1657 (C=O), 1607 (C=C), 1485 (Ar); 1H NMR (500 MHz, CDCl3) δ 8.01 (2H, dd, J = 8.3, 1.2, 2 × 
ArH), 7.74 (1H, d, J = 15.8, COCH), 7.57 - 7.62 (1H, m, ArH), 7.48 - 7.57 (7H, m,7 × ArH); 13C 
NMR (125MHz, CDCl3) δ 190.3, 143.4, 138.1, 133.9, 133.0, 132.3, 129.9, 128.8, 128.6, 
124.9, 122.7 
 
(E)-3-(4-Chlorophenyl)-1-phenylprop-2-en-1-one (22b)92 
 
KOH (505 mg, 9.00 mmol) in water (10 mL) was added to a stirring mixture of 4-
Chlorobenzaldehyde (420 mg, 3.00 mmol) and acetophenone (360 mg, 3.00 mmol) in EtOH 
(10 mL) at 0 °C and the reaction stirred for 1 h at RT. A precipitate formed and this was 
filtered and washed with water (2 x 10 mL) and dried under reduced pressure to give the 
alkene 22b.  
Yellow powder, 627 mg, 2.58 mmol, 86%; Mp 104-106 °C [114-117 °C]92; νmax (film/cm
-1) 
1658 (C=O), 1603 (C=C), 1489 (Ar); 1H NMR (500 MHz, CDCl3) δ 7.98 – 8.05 (2H, m, 2 × ArH), 
7.75 (1H, d, J = 15.8, COCH), 7.54 - 7.62 (3H, m, 3 × ArH), 7.54 - 7.47 (3H, m, 3 × ArH), 7.39 
(2H, d, J = 8.5, 2 × ArH); 13C NMR (125MHz, CDCl3) δ 190.3, 143.4, 138.1, 136.5, 133.5, 
133.0, 129.7, 129.3, 128.8, 128.6, 122.5 
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(E)-3-(3-Bromophenyl)-1-phenylprop-2-en-1-one (22c)93 
 
KOH (505 mg, 9.00 mmol) in water (10 mL) was added to a stirring mixture of 3-
Bromobenzaldehyde (555 mg, 3.00 mmol) and acetophenone (360 mg, 3.00 mmol) in EtOH 
(10 mL) at 0 °C and the reaction stirred for 1 h at RT. A precipitate formed and this was 
filtered and washed with water (2 x 10 mL) and dried under reduced pressure to give 
alkene 22c. 
Yellow powder, 695 mg, 2.42 mmol, 81%; Mp 75-78 °C [83-85 °C]93; νmax (film/cm
-1) 1665 
(C=O), 1607 (C=C), 1314 (Ar); 1H NMR (500 MHz, CDCl3) δ 8.00 - 8.05 (2H, m, 2 × ArH), 7.78 
(1H, t, J = 1.7, ArH), 7.71 (1H, d, J = 15.8, COCH), 7.57 - 7.62 (1H, m, ArH), 7.48 - 7.55 (5H, m, 
5 × ArH), 7.28 (1H, t, J = 7.9, ArH); 13C NMR (125MHz, CDCl3) δ 190.1, 143.0, 138.0, 137.1, 
133.3, 133.1, 130.9, 130.6, 128.8, 128.6, 127.3, 123.3, 123.2 
 
General Procedure A: acetophenone to 1,4-diketone  
A solution of KOH (3 eq.) in water (1M) was added to a stirring mixture of aldehyde (1 eq.) 
and acetophenone (1 eq.) in EtOH (1M) at 0 °C and the reaction stirred for 1 h at RT. A 
precipitate formed and this was filtered and washed with water (2 x 10 mL) and dried to 
give the mixture of E and Z alkenes.  CsCO3 (0.10 eq.) was added to a stirring solution of 
alkenes (1 eq.), 3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (0.10 eq.) and 
freshly distilled acetaldehyde (10 eq.) in anhydrous THF (1M) at RT. After 24 h, the reaction 
was quenched with water (1 mL) before the product extracted with EtOAc (2 x 2 mL), the 
combined organic phase was dried (MgSO4), filtered and concentrated under reduced 
pressure. The residue was purified by flash chromatography (EtOAc/petrol) to give the 
diketone.  
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3-(4-Bromophenyl)-1-phenylpentane-1,4-dione (24a)46 
 
General Procedure A: acetophenone to 1,4-diketone  
Colourless oil, 115 mg, 0.35 mmol, 70%; νmax (film/cm
-1) 1715 (C=O), 1683 (C=O), 1596 
(C=C), 1485 (C=C); 1H NMR (600 MHz, CDCl3) δ 7.93 - 7.96 (2H, m, 2 × ArH), 7.54 - 7.58 (1H, 
m, ArH), 7.47 - 7.50 (2H, m, 2 × ArH), 7.43 - 7.46 (2H, m, 2 × ArH), 7.16 - 7.19 (2H, m, 2 × 
ArH), 4.40 (1H, dd, J = 9.8, 4.0, COCH), 3.97 (1H, dd, J = 18.1, 9.8, COCHH), 3.13 (1H, dd, J = 
18.1, 4.0, COCHH), 2.22 (3H, s, CH3); 
13C NMR (150 MHz, CDCl3) δ 206.9, 197.9, 137.0, 136.4, 
133.5, 132.4, 130.4, 128.8, 128.2, 121.8, 53.3, 42.3, 29.4 
 
3-(4-Chlorophenyl)-1-phenylpentane-1,4-dione (24b)  
 
General Procedure A: acetophenone to 1,4-diketone  
Colourless oil, 30 mg, 0.31 mmol, 62%; νmax (film/cm
-1) 1716 (C=O), 1683 (C=O), 1596 (C=C), 
1489 (C=C); 1H NMR (600 MHz, CDCl3) δ 7.95 (2H, dd, J = 8.3, 1.1, 2 × ArH), 7.54 - 7.58 (1H, 
m, ArH), 7.43 - 7.47 (2H, m, 2 × ArH), 7.31 - 7.35 (2H, m, 2 × ArH) 7.22 - 7.25 (2H, m, 2 × 
ArH), 4.41 (1H, dd, J = 9.9, 3.9, COCH), 3.97 (1H, dd, J = 18.1, 9.9, COCHH), 3.13 (1H, dd, J = 
18.1, 3.9, COCHH), 2.22 (3H, s, CH3); 
13C NMR (150 MHz, CDCl3) δ 207.0, 198.0, 136.5, 136.4, 
133.7, 133.5, 129.8, 129.4, 128.7, 128.2, 53.3, 42.3, 29.4; LRMS: (ES):  287 ([M+H]+, 100), 
278 (50); HRMS: Found (ES): [M+H]+ 287.0832, C17H16O2Cl requires 287.0839 
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3-(3-Bromophenyl)-1-phenylpentane-1,4-dione (24c)  
 
General Procedure A: acetophenone to 1,4-diketone  
Colourless oil, 103 mg, 62%; νmax (film/cm
-1) 1715 (C=O), 1682 (C=O), 1596 (C=C), 1449 
(C=C); 1H NMR (600 MHz, CDCl3) δ 7.93 - 7.96 (2H, m, 2 × ArH), 7.53 - 7.58 (1H, m, ArH), 
7.41 - 7.46 (4H, m, 4 × ArH), 7.20 - 7.24 (2H, m, 2 × ArH), 4.39 (1H, dd, J = 10.1, 3.7, COCH), 
3.98 (1H, dd, J = 18.1, 10.1, COCHH), 3.13 (1H, dd, J = 18.1, 3.7, COCHH), 2.23 (3H, s, CH3); 
13C NMR (150 MHz, CDCl3) δ 206.7, 197.8, 140.3, 136.3, 133.5, 131.4, 131.0, 130.8, 128.8, 
128.2, 127.2, 123.3, 53.5, 42.4, 29.5; LRMS: (ES):  331 ([M+H]+, 100); HRMS: Found (ES): 
[M+H]+ 331.0318, C17H16O2Br requires 331.0334 
 
3-(4-Fluorophenyl)-1-phenylpentane-1,4-dione (24d) 
 
General Procedure A: acetophenone to 1,4-diketone  
Colourless oil, 185 mg, 50%;  νmax (film/cm
-1) 3067 (C-H), 1716 (C=O), 1683 (C=O), 1508 
(C=C); 1H NMR (600 MHz, CDCl3) δ 7.95 (2H, d, J = 8.3, 2 × ArH), 7.56 (1H, t, J = 7.4, ArH), 
7.45 (2H, t, J = 7.4, 2 × ArH), 7.24 - 7.28 (2H, m, 2 × ArH), 7.05 (2H, m, 2 × ArH), 4.42 (1H, dd, 
J = 9.9, 4.1, COCH), 3.97 (1H, dd, J = 18.1, 9.9, COCHH), 3.13 (1H, dd, J = 18.1, 4.1, COCHH), 
2.22 (3H, s, CH3); 
13 C NMR (150 MHz, CDCl3) δ 207.3, 198.1, 162.4 (d, J =246.2), 136.4, 133.8 
(d, J = 3.6), 133.7, 130.0 (d, J = 7.8), 128.7, 128.2, 116.2 (d, J = 21.5), 53.1, 42.5, 29.3; LRMS: 
(EI): 270 ([M]+, 50), 228 (90), 105 (100); HRMS: Found (EI):  [M]+ 270.10550, C17H15O2F 
requires 270.10506 
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3-(4-Iodophenyl)-1-phenylpentane-1,4-dione (24e) 
 
General Procedure A: acetophenone to 1,4-diketone  
Colourless oil, 148 mg, 60%; νmax (film/cm
-1) 3059 (C-H), 1714 (C=O), 1681 (C=O), 1482 
(C=C); 1H NMR (600 MHz, CDCl3) δ 7.94 (2H, d, J = 7.5, 2 × ArH),  7.68 (2H, d, J = 8.3, 2 × 
ArH), 7.56 (1H, t, J = 7.5, ArH), 7.45 (2H, t, J = 7.5, 2 × ArH), 7.05 (2H, d, J = 8.3, 2 × ArH), 
4.37 (1H, dd, J = 9.8, 3.9, COCH), 3.96 (1H, dd, J = 18.0, 9.8, COCHH), 3.12 (1H, dd, J = 18.0, 
3.9, COCHH), 2.22 (3H, s, CH3); 
13 C NMR (150 MHz, CDCl3) δ 206.9, 197.9, 138.4, 137.7, 
136.4, 133.5, 130.4, 128.8, 128.8, 93.3, 53.5, 42.3, 29.4; LRMS: (EI): 378 ([M]+, 40), 336 (30), 
105 (100); HRMS: Found (EI): [M]+ 378.01119, C17H15O2I requires 378.01112 
 
3-(4-Bromophenyl)-2-methyl-5-phenylfuran (25) 
 
TsOH (5 mg, 0.03 mmol) was added to ketone 24a (91 mg, 0.28 mmol) and sulfanilamide 9 
(48 mg, 0.28 mmol) in MeOH (5 mL) and reacted in the μW at 120 °C for 1 h. EtOAc (10 mL) 
and saturated NaHCO3 (5 mL) were added and the product was extracted with EtOAc (3 x 
10 mL) before the solution was dried (MgSO4), filtered and concentrated under reduced 
pressure to give the crude product. The residue was purified by flash chromatography 
(EtOAc/petrol) to give furan 25. 
Yellow oil, 25 mg, 29%; νmax (film/cm
-1) 2985 (C-H), 1479 (C=C), 1465 (C=C), 1373 (C=C); 1H 
NMR (600 MHz, CDCl3) δ 7.67 (2H, d, J = 7.5, 2 × ArH), 7.53 (2H, d, J = 8.3, 2 × ArH), 7.39 
(2H, t, J = 7.5, 2 × ArH), 7.30 (2H, d, J = 8.3, 2 × ArH), 7.25 (1H, t, J = 7.5, ArH), 6.74 (1H, s, 
OCCHC), 1.56 (3H, s, CH3); 
13C NMR (150 MHz, CDCl3) δ 152.0, 147.9, 133.1, 131.8, 130.7, 
129.2, 128.8, 127.3, 123.6, 122.2, 120.4, 106.2, 13.3; LRMS: (CI):  313 ([M+H]+, 70), 277 
Chapter 4  Experimental  
105 
 
(30), 234 (20), 89 (100); HRMS: Found (CI): [M+H]+ 313.02350, C17H14OBr requires 
313.02280 
 
General Procedure B: Pyrrole Formation  
TsOH (0.1 eq.) was added to ketone (1 eq.) and sulfanilamide (3 eq.) in MeOH (5M)  and 
reacted in the mW at 100 °C for 1 h. EtOAc (10 mL) and saturated NaHCO3 (5 mL) were 
added and the product was extracted with EtOAc (3 x 10 mL) before the solution was dried 
(MgSO4), filtered and concentrated under reduced pressure to give the crude product. The 
residue was purified by flash chromatography (EtOAc/petrol) to give the pyrrole. 
 
4-(3-(4-Bromophenyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl)benzenesulfonamide (26a) 
 
General Procedure B: pyrrole formation  
Yellow solid, 11 mg, 0.02 mmol, 79%; Mp 214 – 218 °C; νmax (film/cm
-1) 3410 (N-H), 1656 
(C=C), 1218 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.87 (2H, d, J = 8.7, 2 × ArH), 7.60 (2H, d, 
J = 7.9, 2 × ArH), 7.51 (2H, s, NH2), 7.47 (2H, d, J = 8.1, 2 × ArH), 7.45 (2H, d, J = 8.7, 2 × ArH), 
7.22 (2H, t, J = 8.1, 2 × ArH), 7.15 (1H, t, J = 8.1, ArH), 7.09 (2H, d, J = 7.9, 2 × ArH), 6.64 (1H, 
s, CH on pyrrole), 2.17 (3H, s, CH3); 
13C NMR (150 MHz, DMSO-d6) δ 143.3, 141.2, 135.4, 
133.5, 132.4, 131.5, 129.6, 129.1, 128.4, 128.0, 127.7, 126.8, 126.4, 121.3, 118.6, 109.7, 
12.3; LRMS: (ES): 465 ([M-H]+, 100); HRMS: Found (ES) [M-H]+ 465.0255, C23H18O2N2SBr 
requires 465.0272 
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4-(3-(4-Chlorophenyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl)benzenesulfonamide (26b) 
 
General Procedure B: pyrrole formation  
Yellow solid, 10 mg, 78%; Mp 236 – 240 °C; νmax (film/cm
-1) 3627 (N-H), 1421 (C=C), 1359 
(S=O), 1220 (S=O); 1H NMR (500 MHz, DMSO-d6) δ 7.87 (2H, d, J = 8.5, 2 × ArH)), 7.42 - 7.53 
(8H, m, NH2, 6 × ArH), 7.21 (2H, t, J  = 7.4, 2 × ArH), 7.14 (1H, m, ArH), 7.08 (2H, d, J = 8.5, 2 
× ArH), 6.62 (1H, s, CH on pyrrole), 2.16 (3H, s, CH3); 
13C NMR (125 MHz, DMSO-d6) δ143.3, 
141.2, 135.0, 133.4, 132.4, 130.1, 129.2, 129.0, 128.5, 128.3, 127.9, 127.6, 126.7, 126.4, 
121.3, 109.7, 12.2; LRMS: (ES): 423 ([M+H]+, 100); HRMS: Found (ES): [M+H]+ 423.0944, 
C23H20O2N2SCl requires 423.0934 
 
4-(3-(3-Bromophenyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl)benzenesulfonamide (26c) 
 
General Procedure B: pyrrole formation  
Yellow solid, 15 mg, 76%; Mp 202 – 204 °C; νmax (film/cm
-1) 3567 (N-H), 1420 (C=C), 1359 
(S=O), 1220 (S=O); 1H NMR (500 MHz, DMSO-d6) δ 7.87 (2H, d, J = 8.5, 2 × ArH), 7.65 (1H, t, 
J = 1.7, ArH), 7.44 – 7.50 (5H, m, NH2, 3 × ArH), 7.41 – 7.44 (1H, m, ArH), 7.37 (1H, t, J = 7.7, 
ArH), 7.21 (2H, t, J = 7.2, 2 × ArH), 7.12 – 7.16 (1H, m, ArH), 7.09 (2H, d, J = 8.5, 2 × ArH), 
6.66 (1H, s, CH on pyrrole), 2.17 (3H, s, CH3); 
13C NMR (125MHz, DMSO-d6) δ 143.3, 141.1, 
138.7, 133.5, 132.3, 130.6, 129.9, 129.0, 128.3, 128.2, 127.6, 126.7, 126.5, 126.4, 122.0, 
121.0, 109.8, 12.2; LRMS: (ES): 465 ([M-H]+, 100); HRMS: Found (ES): [M-H]+ 465.0273, 
C23H18O2N2SBr requires 465.0255 
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4-(3-(4-Fluorophenyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl)benzenesulfonamide (26d) 
 
General Procedure B: pyrrole formation  
Yellow oil, 18 mg, 65%; νmax (film/cm
-1) 3277 (N-H), 3059 (C-H), 1596 (C=C), 1498 (C=C), 
1297 (S=O), 1167 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.87 (2H, d, J = 8.7, 2 × ArH), 7.49 - 
7.52 (2H, m, 2 × ArH), 7.51 (2H, s, NH2) , 7.47 (2H, d, J = 8.7, 2 × ArH), 7.25 (2H, t, J = 8.8, 2 × 
ArH), 7.22 (2H, t, J = 7.5, 2 × ArH), 7.15 (1H, t, J = 6.8, ArH), 7.09 (2H, d, J = 8.7, 2 × ArH), 
6.61 (1H, s, CH on pyrrole), 2.16 (3H, s, CH3); 
13 C NMR (150 MHz, DMSO-d6) δ 160.6 (d, J = 
242.0), 143.2, 141.3, 133.2, 132.6 (d, J = 3.0), 132.4, 129.4 (d, J = 7.7), 129.1, 128.4, 127.6, 
126.7, 126.3, 121.61, 121.58, 115.4 (d, J = 21.5), 109.9, 12.2; LRMS: (ES):  405 ([M-H]+, 100 ); 
HRMS: Found  (ES): [M-H]+  405.1080, C23H18N2O2SF requires 405.1073 
 
4-(3-(4-Iodophenyl)-2-methyl-5-phenyl-1H-pyrrol-1-yl)benzenesulfonamide (26e) 
 
General Procedure B: pyrrole formation  
Yellow oil, 21 mg, 72%; νmax (film/cm
-1) 3245 (N-H), 2922 (C-H), 2593 (C=C), 1326 (S=O), 
1155 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.87 (2H, d, J = 8.7, 2 × ArH), 7.76 (2H, d, J = 8.3, 
2 × ArH), 7.51 (2H, s, NH2), 7.47 (2H, d, J = 8.7, 2 × ArH), 7.31 (2H, d, J = 8.3, 2 × ArH), 7.22 
(2H, t, J = 7.2, 2 × ArH), 7.15 (1H, t, J = 7.2, ArH), 7.08 (2H, d, J = 7.2, 2 × ArH), 6.63 (1H, s, CH 
on pyrrole), 2.17 (3H, s, CH3); 
13 C NMR (150 MHz, DMSO-d6) δ 143.3, 141.2, 137.3, 135.7, 
133.5, 132.4, 129.8, 129.1, 128.4, 128.0, 127.7, 126.8, 126.4, 121.4, 109.6, 91.1, 12.3; 
LRMS: (ES): 513 ([M-H]+, 100); HRMS: Found (ES): [M-H]+ 513.0145, C23H18N2O2SI requires 
513.0134 
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3-(4-Bromophenyl)-1-(pyridin-2-yl)pentane-1,4-dione (28a) 
 
General Procedure A: acetophenone to 1,4-diketone  
Colourless oil, 48 mg, 22%; νmax (film/cm
-1) 2924 (C-H), 1715 (C=O), 1696 (C=O), 1486 (C=C); 
1H NMR (500 MHz, CDCl3) δ 8.66 (1H, dq, J = 4.7, 1.2, ArH), 7.98 (1H, dt, J = 7.8, 1.2, ArH), 
7.82 (1H, td, J = 7.8, 1.2, ArH), 7.44 - 7.48 (3H, m, 3 × ArH), 7.18 (2H, d, J = 8.4, 2 × ArH), 
4.35 (1H, dd, J = 10.2, 3.9, COCH), 4.19 (1H, dd, J = 18.9, 10.2, COCHH), 3.40 (1H, dd, J = 
18.9, 3.9, COCHH), 2.20 (3H, s, CH3); 
13 C NMR (125MHz, CDCl3) δ 206.8, 199.6, 152.9, 149.1, 
137.1, 137.0, 132.2, 130.2, 127.4, 121.9, 121.7, 53.5, 41.4, 29.2; LRMS: (ES): 332 ([M+H]+, 
100), 273 (80%); HRMS: Found (ES): [M+H]+  332.0287, C16H15NO2Br requires 332.0286 
 
3-(4-Bromophenyl)-1-(pyridin-3-yl)pentane-1,4-dione (28b) 
 
General Procedure A: Acetophenone to 1,4-diketone  
Colourless oil, 88 mg, 42%; νmax (film/cm
-1) 2911 (C-H), 1707 (C=O), 1685 (C=O), 1584 (C=C); 
1H NMR (600 MHz, CDCl3) δ 9.11 (1H, s, ArH), 8.71 (1H, d, J = 2.3, ArH), 8.15 (1H, dt, J = 7.9, 
2.3, ArH), 7.43 (2H, d, J = 8.5, 2 × ArH), 7.35 (1H, dd, J = 7.9, 4.9, ArH), 7.12 (2H, d, J = 8.5, 2 
× ArH), 4.35 (1H, dd, J = 10.2, 3.8, COCH), 3.91 (1H, dd, J = 18.1, 10.2, COCHH), 3.05 (1H, dd, 
J = 18.1, 3.8, COCHH), 2.14 (3H, s, CH3); 
13 C NMR (150 MHz, CDCl3) δ 206.5, 196.8, 153.8, 
149.6, 136.6, 135.5, 132.5, 131.7, 130.1, 123.8, 122.0, 53.2, 42.2, 29.2; LRMS: (ES): 332 
([M+H]+, 100), 289 (50); HRMS: Found (ES): [M+H]+  332.0272, C16H15NO2Br requires 
332.0286 
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4-(3-(4-Bromophenyl)-2-methyl-5-(pyridin-2-yl)-1H-pyrrol-1-yl)benzenesulfonamide (29a) 
 
General Procedure B: pyrrole formation  
Yellow oil, 15 mg, 34%; νmax (film/cm
-1) 3265 (N-H), 3068 (C-H), 1592 (C=C), 1484 (C=C), 
1334 (S=O), 1163 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 8.22 (1H, td, J = 2.4, 0.9, ArH), 7.87 
(2H, d, J = 8.7, 2 × ArH), 7.66 (1H, td, J = 7.6, 1.7, ArH), 7.61 (2H, d, J = 8.3, 2 × ArH), 7.50 
(2H, s, NH2), 7.45 (2H, d, J = 8.7, 2 × ArH), 7.46 (2H, d, J = 8.3, 2 × ArH), 7.35 (1H, d, J = 7.6, 
ArH), 7.07 (1H, ddd, J = 7.6, 4.8, 0.9, ArH), 6.97 (1H, s, CH on pyrrole), 2.15 (3H, s, CH3); 
13 C 
NMR (150 MHz, DMSO-d6) δ 150.7, 148.7, 143.0, 142.1, 136.5, 135.2, 132.8, 131.5, 129.6, 
128.7, 126.5, 121.5, 121.4, 120.9, 118.8, 111.7, 12.3; LRMS: (ES): 468 ([M+H]+, 100); HRMS: 
Found (ES): [M+H]+ 468.0399, C22H19N3O2SBr requires 468.0381 
 
4-(3-(4-Bromophenyl)-2-methyl-5-(pyridin-3-yl)-1H-pyrrol-1-yl)benzenesulfonamide (29b) 
 
General Procedure B: pyrrole formation  
Yellow oil, 18 mg, 38%; νmax (film/cm
-1) 3333 (N-H), 2965 (C-H), 1593 (C=C), 1485 (C=C), 
1345 (S=O), 1164 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 8.34 (1H, dd, J = 4.5, 1.5, ArH), 8.33 
(1H, d, J = 1.5, ArH), 7.90 (2H, d, J = 8.3, 2 × ArH), 7.62 (2H, d, J = 8.7, 2 × ArH), 7.53 (2H, s, 
NH2), 7.52 (1H, d, J = 8.7, 2 × ArH), 7.46 (1H, d, J = 8.3, 2 × ArH), 7.42 (1H, dt, J = 8.0, 1.9, 
ArH), 7.25 (1H, dd, J = 8.0, 4.5, ArH), 6.80 (1H, s, CH on pyrrole), 2.19 (3H, s, CH3); 
13 C NMR 
(150 MHz, DMSO-d6) δ 148.1, 147.2, 143.6, 140.7, 135.2, 134.6, 131.5, 130.1, 129.6, 129.2, 
129.0, 128.3, 126.9, 123.4, 121.6, 118.8, 110.7, 12.3; LRMS: (ES): 468 ([M+H]+, 100), 389 
(20); HRMS: Found (ES): [M+H]+  468.0381, C22H19N3O2SBr requires 468.0381 
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4-(3-(4-Bromophenyl)-5-(furan-2-yl)-2-methyl-1H-pyrrol-1-yl)benzenesulfonamide (32) 
 
General Procedure B: pyrrole formation  
Yellow oil, 16 mg, 23% over 2 steps; νmax (film/cm
-1) 2921 (C-H), 2590 (C=C), 1329 (S=O), 
1157 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.98 (2H, d, J = 8.3, 2 × ArH), 7.60 (4H, d, J = 8.3, 
4 × ArH), 7.57 (2H, s, NH2), 7.53 (1H, s, OCH), 7.43 (2H, d, J = 8.3, 2 × ArH), 6.73 (1H, s, CH on 
pyrrole), 6.35 (1H, m, ArH), 5.46 (1H, d, J = 3.4, ArH), 2.12 (3H, s, CH3); 
13 C NMR (150 MHz, 
DMSO-d6) δ 146.4, 144.2, 141.7, 140.9, 135.1, 131.5, 129.5, 129.2, 128.2, 127.0, 124.5, 
121.0, 118.7, 111.2, 108.1, 105.1, 11.9; LRMS: (ES): 457 (M+H]+, 100), 370 (40), 332 (40), 
279 (40); HRMS: Found (ES): [M+H]+ 457.0196, C21H18N2O3SBr requires 457.0222 
 
2-(4-Sulfamoylphenyl)hydrazin-1-ium chloride (33) 
 
Sulfanilamide (1.16 g, 6.7 mmol) was added to a stirring conc. HCl (5 mL) at RT then cooled 
to -5 °C. A solution of NaNO2 (489 mg, 7.1 mmol) in water (3 mL) was added to the reaction 
mixture dropwise over 5 min, then allowed to stir for 1 h. The solution was then cooled to -
20 °C before the addition of SnCl2 (2.9 g, 12.1 mmol) in conc. HCl (3 mL) dropwise over 5 
mins. The solution was stirred at RT for 1 h before the precipitate was filtered and washed 
with water to give hydrazine 33. 
Orange powder, 1.06 g, 85%; Mp 210 – 212 °C; νmax (film/cm
-1) 3257 (N-H), 3000 (C-H), 1594 
(C=C), 1513 (C=C), 1315 (S=O), 1159 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 10.41 (2H, br. s, 
NHNH2), 8.84 (1H, br. s, NHNH2), 7.69 (2H, d, J = 8.7, 2 × ArH), 7.19 (2H, br. s, SO2NH2), 7.01 
(2H, d, J = 8.7, 2 × ArH); 13C NMR (150 MHz, DMSO-d6) δ 148.3, 136.2, 126.9, 113.3; LRMS: 
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(CI): 187 ([M-Hl]+, 70), 172 ([M-NH3]
+, 70), 156 (100); HRMS: Found (CI): [M-Hl]+ 
187.040892, C6H9N3O2S requires 187.04100 
 
General Procedure C: Acetophenone to Pyrazoline  
KOH (3 eq.) in water (1M) was added to a stirring mixture of aldehyde (1 eq.) and 
acetophenone (1 eq.) in EtOH (1M) at 0 °C and the reaction stirred for 1 h at RT. A 
precipitate formed and this was filtered and washed with water (2 x 10 mL) and dried to 
give the mixture of E and Z alkenes.  2-(4-Sulfamoylphenyl)hydrazin-1-ium chloride 33 (1.5 
eq.)  and alkenes (1 eq.) in EtOH (2 mmolmL-1) were heated to 100 °C for 12 h. After which 
the solvent was removed under reduced pressure and the residue was purified by flash 
chromatography (EtOAc /petrol) to give the pyrazoline.  
 
4-(3-(4-Bromophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide (37a) 
 
General Procedure C: Acetophenone to pyrazoline  
Yellow oil, 68mg, 87%; νmax (film/cm
-1) 3249 (N-H), 2924 (C-H), 1592 (C=C), 1506 (C=C), 1329 
(S=O), 1154 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.73 (2H, d, J = 8.7, 2 × ArH), 7.65 (2H, d, 
J = 8.7, 2 × ArH,), 7.58 (2H, d, J = 9.0, 2 × ArH), 7.34 (1H, t, J = 7.5, ArH), 7.23 - 7.28 (2H, m, 2 
× ArH), 7.08 (2H, d, J = 9.0, 2 × ArH), 7.03 - 7.05 (2H, m, 2 × ArH), 5.67 (1H, dd, J = 12.3, 5.3, 
CH), 3.97 (1H, dd, J = 17.6, 12.3, CHH),  3.19 (1H, dd, J = 17.6, 5.3, CHH); 13 C NMR (150 MHz, 
DMSO-d6) δ = 157.1, 148.7, 145.7, 141.5, 133.3, 131.7, 129.2, 128.0, 127.7, 127.2, 125.8, 
122.5, 112.1, 62.5, 42.8; LRMS: (EI): 455 ([M]+, 100), 403 (30); HRMS: Found (EI): [M]+ 
455.03041, C21H18O2N3SBr requires 455.02976
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4-(3-(4-Bromophenyl)-5-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide 
(37b) 
 
General Procedure C: Acetophenone to pyrazoline  
Orange oil, 30 mg, 37%; νmax (film/cm
-1) 3256 (N-H), 2935 (C-H), 1593 (C=C), 1506 (C=C), 
1326 (S=O), 1155 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.75 (2H, d, J = 8.5, 2 × ArH), 7.66 
(2H, d, J = 8.5, 2 × ArH), 7.62 (2H, d, J = 9.0, 2 × ArH), 7.56 (1H, d, J = 1.9, OCH), 7.23 (2H, d, J 
= 9.0, 2 × ArH), 7.08 (2H, s, NH2), 6.51 (1H, d, J = 3.0, OCCH), 6.38 (1H, dd, J = 3.0, 1.9, 
OCHCH), 5.80 (1H, dd, J = 12.1, 4.9, CH), 3.82 (1H, dd, J = 17.4, 12.1, CHH), 3.43 (1H, dd, J = 
17.4, 4.9, CHH); 13C NMR (150 MHz, DMSO-d6) δ 152.1, 149.0, 145.7, 143.2, 133.6, 131.8, 
131.0, 128.0, 127.1, 122.5, 112.3, 110.4, 108.4, 56.1, 38.1; LRMS: (EI): 445 ([M]+, 20), 379 
(30), 84 (100); HRMS: Found (EI): [M]+ 445.00948, C19H16O3N3SBr requires 445.00903  
 
4-(3-(4-Bromophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide 
(37c) 
 
General Procedure C: Acetophenone to pyrazoline  
Orange solid, 64 mg, 69%; Mp 89 – 94 °C; νmax (film/cm
-1) 3360 (N-H), 2971 (C-H), 1593 
(C=C), 1366 (N-O), 1349 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 8.22 (2H, d, J = 9.0, 2 × ArH), 
7.73 (2H, d, J = 8.7, 2 × ArH), 7.65 (2H, d, J = 8.7, 2 × ArH), 7.60 (2H, d, J = 9.0, 2 × ArH), 7.53 
(2H, d, J = 8.7, 2 × ArH), 7.09 (2H, d, J = 8.7, 2 × ArH), 7.08 (2H, s, NH2), 5.86 (1H, dd, J = 
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12.1, 5.1, CH), 4.02 (1H, dd, J = 18.0, 12.1, CHH), 3.25 (1H, dd, J = 18.0, 5.1 CHH); 13C NMR 
(150 MHz, DMSO-d6) δ 148.92, 148.90, 147.0, 145.4, 133.7, 131.8, 130.8, 128.1, 127.4, 
127.3, 124.5, 122.7, 112.2, 61.9, 42.4; LRMS: (ES): 499 ([M-H]+, 100), 318 (40); HRMS: 
Found (ES): [M-H]+ 499.0097, C21H16O4N4SBr requires 499.0076 
 
 4-(3-(4-Bromophenyl)-5-(4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-1-
yl)benzenesulfonamide (37d) 
 
General Procedure C: Acetophenone to pyrazoline  
Orange solid, 133 mg, 13%, Mp 129 – 132 °C; νmax (film/cm
-1) 3330 (O-H), 2962 (C-H), 1592 
(C=C), 1510 (C=C), 1328 (S=O), 1151 (S=O); 1H NMR (600 MHz, DMSO-d6) δ  9.44 (1H, s, OH), 
7.72 (2H, d, J = 8.7, 2 × ArH), 7.64 (2H, d, J = 8.3, 2 × ArH), 7.58 (2H, d, J = 8.7, 2 × ArH), 7.08 
(2H, d, J = 8.7, 2 × ArH), 7.05 (2H, d, J = 8.3, 2 × ArH), 7.03 (2H, s, NH2), 6.70 (2H, d, J = 8.7, 2 
× ArH), 5.53 (1H, dd, J  = 12.1, 5.2, CH), 3.90 (1H, dd, J = 17.7, 12.1 CHH), 3.14 (1H, dd, J = 
17.7, 5.2 CHH); 13 C NMR (150 MHz, DMSO-d6) δ 156.8, 148.6, 145.8, 133.2, 131.69, 131.71, 
131.2, 128.0, 127.1, 127.0, 122.4, 115.8, 112.2, 62.3, 42.8; LRMS: (ES): 470 ([M-H]+, 100), 
301 (20), 276 (20); HRMS: Found (ES): [M-H]+  470.0182, C21H17O2N3SBr requires 470.0174 
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4-(3-(4-Bromophenyl)-5-(perfluorophenyl)-4,5-dihydro-1H-pyrazol-1-
yl)benzenesulfonamide (37e) 
  
General Procedure C: Acetophenone to pyrazoline  
Yellow powder, 29 mg, 33%, Mp 219 – 222 °C; νmax (film/cm
-1) 3350 (N-H), 2970 (C-H), 1645 
(C=C), 1368 (S=O), 991 (C-F);  1H NMR (600 MHz, DMSO-d6) δ 7.73 (2H, d, J = 8.7, 2 × ArH), 
7.68 (2H, d, J = 8.7, 2 × ArH), 7.65 (2H, d, J = 9.0, 2 × ArH), 7.12 (2H, s, NH2), 7.06 (2H, d, J = 
9.0, 2 × ArH), 6.02 (1H, dd, J = 13.1, 5.3, CH), 4.01 (1H, dd, J = 17.8, 13.1 CHH), 3.52 (1H, dd, 
J = 17.8, 5.3, CHH); 13C NMR (150 MHz, DMSO-d6) δ 149.2, 145.1, 134.1, 131.8, 130.6, 128.0, 
127.5, 122.8, 111.8, 52.7, 40.1 - peaks missing due to multiple couplings with 19F; LRMS: 
(ES): 554 ([M-H]+, 100); HRMS: Found (ES): [M-H]+ 543.9784, C21H12O2F5N3SBr requires 
543.9754 
 
4-(3,5-Bis(4-bromophenyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide (37f) 
 
General Procedure C: Acetophenone to pyrazoline  
Orange solid, 158 mg, 32%; Mp 125 – 128 °C;  νmax (film/cm
-1) 3253 (N-H), 2971 (C-H), 1590 
(C=C), 1488 (C=C), 1383 (S=O), 1151 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.72 (2H, d, J = 
8.7, 2 × ArH), 7.65 (2H, d, J = 8.7, 2 × ArH), 7.60 (2H, d, J = 8.9, 2 × ArH), 7.55 (2H, d, J = 8.5, 
2 × ArH), 7.21 (2H, d, J = 8.5, 2 × ArH), 7.08 (2H, d, J = 8.9, 2 × ArH), 7.05 (2H, s, NH2), 5.68 
(1H, dd, J = 12.1, 5.1, CH), 3.96 (1H, dd, J = 17.6, 12.1, CHH), 3.20 (1H, dd, J = 17.6, 5.1, 
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CHH), 13C NMR (150 MHz, DMSO-d6) δ 148.8, 145.5, 140.9, 133.5, 132.1, 131.7, 131.0, 
128.2, 128.1, 127.2, 122.6, 120.8, 112.2, 61.9, 42.5; LRMS: (EI): 533 ([M]+, 100); HRMS: 
Found (EI): [M]+ 532.93685, C21H17O2N3SBr2requires 532.94027 
 
4-(3-(4-Bromophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-
yl)benzenesulfonamide (37g) 
 
General Procedure C: Acetophenone to pyrazoline  
Orange oil, 30 mg, 38%; νmax (film/cm
-1) 3265 (N-H), 2970 (C-H), 1595 (C=C), 1492 (C=C), 
1353 (S=O), 1164 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.73 (2H, d, J = 8.5, 2 × ArH), 7.65 
(2H, d, J = 8.5, 2 × ArH), 7.58 (2H, d, J = 9.0, 2 × ArH), 7.17 (2H, d, J = 8.8, 2 × ArH), 7.09 (2H, 
d, J = 9.0, 2 × ArH), 7.04 (2H, s, NH2),  6.90 (2H, d, J = 8.8, 2 × ArH), 5.61 (1H, dd, J = 12.3, 
5.1, CH), 3.93 (1H, dd, J = 17.8, 12.3, CHH), 3.70 (3H, s, OCH3), 3.16 (1H, dd, J = 17.8, 5.1, 
CHH); 13C NMR (150 MHz, DMSO-d6) δ 158.6, 153.8, 145.7, 140.8, 131.7, 131.1, 127.9, 
127.1, 127.0, 126.9,  122.4, 114.4, 112.2, 62.1, 55.0, 30.4; LRMS: (ES): 484 ([M-H]+, 100), 
460 (25); HRMS: Found (ES): [M-H]+ 484.0330, C22H19O3N3SBr requires 484.0313 
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4-(3-(4-Bromophenyl)-5-(4-hydroxy-3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-
yl)benzenesulfonamide (37h) 
 
General Procedure D: Oxidation with DDQ 
Orange oil, 185 mg, 37%; νmax (film/cm
-1) 3489 (O-H), 3247 (N-H), 1593 (C=C), 1518 (C=C), 
1301 (S=O), 1146 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 9.02 (1H, s, OH), 7.73 (2H, d, J = 
8.5, 2 × ArH), 7.65 (2H, d, J = 8.5, 2 × ArH), 7.59 (2H, d, J = 8.9, 2 × ArH), 7.10 (2H, d, J = 8.9, 
2 × ArH), 7.03 (2H, s, NH2), 6.88 (1H, s, ArH), 6.69 (1H, d, J = 7.9, ArH), 6.57 (1H, d, J = 7.9, 
ArH), 5.50 (1H, dd, J = 12.1, 5.6, CH), 3.91 (1H, dd, J = 17.5, 12.1, CHH), 3.72 (3H, s, OCH3), 
3.18 (1H, dd, J = 17.5, 5.6, CHH); 13C NMR (150 MHz, DMSO-d6) δ 148.7, 147.9, 145.99, 
145.97, 133.2, 132.4, 131.7, 131.2, 128.0, 127.1, 122.4, 117.9, 115.9, 112.2, 110.1, 62.7, 
55.6, 42.9; LRMS: (ES): 500 ([M-H]+, 40), 283 (60), 255 (100), 212 (60); HRMS: Found (ES): 
[M-H]+ 500.0280, C22H19O4N3SBr requires 500.0293 
 
General Procedure D: Oxidation with DDQ 
Pyrazoline (1 eq.) and 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) (1.5 eq.) in PhMe (1M) 
were heated to 90 °C and stirred for 12 h. The solution was then concentrated under 
reduced pressure before purification by flash chromatography (EtOAc/petrol) to give the 
pyrazole. 
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4-(3-(4-Bromophenyl)-5-phenyl-1H-pyrazol-1-yl)benzenesulfonamide (35a) 
 
General Procedure D: Oxidation with DDQ 
Brown solid, 35 mg, 59%, Mp 100 – 105 °C; νmax (film/cm
-1) 3405 (N-H), 2926 (C-H), 1596 
(C=C), 1485 (C=C), 1339 (S=O), 1162 (S=O); 1H NMR (600Hz, DMSO-d6) δ 7.90 (2H, d, J = 8.9, 
2 × ArH), 7.84 (2H, d, J = 8.7, 2 × ArH), 7.67 (2H, d, J = 8.7, 2 × ArH), 7.52 (2H, d, J = 8.9, 2 × 
ArH), 7.49 (2H, s, NH2), 7.41 - 7.45 (3H, m, 3 × ArH), 7.31 - 7.35 (2H, m, 2 × ArH), 7.26 (1H, s, 
CH on pyrazole); 13C NMR (150 MHz, DMSO-d6) δ 150.7, 144.7, 142.9, 141.9, 131.8, 131.6, 
129.6, 129.0, 128.9, 128.7, 127.5, 126.7, 125.2, 121.5, 106.5; LRMS: (EI): 453 ([M]+,100); 
HRMS: Found (EI): [M]+ C21H16O2N3SBr 453.01461, requires 453.01411  
 
4-(3-(4-Bromophenyl)-5-(furan-2-yl)-1H-pyrazol-1-yl)benzenesulfonamide (35b) 
 
General Procedure D: Oxidation with DDQ 
Orange oil, 30 mg, 37%; νmax (film/cm
-1) 3040 (C-H), 1595 (C=C), 1499 (C=C), 1342 (S=O), 
1162 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.94 (2H, d, J = 8.7, 2 × ArH), 7.89 (2H, d, J = 8.7, 
2 × ArH), 7.79 (1H, d, J = 1.7, OCCH), 7.67 (2H, d, J = 8.3, 2 × ArH), 7.65 (2H, d, J = 8.3, 2 × 
ArH), 7.54 (2H, s, NH2), 7.37 (1H, s, CH on pyrazole), 6.62 (1H, dd, J = 3.4, 1.7, OCCH), 6.48 
(1H, d, J = 3.4, OCHCH); 13C NMR (150 MHz, DMSO-d6) δ 150.8, 144.3, 143.6, 142.8, 142.1, 
135.4, 131.9, 131.2, 127.6, 126.8, 125.3, 121.7, 111.9, 110.6, 105.3; LRMS: (CI): 444 
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([M+H]+, 30), 366 (100%); HRMS: Found (CI): [M+H]+ 444.00150, C19H15O3N3SBr requires 
444.00175 
 
4-(3-(4-Bromophenyl)-5-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide (35c) 
 
General Procedure D: Oxidation with DDQ 
Brown oil, 15 mg, 94%; νmax (film/cm
-1) 3252 (N-H), 2923 (C-H), 1595 (C=C), 1515, 1342 
(S=O), 1148 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 8.27 (2H, d, J = 8.9, 2 × ArH), 7.90 (2H, d, 
J = 8.7, 2 × ArH), 7.87 (2H, d, J = 8.7, 2 × ArH), 7.68 (2H, d, J = 8.7, 2 × ArH), 7.60 (2H, d, J = 
8.9, 2 × ArH), 7.55 (2H, d, J = 8.7, 2 × ArH), 7.52 (2H, s, NH2), 7.44 (1H, s, CH on pyrazole); 
13C 
NMR (150 MHz, DMSO-d6) δ 151.0, 147.3, 143.2, 142.6, 141.5, 135.8, 131.9, 131.2, 129.9, 
127.0, 125.4, 124.0, 121.8, 107.7; LRMS: (ES): 497 ([M-H]+, 100); HRMS: Found (ES): [M-H]+ 
496.9944, C21H14O4N4SBr requires 496.9919 
 
4-(3-(4-Bromophenyl)-5-(4-hydroxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide (35d) 
 
General Procedure D: Oxidation with DDQ 
Orange solid, 33 mg, 83%; Mp 224 – 228 °C; νmax (film/cm
-1) 3265 (N-H), 2920 (C-H), 1596 
(C=C), 1492 (C=C), 1341 (S=O), 1162 (S=O); 1H NMR (600 MHz, DMSO-d6) δ  9.82 (1H, s, OH), 
7.89 (2H, d, J = 8.7, 2 × ArH), 7.85 (2H, d, J = 8.7, 2 × ArH), 7.66 (2H, d, J = 8.3, 2 × ArH), 7.52 
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(2H, d, J = 8.3, 2 × ArH), 7.45 (2H, s, NH2), 7.12 (1H, s, CH on pyrazole), 7.13 (2H, d, J = 8.1, 2 
× ArH), 6.80 (2H, d, J = 8.1, 2 × ArH); 13C NMR (150 MHz, DMSO-d6) δ 158.0, 150.5, 145.0, 
142.6, 142.1, 131.79, 131.75, 130.1, 127.5, 126.6, 125.0, 121.4, 120.2, 115.6, 105.7; LRMS: 
(ES): 470 ([M+H]+, 100), 454 (30), 180 (60); HRMS: Found (ES): [M+H]+ 470.0157, 
C21H17O2N3SBr requires 470.0174 
 
4-(3-(4-Bromophenyl)-5-(perfluorophenyl)-1H-pyrazol-1-yl)benzenesulfonamide (35e) 
 
General Procedure D: Oxidation with DDQ 
Brown oil, 10 mg, 63%; νmax (film/cm
-1) 3046 (C-H), 1596 (C=C), 1492 (C=C), 1162 (S=O), 988; 
1H NMR (600 MHz, DMSO-d6) δ 7.91 (2H, d, J = 8.7, 2 × ArH), 7.87 (2H, d, J = 8.7, 2 × ArH), 
7.69 (2H, d, J = 8.7, 2 × ArH), 7.65 (2H, d, J = 8.7, 2 × ArH), 7.53 (2H, s, NH2), 7.47 (1H, s, CH 
on pyrazole); 13C NMR (150 MHz, DMSO-d6) δ 151.4, 143.2, 141.2, 132.0, 130.8, 128.5, 
127.7, 127.2, 123.3, 122.0, 109.9 peaks missing/broad peaks dues to coupling with 19F 
nuclei; LRMS: (ES): 554 ([M+H]+, 100); HRMS: Found (ES): [M+H]+ 543.9723, C21H12O2F5N3SBr 
requires 543.9754 
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4-(3,5-Bis(4-bromophenyl)-1H-pyrazol-1-yl)benzenesulfonamide (35f) 
 
General Procedure D: Oxidation with DDQ 
Orange solid, 32 mg, 79%; Mp 238 – 240 °C; νmax (film/cm
-1) 3189 (N-H), 3058 (C-H), 1595 
(C=C), 1480 (C=C), 1338 (S=O), 1161 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.90 (2H, d, J = 
8.7, 2 × ArH), 7.87 (2H, d, J = 8.7, 2 × ArH), 7.68 (2H, d, J = 8.7, 2 × ArH), 7.65 (2H, d, J = 8.7, 
2 × ArH), 7.54 (2H, d, J = 8.7, 2 × ArH), 7.49 (2H, s, NH2), 7.31 (1H, s, CH on pyrazole), 7.28 
(2H, d, J = 8.7, 2 × ArH); 13C NMR (150 MHz, DMSO-d6) δ 150.8, 143.5, 143.0, 141.7, 131.87, 
131.86, 131.5, 130.7, 128.8, 127.5, 126.8, 125.3, 122.5, 121.6, 106.8; LRMS: (ES): 530 ([M-
H]+, 30), 495 (50), 481 (100); HRMS: Found (ES): [M-H]+ 529.9173, C21H14O2N3SBr2 requires 
529.9185 
 
4-(3-(4-Bromophenyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide (35g) 
 
General Procedure D: Oxidation with DDQ 
Orange oil, 30 mg, 35%; νmax (film/cm
-1) 3424 (N-H), 3045 (C-H), 1591 (C=C), 149 (C=C), 1335 
(S=O), 1163 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.89 (2H, d, J = 8.7, 2 × ArH), 7.85 (2H, d, 
J = 8.7, 2 × ArH), 7.67 (2H, d, J = 8.7, 2 × ArH), 7.53 (2H, d, J = 8.7, 2 × ArH), 7.47 (2H, s, NH2), 
7.26 (2H, d, J = 8.7, 2 × ArH), 7.18 (1H, s, CH on pyrazole), 6.99 (2H, d, J = 8.7, 2 × ArH),  3.78 
(3H, s, OCH3); 
13C NMR (150 MHz, DMSO-d6) δ 159.6, 150.6, 144.6, 142.7, 142.1, 131.8, 
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131.7, 130.1, 127.5, 126.7, 125.1, 121.8, 121.4, 114.3, 106.0, 55.3; LRMS: (ES): 482 ([M-H]+, 
100), 460 (25); HRMS: Found (ES): [M-H]+ 482.0174, C22H17O3N3SBr requires 482.0182 
 
4-(3-(4-Bromophenyl)-5-(4-hydroxy-3-methoxyphenyl)-1H-pyrazol-1-
yl)benzenesulfonamide (35h) 
  
General Procedure C: Acetophenone to pyrazoline  
Orange solid, 15 mg, 18%; Mp 206 – 208 °C; νmax (film/cm
-1) 3296 (O-H, broad), 2976 (C-H), 
1596 (C=C), 1495 (C=C), 1341 (S=O), 1162 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 9.43 (1H, s, 
OH), 7.89 (2H, d, J = 8.3, 2 × ArH), 7.86 (2H, d, J = 8.3, 2 × ArH), 7.67 (2H, d, J = 8.3, 2 × ArH), 
7.53 (2H, d, J = 8.7, 2 × ArH), 7.48 (2H, s, NH2), 7.18 (1H, s, CCHCOMe),  6.85 (1H, s, CH on 
pyrazole), 6.78 (1H, d, J = 8.0, CHCHCOH), 6.68 (1H, dd, J = 8.0, 1.7, CHCHCOH), 3.63 (3H, s, 
OCH3); 
13C NMR (150 MHz, DMSO-d6) δ 150.4, 147.5, 147.3, 145.1, 142.7, 142.2, 131.80, 
131.77, 127.5, 126.6, 125.2, 121.6, 121.4, 120.3, 115.7, 112.8, 105.6, 55.5; LRMS: (ES): 498 
([M-H]+, 10), 482 (20), 283 (20), 255 (60), 212 (100); HRMS: Found (ES): [M-H]+ 498.0123, 
C22H17O4N3SBr requires 498.0115 
 
(E)-1,3-Bis(4-hydroxyphenyl)prop-2-en-1-one (40)94 
 
BF3.OEt2 (0.43 mL, 3.5 mmol) was added over 5 mins to a solution of 4-
Hydroxyacteophenone (953 mg, 7.0 mmol) and 4-hydroxybenzaldehyde (855 mg, 7.0 
mmol) in dioxane (3 mL) and stirred at RT for 3 h. Et2O (40 mL) was added before the 
solution was washed with water (3 × 45 mL), dried (MgSO4) and filtered. The solvent was 
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removed under reduced pressure and the residue was purified by flash chromatography 
(EtOAc/Petrol) to give the chalcone 40.  
Orange powder, 960 mg, 57%; Mp 200 – 202 °C [196 – 198 °C]94; νmax (film/cm
-1) 3289 (O-
H), 2011 (C-H), 1641 (C=O), 1581 (C=C), 1544 (C=C); 1H NMR (600 MHz, MeOD) δ 7.99 (2H, 
d, J = 8.7, 2 × ArH), 7.70 (1H, d, J = 15.4 CH), 7.58 (2H, d, J = 8.7, 2 × ArH), 7.55 (1H, d, 15.4, 
CH), 6.89 (2H, d, J = 8.7, 2 × ArH), 6.84 (2H, d, J = 8.7, 2 × ArH), 4.95 (2H, br. s, OH); 13C NMR 
(150 MHz, MeOD) δ 191.1, 163.8, 161.5, 145.8, 132.3, 131.7, 131.2, 127.9, 119.5, 116.9, 
116.4; LRMS: (EI): 240 ([M]+, 100), 121 (40); HRMS: Found (EI): [M]+ 240.077980, C15H12O3 
requires 240.07810 
 
4-(3,5-Bis(4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide (41) 
  
General Procedure C: Acetophenone to pyrazoline 
Orange solid, 95 mg, 55%; Mp 163 – 167 °C; νmax (film/cm
-1) 3316 (O-H, broad), 1590 (Ar), 
1503 (Ar), 1151 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 9.88 (1H, s, OH), 9.42 (1H, s, OH), 
7.62 (2H, d, J = 8.7, 2 × ArH), 7.55 (2H, d, J = 9.0, 2 × ArH), 7.04 (2H, d, J = 8.7, 2 × ArH), 7.01 
(2H, d, J = 9.0, 2 × ArH), 6.99 (2H, s, NH2), 6.83 (2H, d, J = 8.7, 2 × ArH), 6.70 (2H, d, J = 8.7, 2 
× ArH), 5.44 (1H, dd, J = 12.0, 5.1, NCH), 3.85 (1H, dd, J = 17.4, 12.0, CHCHH), 3.07 (1H, dd, J 
= 17.4, 5.1, CHCHH); 13C NMR (150 MHz, DMSO-d6) δ 158.8, 156.7, 150.0, 146.2, 132.2, 
132.0, 127.8, 127.5, 127.1, 127.0, 115.7, 115.6, 111.7, 61.8, 43.2; LRMS: (CI): 409 ([M]+, 
100), 172 (sulfanilamide, 25), 156 (35); HRMS: Found (CI): [M]+ 409.10944, C21H19O4N3S, 
requires 409.10908; anal. cald. For C21H19O4N3S C, 61.60; H, 4.68; N, 10.26 Found: C, 59.30; 
H, 5.09; N, 9.20        
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4-(3,5-Bis(4-hydroxyphenyl)-1H-pyrazol-1-yl)benzenesulfonamide (42) 
 
(E)-1,3-bis(4-hydroxyphenyl)prop-2-en-1-one 40 (100 Mg, 0.42 mmol) in EtOH (2 mL) was 
added 2-(4-Sulfamoylphenyl)hydrazin-1-ium chloride 33 (79 mg, 0.42 mmol) heated at 80 
°C for 24 h. The solution was cooled to RT and concentrated under reduced pressure. The 
residue was purified by flash chromatography (EtOAc/Petrol 1:1). The pyrazoline was 
dissolved in AcOH (2 mL) and to this solution was added Pd on Carbon, under an 
atmosphere of O2 at 80 °C for 2h. The solution was cooled and filtered through Celite 
washing with EtOAc and purified by flash chromatography (EtOAc/ petrol) to give pyrazole 
42. 
Bright orange oily solid, 58 mg, 34% over 2 steps; νmax (film/cm
-1) 3155 (O-H, broad), 1613 
(Ar), 1592 (Ar), 1497 (Ar), 1155 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 9.83 (1H, br. s, OH), 
9.65 (1H, br. s, OH), 7.83 (2H, d, J = 8.7, 2 × ArH), 7.73 (2H, d, J = 8.7, 2 × ArH), 7.48 (2H, d, J 
= 8.7, 2 × ArH), 7.45 (2H, s, NH2), 7.12 (2 H, d, J = 8.3, 2 × ArH), 6.84 (2H, d, J = 8.7, 2 × ArH), 
6.79 (2H, d, J = 8.3, 2 × ArH); 13C NMR (150 MHz, DMSO-d6) δ 157.9, 157.7, 151.9, 144.5, 
142.4, 142.2, 130.1, 126.9, 126.6, 124.7, 123.5, 120.5, 115.6, 115.5, 105.1; LRMS: (CI): 407 
([M]+, 100); HRMS: Found (CI): [M]+ 407.09419, C21H17O4N3S, requires 407.09343 
 
N-Benzyl-4-bromobenzamide (46)95 
 
Benzylamine (0.99 mL) was dissolved in water (5 mL) and Na2CO3 (0.74 g) and the 4-
bromobenzoyl chloride was added portionwise. The solution was stirred for 30 min then 
the product was extracted with DCM (3 x 10 mL) and dried (MgSO4). This solution was then 
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put through a silica plug (DCM) and the solvent removed under reduced pressure to give 
amide 46. 
Fluffy white crystals, 695 mg, 69%; Mp 155-158 °C [160-163 °C]95; νmax (film/cm
-1) 3313 (N-
H), 3029 (C-H), 1639 (C=O), 1549 (Ar), 1482 (Ar) 1320 (Ar); 1H NMR (500 MHz, CDCl3) δ 7.66 
(2H, d, J = 8.7, 2 × ArH), 7.57 (2H, d, J = 8.7, 2 × ArH), 7.30 - 7.40 (5H, m, 5 × ArH), 6.33 (1H, 
br. s, NH), 4.64 (2H, d, J = 5.7, CH2); 
13C NMR (125 MHz, CDCl3) δ 175.6, 146.7, 137.9, 133.3, 
131.9, 129.0, 128.6, 128.1, 127.9, 44.4; LRMS: (EI): 289 ([M]+, 80), 185 ([BnNH3]
+, 100); 
HRMS: Found (EI): [M]+ 289.009877, C14H12BrNO requires 289.00968 
 
 N-Benzoyl-4-bromobenzamide (44)96    
 
A solution of CrO3 in MeCN (0.1 mL, 0.05 mmol) was added to a stirring solution of periodic 
acid (1.1 g, 6.0 mmol) in MeCN (10 mL). After 30 min, acetic anhydride (614 mg, 6.0 mmol) 
was added dropwise then cooled to 0 °C and the amide 46 (290 mg, 1 mmol) added. After 
18 h, water (10 mL) was added, before the product was extracted with EtOAc (2 x 10 mL). 
The combined organic fractions were washed with sat. NaHCO3 (10 mL), sat Na2S2O3 (10 
mL) and brine (10 mL) before the solution was dried (MgSO4) and solvent removed under 
reduced pressure. The residue was purified by flash chromatography (EtOAc/petrol) to give 
diimide 44. 
Colourless oil, 126 mg, 41%; νmax (film/cm
-1) 3275 (N-H), 3065 (C-H), 1716 (C=O), 1676 
(C=O), 1588 (Ar), 1466 (Ar); 1H NMR (500 MHz, CDCl3) δ 9.03 (1H, br. s., NH), 7.87 (2H, d, J = 
8.7, 2 × ArH), 7.73 (2H, d, J = 8.7, 2 × ArH), 7.63 (3H, m, 3 × ArH), 7.51 (2H, t, J = 7.3, 2 × 
ArH); 13C NMR (125 MHz, CDCl3) δ 166.49, 166.45, 133.4, 133.1, 132.3, 132.1, 129.8, 129.0, 
128.2, 128.1; LRMS: (EI): 303 ([M]+, 20), 185 ([BnNH3]
+, 30), 105 (30); HRMS: Found (EI): 
[M]+ 302.989417, C14H10BrNO2 requires 302.98894 
 
 
 
Chapter 4  Experimental  
125 
 
 (E)-4-(2-(4-Bromobenzylidene)hydrazinyl)benzenesulfonamide (51) 
 
2-(4-Sulfamoylphenyl)hydrazin-1-ium chloride (258 mg, 3.0 mmol) and 4-
bromobenzaldehyde (295 mg, 1.5 mmol) in EtOH were heated at reflux for 2 h after which 
the reaction was cooled and the product crystallised out to give hydrazone 51. 
Orange powder, 515 mg, 98%; Mp 167 – 170 °C; νmax (film/cm
-1) 3270 (N-H), 1594 (Ar), 1487 
(Ar), 1326 (S=O), 1146 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 10.90 (1H, s, CHN), 7.91 (1H, s, 
NH), 7.67 (2H, d, J = 8.9, 2 × ArH), 7.65 (2H, d, J = 8.7, 2 × ArH), 7.60 (2H, d, J = 8.9, 2 × ArH), 
7.15 (2H, d, J = 8.7, 2 × ArH), 7.10 (2H, s, NH2); 
13C NMR (150 MHz, DMSO-d6) δ 147.6, 137.7, 
134.6, 133.8, 131.7, 127.9, 127.5, 121.5, 111.3; LRMS: (ES): 352 ([M-H]+, 100); HRMS: Found 
(ES): [M-H]+ 351.9755, C13H11O2N3SBr requires 351.9755 
 
 (Z)-4-Bromo-N-(4-sulfamoylphenyl)benzohydrazonoyl chloride (52) 
  
Dimethylsulfide (177 mg, 1.33 mmol) was added dropwise to an ice-cold dry solution of N-
chlorosuccinimide (165 mg, 2.63 mmol in anhydrous DCM (3 mL). After 30 mins the 
solution was cooled to -78 °C and a solution of (E)-4-(2-(4-
Bromobenzylidene)hydrazinyl)benzenesulfonamide (156 mg, 0.44 mmol)  in anhydrous 
DCM (3 mL) was added dropwise over 10 mins. After the addition, the solution was stirred 
at this temperature for 1 h before warming to RT and allowed to stir for 18 h. The solution 
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was washed with water and brine before being dried (MgSO4) and purified by flushing 
through a silica pad (EtOAc/petrol) to give hydrazonyl chloride 52. 
Off white solid, 35 mg, 20%; Mp 195 – 199 °C; νmax (film/cm
-1) 3345 (NH), 3322 (NH), 3253 
(NH), 2922 (C-H), 1597 (Ar), 1510 (Ar), 1316 (S=O), 1137 (S=O); 1H NMR (600 MHz, DMSO-
d6) δ 10.39 (1H, s, NH), 7.87 (2H, d, J = 8.7, 2 × ArH), 7.72 (2H, d, J = 9.0, 2 × ArH), 7.69 (2H, 
d, J = 8.7, 2 × ArH), 7.47 (2H, d, J = 9.0, 2 × ArH), 7.18 (2H, s, NH2); 
13C NMR (150 MHz, 
DMSO-d6) δ 146.6, 135.7, 133.2, 131.8, 128.2, 127.3, 123.5, 123.1, 113.2; LRMS: (ES): 386 
([M-H]+, 100); HRMS: Found (ES): [M-H]+ 385.9368, C13H10O2N3ClSBr requires 385.9366 
 
1-Bromo-4-(nitromethyl)benzene (57)49 
 
AgNO2 was added to a solution of bromobenzylbromide in Et2O (20 mL). The solution was 
stirred in the dark for 18 h before filtering off AgBr and solvent removed from the filtrate 
under reduced pressure. The residue was purified by flash chromatography (EtOAc/petrol) 
to give nitro-compound 57. 
White crystals, 720 mg, 55%; Mp 54 – 56 °C, [55 – 56 °C]49;  νmax (film/cm
-1) 1552 (Ar), 1588 
(Ar), 1370; 1H NMR (500 MHz, CDCl3) δ 7.58 (2H, d, J = 8.4, 2 × ArH), 7.34 (2H, d, J = 8.4, 2 × 
ArH), 5.39 (2H, s, CH2); 
13C NMR (125MHz, CDCl3) δ 132.4, 131.7, 128.6, 124.7, 79.3; LRMS:  
(CI): 169 ([M-NO2]
+, 100) 
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 (Z)-4-(2-((4-Bromophenyl)(nitro)methylene)hydrazinyl)benzenesulfonamide (58) 
 
Sulfanilamide (992 mg, 5.8 mmol) was added to a stirring conc. HCl (5 mL) at RT then 
cooled to -5 °C. A solution of NaNO2 (415 mg, 6.02 mmol) in water (3 mL) was added to the 
sulfanilamide solution dropwise over 5 min, then allowed to stir for 30 mins. NaOAc (4.7 g, 
58 mmol) was then added one portion and stirred vigorously. Then an aliquot of the 
solution (7.5 mL) was added to a solution of nitrobenzene 57 (300 mg, 1.40 mmol) and 
NaOH (58 mg, 1.4 mmol) in a solution of EtOH/H2O (30 mL, 4:1). The solution was allowed 
to stir for 1 h before the precipitate was filtered and the solid was dried to give 
nitrohydrazone 58.  
Orange solid; 437 mg, 79%; Mp 165 – 167 °C; νmax (film/cm
-1) 3385 (N-H), 3265 (N-H), 1549 
(Ar), 1492 (Ar), 1143 (S=O); 1H NMR (500 MHz, DMSO-d6) δ 12.03 (1H, s, NH) 7.97 (2H, d, J = 
8.2, 2 × ArH) 7.63 (2H, d, J = 8.6, 2 × ArH) 7.57 (2H, d, J = 8.6, 2 × ArH) 7.45 (2H, d, J = 8.2, 2 
× ArH) 4.76 (2H, s, NH2); 
13C NMR (125 MHz, DMSO-d6) δ 163.7, 143.4, 142.4, 131.9, 130.1, 
127.6, 127.3, 124.0, 116.9; LRMS: (ES): 497 ([M-H]+, 10), 369 (100); HRMS: Found (ES): [M-
H]+ 396.9619, C13H10N4O4SBr requires 396.9606 
 
General Procedure E: Triazole formation  
To hydrazonyl chloride/nitrohydrazone in MeCN (1M), was added triethylamine (NEt3) (1.2 
eq.) and primary amine (1.2 eq.) and stirred at RT for 15 h. The solvent was removed under 
reduced pressure before addition of MeCN (2 mL) followed by tetrapropylammonium 
perruthenate (TPAP) and N-methylmorpholine oxide (NMO) and stirred for 3 h. The solvent 
was removed under reduced pressure and the residue was purified by flash 
chromatography (EtOAc/petrol).  
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4-(3-(4-Bromophenyl)-5-phenyl-1H-1,2,4-triazol-1-yl)benzenesulfonamide (54a) 
 
General Procedure E: Triazole formation 
Yellow solid, 23 mg, 50%; Mp 182 – 186 °C; νmax (film/cm
-1) 3315 (N-H), 2922 (C-H), 1599 
(Ar), 1484 (Ar), 1342 (S=O), 1162 (S=O); 1H NMR (500 MHz, DMSO-d6) δ 8.06 (2H, d, J = 8.4, 
2 × ArH), 7.92 (2H, d, J = 8.5, 2 × ArH), 7.73 (2H, d, J = 8.4, 2 × ArH), 7.67 (2H, d, J = 8.5, 2 × 
ArH), 7.53 (2H, s, NH2), 7.43 - 7.55 (5H, m, 5 × ArH); 
13C NMR (125 MHz, DMSO-d6) δ 160.2, 
155.1, 144.3, 140.0, 132.0, 130.5, 129.4, 128.9, 128.8, 128.0, 127.3, 127.0, 126.0, 123.1; 
LRMS: (CI): 454 ([M]+, 100), 353 (25), 170 (35), 106 (100); HRMS: Found (CI): [M]+ 
454.010788, C20H15O2N4SBr requires 454.00991; anal. cald. For C20H15O2N4SBr C, 50.97; H, 
3.21; N, 11.89; Found: C, 48.63; H, 3.85; N, 10.69 
 
4-(3-(4-Bromophenyl)-5-(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl)benzenesulfonamide 
(54b) 
 
General Procedure E: Triazole formation  
Yellow solid, 19 mg, 40%; Mp 290 – 294 °C; νmax (film/cm
-1) 3400 (N-H), 1655 (Ar), 1023 
(S=O); 1H NMR (600 MHz, DMSO-d6) δ 8.05 (2H, d, J = 8.3, 2 × ArH), 7.94 (2H, d, J = 8.5, 2 × 
ArH), 7.73 (2H, d, J = 8.3, 2 × ArH), 7.69 (2H, d, J = 8.5, 2 × ArH), 7.56 (2H, s, NH2), 7.47 (2H, 
d, J = 8.7, 2 × ArH), 7.02 (2H, d, J = 8.7, 2 × ArH) 3.80 (3H, s, CH3); 
13C NMR (150 MHz, 
DMSO-d6) δ 160.8, 160.1, 155.0, 144.3, 140.3, 132.0, 130.5, 129.5, 128.1, 127.1, 126.0, 
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123.1, 119.4, 114.3, 55.4; LRMS: (CI): 485 ([M+H]+, 30), 173 (35), 85 (100); HRMS: Found 
(CI): [M+H]+ 485.026337, C21H18O3N4SBr requires 485.02830 
 
4-(3-(4-Bromophenyl)-5-(4-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzenesulfonamide 
(54c) 
 
General Procedure E: Triazole formation  
Yellow solid, 50 mg, 42%; Mp 250 – 252 °C; νmax (film/cm
-1) 3310 (N-H), 2923 (C-H), 1590 
(Ar), 1337 (S=O), 1157 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 10.11 (1H, s, OH), 8.04 (2H, d, 
J = 8.3,  2 × ArH), 7.93 (2H, d, J = 8.7, 2 × ArH), 7.73 (2H, d, J = 8.3, 2 × ArH), 7.67 (2H, d, J = 
8.7, 2 × ArH), 7.55 (2H, s, NH2), 7.35 (2H, d, J = 8.7, 2 × ArH), 6.81 (2H, d, J = 8.7, 2 × ArH); 
13C NMR (150 MHz, DMSO-d6) δ 160.0, 159.4, 155.4, 144.1, 140.3, 132.0, 130.6, 129.6, 
128.1, 127.0, 126.0, 123.0, 117.7, 115.6; LRMS: (CI): 471 ([M+H]+, 100), 219 (20); HRMS: 
Found (CI): [M+H]+ 471.009846, C20H16O3N4SBr requires 471.01210 
 
4-(3-(4-Bromophenyl)-5-propyl-1H-1,2,4-triazol-1-yl)benzenesulfonamide (54d) 
 
General Procedure E: Triazole formation 
Yellow solid, 24 mg, 29%; Mp 204 – 208 °C; νmax (film/cm
-1) 3321 (N-H), 3073 (C-H), 1597 
(Ar), 1497 (Ar), 1340 (S=O), 1161 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 8.02 (2H, d, J = 8.7, 
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2 × ArH), 7.99 (2H, d, J = 8.5, 2 × ArH), 7.87 (2H, d, J = 8.7, 2 × ArH), 7.70 (2H, d, J = 8.5, 2 × 
ArH), 7.58 (2H, s, NH2), 2.87 (2H, t, J = 7.5, C(N)CH2), 1.75 (2H, sxt, J = 7.5, CH2CH3), 0.92 (3H, 
t, J = 7.5, CH3); 
13C NMR (150 MHz, DMSO-d6) δ 159.7, 157.4, 144.1, 139.4, 131.9, 129.7, 
128.0, 127.1, 125.3, 122.9, 28.0, 20.3, 13.6; LRMS: (CI): 421 ([M+H]+, 100), 343 (10); HRMS: 
Found (CI): [M+H]+ 421.032564, C17H18O2N4SBr requires 421.03338 
 
4-(5-Benzyl-3-(4-bromophenyl)-1H-1,2,4-triazol-1-yl)benzenesulfonamide (54e) 
 
General Procedure E: Triazole formation 
Yellow solid, 38 mg, 45%; Mp 203 – 205 °C; νmax (film/cm
-1) 3365 (N-H), 3266 (N-H), 1595 
(Ar), 1494 (Ar), 1328 (S=O), 1157 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.99 (2H, d, J = 8.7, 
2 × ArH), 7.98 (2H, J = 8.3, 2 × ArH), 7.83 (2H, d, J = 8.7, 2 × ArH), 7.70 (2H, d, J = 8.3, 2 × 
ArH), 7.57 (2H, s, NH2), 7.28 (2H, t, J = 7.3, 2 × ArH), 7.22 (1H, t, J = 7.3, ArH), 7.17 (2H, d, J = 
7.3, 2 × ArH ), 4.34 (2H, s, CH2); 
13C NMR (150 MHz, DMSO-d6) δ 159.9, 156.1, 144.3, 139.3, 
135.8, 132.0, 129.5, 128.7, 128.6, 128.0, 127.1, 126.9, 125.4, 123.0, 32.1; LRMS: (CI): 469 
([M]+, 100); HRMS: Found (CI): [M]+ 469.030795, C21H17O2N4SBr requires 469.03338 
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4-(3-(4-Bromophenyl)-5-phenethyl-1H-1,2,4-triazol-1-yl)benzenesulfonamide (54f) 
 
General Procedure E: Triazole formation 
Orange powder, 32 mg, 33%; Mp 184 – 186 °C; νmax (film/cm
-1) 3282 (N-H), 3015 (C-H), 1495 
(Ar), 1332 (S=O), 1159 (S=O); 1H NMR (600 MHz, DMSO-d6) δ  8.02 (2H, d, J = 8.7, 2 × ArH), 
7.98 (2H, d, J = 8.7, 2 × ArH), 7.74 (2H, d, J = 8.5, 2 × ArH), 7.72 (2H, d, J = 8.5, 2 × ArH), 7.56 
(2H, s, NH2), 7.23 - 7.27 (2H, m, 2 × ArH), 7.16 - 7.20 (3H, m, 3 × ArH), 3.19 (2H, t, J = 7.8, 
C(N)CH2), 3.09 (2H, t, J = 7.8, PhCH2); 
13C NMR (150 MHz, DMSO-d6) δ 159.7, 156.8, 144.1, 
140.3, 139.3, 132.0, 129.6, 128.44, 128.38, 128.0, 127.1, 126.3, 125.2, 122.9, 32.7, 28.2; 
LRMS: (CI): 483 ([M+H]+, 100), 111 (55); HRMS: Found (CI): [M+H]+ 483.047112, 
C22H20O2N4SBr requires 483.04903 
 
4-(3-(4-Bromophenyl)-5-cyclohexyl-1H-1,2,4-triazol-1-yl)benzenesulfonamide (54g) 
 
General Procedure E: Triazole formation 
Brown solid, 32 mg, 35%,; Mp 209 – 214 °C; νmax (film/cm
-1) 3354 (N-H), 2930 (C-H), 1495 
(Ar), 1336 (S=O), 1163 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 8.03 (2H, d, J = 8.5, 2 × ArH), 
7.98 (2H, d, J = 8.7, 2 × ArH), 7.84 (2H, d, J = 8.5, 2 × ArH),  7.69 (2H, d, J = 8.7, 2 × ArH), 7.59 
(2H, s, NH2), 2.87 (2H, tt, J = 11.5, 3.5, CH(CH2)2), 1.89 (2H, br. d, J = 12.8, 2 × cyclohexylCH), 
1.72 - 1.78 (2H, m, 2 × cyclohexylCH), 1.58 - 1.68 (3H, m, 3 × cyclohexylCH), 1.26 (3H, br. s, 3 
× cyclohexylCH); 13C NMR (150 MHz, DMSO-d6) δ 161.3, 159.7, 144.4, 139.4, 131.9, 129.7, 
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128.0, 127.2, 125.9, 122.8, 34.7, 31.2, 25.3, 14.1; LRMS: (CI): 461 ([M]+, 100); HRMS: Found 
(CI): [M]+ 461.063421, C20H21O2N4SBr requires 461.0646 
 
4-(3-(4-Bromophenyl)-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-1,2,4-triazol-1-
yl)benzenesulfonamide (54h) 
 
General Procedure E: Triazole formation 
Yellow solid, 36 mg, 34%; Mp 175 – 178 °C; νmax (film/cm
-1) 3262 (N-H), 2927 (C-H), 1598 
(Ar), 1333 (S=O), 1156 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 8.03 (2H, d, J = 8.5, 2 × ArH), 
7.99 (2H, d, J = 8.6, 2 × ArH), 7.90 (2H, d, J = 8.5, 2 × ArH), 7.71 (2H, d, J = 8.6, 2 × ArH), 7.57 
(2H, s, NH2), 4.04 (2H, t, J = 6.1, OCH2), 3.10 (2H, t, J = 6.1, OCH2CH2), 0.73 (9H, s, C(CH3)3), -
0.07 (6H, s, 2 × SiCH3); 
13C NMR (150 MHz, DMSO-d6) δ 159.9, 155.7, 144.2, 139.4, 132.0, 
129.6, 127.9, 127.1, 125.3, 122.9, 61.1, 29.7, 25.6, 17.9, -5.5; LRMS: (CI): 537 ([M+H]+, 100), 
481 (65); 414 (25), 219 (25); HRMS: Found (CI): [M+H]+ 537.099346, C22H30O3N4SBrSi 
requires 537.09913 
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Amino(4-(3-(4-bromophenyl)-5-(2-(triethoxysilyl)ethyl)-1H-1,2,4-triazol-1-yl)phenyl)(l1-
oxidanyl)-l5-sulfanone (54i) 
 
General Procedure E: Triazole formation 
Pink solid, 17 mg, 15%; Mp 118 – 121 °C; νmax (film/cm
-1) 3266 (N-H), 2975 (C-H), 1596 (Ar), 
1492 (Ar), 1404 (S=O), 1067 (S=O); 1H NMR (600 Hz, DMSO-d6) δ 8.02 (2H, d, J = 8.7, 2 × 
ArH), 7.99 (2H, d, J = 8.5, 2 × ArH), 7.86 (2H, d, J = 8.7, 2 × ArH), 7.70 (2H, J = 8.5, 2 × ArH), 
7.58 (2H, s, NH2), 3.68 (6H, q, J = 7.2, 3 × OCH2), 2.88 - 2.94 (2H, m, CNCH2), 1.05 (2H, m, 
SiCH2), 1.07 (9H, t, J = 7.2, 3 × CH3); 
13C NMR (150 MHz, DMSO-d6) δ 159.6, 158.7, 144.2, 
139.4, 131.9, 129.7, 127.9, 127.0, 125.4, 122.8, 57.8, 20.1, 18.1, 8.1; LRMS: (CI): 569 ([M]+, 
100), 525 (70); HRMS: Found (CI): [M]+  569.086787, C22H29O5N4SBrSi requires 569.0889 
 
Tert-butyl (2-(3-(4-bromophenyl)-1-(4-sulfamoylphenyl)-1H-1,2,4-triazol-5- 
yl)ethyl)carbamate (54j) 
 
General Procedure E: Triazole formation 
Red solid, 131 mg, 35%; Mp 97 – 98 °C; νmax (film/cm
-1) 3251 (N-H), 2976 (C-H), 1685 (C=O), 
1497 (Ar), 1335 (S=O), 1158 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 8.01 (2H, d, J = 9.1, 2 × 
ArH), 8.00 (2H, d, J = 8.9, 2 × ArH), 7.86 (2H, d, J = 9.1, 2 × ArH), 7.71 (2 H, d, J = 8.9, 2 × 
ArH), 7.58 (2H, s, NH2), 6.99 (1H, t, J = 5.8, NH), 3.36 (2H, q, J = 7.1,  NHCH2), 3.01 (2H, t, J = 
Chapter 4  Experimental  
134 
 
7.1, NHCH2CH2), 1.32 (9H, C(CH3)3); 
13C NMR (150 MHz, DMSO-d6) δ 159.7, 155.6, 155.4, 
144.1, 139.3, 131.9, 129.7, 128.0, 127.1, 125.3, 122.9, 77.8, 38.0, 28.2, 27.1; LRMS: (CI): 522 
([M]+, 20), 468 (100); HRMS: Found (CI): [M]+ 522.081428, C21H24O4N5SBr requires 
522.08106 
 
4-(3-(4-bromophenyl)-5-(2-hydroxyethyl)-1H-1,2,4-triazol-1-yl)benzenesulfonamide (59h) 
 
TBAF (1M in THF, 0.136 mL, 0.136 mmol) was added to a stirring solution of 54h (31 mg, 
0.068 mmol) in THF (1 mL). After 20 min the solvent was removed under reduced pressure 
before the residue was purified by flash chromatography (EtOAc) to give alcohol 59h.  
Yellow powder, 20 mg, 70%; Mp 249 – 252 °C; νmax (film/cm
-1) 3380 (O-H, broad), 1460 (Ar), 
993; 1H NMR (600 MHz, DMSO-d6) δ 8.02 (2H, d, J = 8.7, 2 × ArH), 8.00 (2H, d, J = 8.3, 2 × 
ArH), 7.91 (2H, d, J = 8.7, 2 × ArH), 7.71 (2H, d, J = 8.3, 2 × ArH), 7.58 (2H, s, NH2), 4.92 (1H, 
t, J = 5.3, OH), 3.83 (2H, q, J = 6.4, OCH2), 3.03 (2H, t, J = 6.4, OCH2CH2); 
13C NMR (150 MHz, 
DMSO-d6) δ 159.8, 155.9, 144.2, 139.4, 131.9, 129.7, 128.0, 127.0, 125.5, 122.9, 59.0, 30.0; 
LRMS: (CI): 422 ([M-H]+, 100), 257 (25), 389 (25); HRMS: Found (CI): [M-H]+ 423.011994, 
C16H15O3N4SBr requires 423.01265 
 
 
 
 
 
 
Chapter 4  Experimental  
135 
 
2-(3-(4-Bromophenyl)-1-(4-sulfamoylphenyl)-1H-1,2,4-triazol-5-yl)ethan-1-aminium 
chloride (59j) 
 
HCl (4M in dioxane, 0.8 mL, 3.2 mmol) was added to solution of 59j (107 mg, 0.2 mmol) in 
dioxane (2 mL) at 0 °C. After 1h stirring at RT the solvent was removed under reduced 
pressure to give hydrochloride salt 59j.  
Orange solid, 85 mg, 91%; Mp 109 – 114 °C; νmax (film/cm
-1) N-H too broad, 2922 (C-H), 
1594 (Ar), 1330 (S=O), 1159 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 8.24 (3H, br. s, NH3), 
8.05 (2H, d, J = 8.3, 2 × ArH), 8.04 (2H, d, J = 8.3, 2 × ArH), 7.89 (2H, d, J = 8.3, 2 × ArH), 7.72 
(2H, d, J = 8.3, 2 × ArH), 7.64 (2H, s, NH2), 3.30 (2H, m, NCH2), 3.27 (2H, m, NCH2CH2); 
13C 
NMR (150 MHz, DMSO-d6) δ 159.8, 154.2, 144.3, 139.0, 132.0, 129.4, 128.1, 127.2, 125.2, 
123.1, 36.5, 24.4; LRMS: (CI): 422 ([M]+, 55), 394 (100), 219 (50), 121 (35); HRMS: Found 
(CI): [M]+ 422.02796, C16H17O2N5SBr requires 422.02863 
 
N-((4-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)phenyl)sulfonyl)acetamide (60) 
 
Maleic anhydride (98 mg, 1.0 mmol), sulfanilamide (172 mg, 1.0 mmol) and NaOAc (30 mg, 
0.37 mmol) in AcOAc (4 mL) were heated to 100 °C. After 1 h, the solution was poured into 
ice-water (20 mL) and the product was extracted with EtOAc (3 × 10 mL) and the combined 
organic fractions were dried (MgSO4) and filtered. The solvent was removed under reduced 
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pressure and the residue purified was purified by column chromatography (EtOAc/petrol) 
to give maleimide 60. 
White solid, 62%; Mp 166 – 167 °C; νmax (film/cm
-1) 3389 (N-H), 2848 (C-H), 1711 (C=O), 
1655 (C=O), 1591 (C=C), 1335 (S=O), 1154 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 12.20 (1H, 
s, NH), 8.02 (2H, d, J = 8.7, 2 × ArH), 7.63 (2H, d, J = 8.7, 2 × ArH), 7.26 (2H, s, CH=CH), 1.94 
(3H, s, CH3); 
13C NMR (150 MHz, DMSO-d6) δ 169.4, 169.0, 137.7, 136.1, 135.0, 128.4, 126.5, 
23.3; HRMS: Found (CI): [M+H]+ 295.03848, C12H11N2O5S requires 295.03832 
 
N-((4-(3-Bromo-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)phenyl)sulfonyl)acetamide (61) 
 
Bromine (0.1 mL, 20 mmol) was added to a stirring solution of maleimide 60 (529 mg, 1.8 
mmol) in Et2O (2.5 mL) and heated at reflux for 1 h. The mixture was cooled to 0 °C and 
NEt3 (0.28 mL, 20 mmol) was added and stirred for 1 h. The solution was diluted with water 
(4 mL) and EtOAc (4 mL), before the solution was extracted with EtOAc (3 × 5 mL) and the 
combined organic fractions were washed with brine (10 mL), dried (MgSO4) and filtered. 
The solvent was removed under reduced pressure and the residue was purified by column 
chromatography (EtOAc/petrol) to give bromide 61. 
Yellow solid, 31% over 2 steps; Mp 209 – 211 °C;  νmax (film/cm
-1) 3265 (N-H), 1597 (C=C), 
1347 (S=O) 1158 (S=O); 1H NMR (500 MHz, CDCl3) δ 8.16 (2H, d, J = 8.8, 2 × ArH), 7.65 (2H, 
d, J = 8.8, 2 × ArH), 7.08 (1H, s, BrC=CH), 2.09 (3H, s, CH3); 
13C NMR (125 MHz, CDCl3) δ 
167.49, 167.47, 166.6, 137.5, 136.3, 132.2, 129.7, 129.6, 125.5, 23.7; HRMS: Found (CI): 
[M+H]+ 372.94875, C12H10N2O5SBr requires 372.94883 
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4-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzenesulfonamide (62) 
 
Maleic anhydride (1.40 g, 14 mmol), sulfanilamide (3.9 g, 23 mmol) and P4O10 (3.0 g, 10 
mmol) in dioxane (20 mL) were heated to 110 °C. After 18 h, the solution was filtered whilst 
hot and the filtrate was cooled and ice-water (20 mL) added. The precipitate that formed 
was collected to give maleimide 62. 
White solid, 54%; Mp 240 - 243 °C; νmax (film/cm
-1) 3367 (N-H), 3262 (N-H), 1721 (C=O), 
1702 (C=O) 1422 (C=C), 1299 (S=O) 1153 (S=O); 1H NMR (600 MHz, DMSO-d6) δ 7.92 (2H, d, 
J = 8.7, 2 × ArH), 7.56 (2H, d, J = 8.7, 2 × ArH), 7.46 (2H, s, CH=CH), 7.23 (2H, s, NH2); 
13C 
NMR (150 MHz, DMSO-d6) δ 169.6, 142.9, 134.9, 134.5, 126.8, 126.4; HRMS: Found (CI): 
[M+H]+  253.02830, C10H9N2O4S requires 253.02830 
 
4-(2,5-Dioxo-3-(phenylthio)pyrrolidin-1-yl)benzenesulfonamide (63) 
 
A solution of thiophenol (116 mg, 1.05 mmol) in benzene (1 mL) was added to a stirring 
solution of maleimide 62 (252 mg, 1.0 mmol) in benzene (1 mL) before NEt3 (14 mg, 0.14 
mmol) was added. After 18 h, the solvent was removed under reduced pressure to give the 
succinimide.  
Pink solid, 54%; Mp 228 – 232 °C; νmax (film/cm
-1) 3367 (N-H), 3265 (N-H), 1712 (C=O), 1697 
(C=O), 1304 (S=O), 1155 (S=O); 1H NMR (500 MHz, DMSO-d6) δ 7.90 (2H, d, J = 8.8, 2 × ArH), 
7.50 - 7.56 (2H, m, 2 × ArH), 7.44 (2H, s, NH2), 7.38 - 7.42 (3H, m, 3 × ArH), 7.28 (2H, d, J = 
8.8, 2 × ArH), 4.54 (1H, dd, J = 9.4, 4.1, CHSPh), 3.44 (1H, dd, J = 18.4, 9.4, CHHCHSPh), 2.84 
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(1 H, dd, J = 18.4, 4.1, CHHCHSPh); 13C NMR (125 MHz, DMSO-d6) δ 174.7, 173.7, 143.8, 
134.8, 133.1, 131.3, 129.4, 128.7, 127.3, 126.4, 43.8, 36.4; HRMS: Found (CI): [M]+  
362.03794, C16H14N2O4S2 requires 362.03950 
 
General Procedure F: Propargylic Alcohol Formation 58: n-Butyllithium (1.6M in hexanes, 
1.2 eq.) was added dropwise to a stirred solution of alkyne (1 eq.) in dry THF (1 mLmmol-1) 
at -78 ˚C under an argon atmosphere. After 1 h aldehyde or ketone (1 eq.) was added and 
the resulting solution was stirred for 5 min at 0 ˚C and 1h at rt. The reaction was quenched 
with saturated NH4Cl solution and the organic phase extracted with Et2O. The combined 
organic phases were washed with brine, dried (MgSO4) and concentrated under reduced 
pressure. The residue was purified by column chromatography (EtOAc/petrol) to give the 
propargylic alcohol. 
 
1-(p-Tolyl)hex-1-yn-3-ol (70a) 
 
General Procedure F: Propargylic alcohol formation 
Yellow oil, 96%; νmax (film/cm
-1) 3331 (O-H), 2959 (C-H), 2932 (C-H), 1509 (Ar); 1H NMR (600 
MHz, CDCl3) δ 7.32 (2H, d, J = 7.9, 2 × ArH), 7.10 (2H, d, J = 7.9, 2 × ArH), 4.60 (1H, t, J = 6.6, 
CHOH), 2.34 (3H, s, ArCH3), 2.28 (1H, br. s, OH), 1.72 - 1.84 (2H, m, CHCH2), 1.54 (2H, sx, J = 
7.4, CH2CH3), 0.98 (3H, t, J = 7.4, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 138.6, 131.7, 129.2, 
119.7, 89.7, 85.0, 62.9, 40.1, 21.6, 18.7, 13.9; HRMS: Found (EI):  [M]+ 188.119621, C13H16O 
requires 188.12012; 
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(Z)-2-Iodo-1-(p-tolyl)hex-2-en-1-one (73a) 
 
N-Iodosuccinimide (NIS) (124 mg, 0.55 mmol) was added to a stirring solution of 
propargylic alcohol 70a (0.5 mmol) and Ph3PAuNTf2 (2 mol%) in PhMe (2mL). Once the 
reaction was complete (TLC), the solvent was removed under reduced before the residue 
was purified by column chromatography (EtOAc/petrol) to give iodoenone 73a. 
Yellow oil, 71%; νmax (film/cm
-1) 2960 (C-H), 2198 (C≡C), 1657 (C=O), 1603 (Ar), 1456 (Ar), 
1258, 1179; 1H NMR (600 MHz, CDCl3) δ 7.62 (2H, d, J = 8.1, 2 × ArH), 7.24 (2H, d, J = 8.1, 2 × 
ArH), 6.58 (1H, t, J = 7.0, CH), 2.39 - 2.44 (2H, m, CHCH2), 2.41 (3H, s, ArCH3), 1.55 (2H, sx, J 
= 7.5, CH2CH3), 0.99 (3H, t, J = 7.5, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 192.0, 153.4, 
143.5, 133.1, 130.1, 129.2, 108.4, 39.6, 21.8, 21.3, 14.1; HRMS: Found (EI): [M]+ 
314.015395, C13H15OI requires 314.01676 
 
5-Propyl-3-(p-tolyl)-1H-pyrazole (72) 
 
N-Iodosuccinimide (NIS) (124 mg, 0.55 mmol) was added to a stirring solution of 
propargylic alcohol 70a (0.5 mmol) and Ph3PAuNTf2 (2 mol%) in PhMe (2mL). Once the 
reaction was complete (TLC), the solvent was removed under reduced to give the crude 
iodoenone. Hydrazine (3 eq.) and MeOH (1 mL) was added to this crude product and stirred 
or 3 h at RT before the solvent was removed under reduced pressure to give a residue that 
was was purified by column chromatography (EtOAc/Petrol) to give the pyrazole 72.   
Yellow oil, 44 mg, 45%; νmax (film/cm
-1) 3191 (N-H), 2959 (C-H), 2929 (C-H), 1682 (C=O), 
1510 (C=C); 1H NMR (600 MHz, CDCl3) δ 7.60 (2H, d, J = 7.9, 2 × ArH), 7.20 (2 H, d, J = 7.9, 2 
× ArH), 6.33 (1H, s, CH), 2.64 (2H, t, J = 7.4, CCH2), 2.37 (3H, s, ArCH3), 1.71 (2H, sx, J = 7.4, 
CH2CH3), 0.99 (3H, t, J = 7.4 CH2CH3); 
13C NMR (150 MHz, CDCl3) 149.8, 148.1, 137.8, 129.7, 
129.5, 125.6, 101.0, 28.7, 22.7, 21.4, 14.0; HRMS: Found (EI):  [M]+ 200.131019, C13H16N2 
requires 200.13135; 
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1-(o-Tolyl)hex-1-yn-3-ol (70b) 
 
General Procedure F: Propargylic alcohol formation 
Yellow oil, 87%; νmax (film/cm
-1) 3323 (O-H), 2958 (C-H), 2954 (C-H), 2872 (C-H), 1485 (Ar), 
1456 (Ar); 1H NMR (500 MHz, CDCl3) δ 7.40 (1H, d, J = 7.7, ArH), 7.17 - 7.23 (2H, m, 2 × ArH), 
7.12 (1H, td, J = 7.7, 1.9, ArH), 4.65 (1H, t, J = 6.6, CHOH), 2.43 (3H, s, ArCH3), 2.13 (1H, br. s, 
OH), 1.80 (2H, m, CHCH2), 1.57 (2H, sx, J = 7.5, CH2CH3), 0.99 (3H, t, J = 7.5, CH2CH3); 
13C 
NMR (125 MHz, CDCl3) δ 140.2, 132.1, 129.5, 128.4, 125.6, 122.5, 94.3, 83.7, 63.0, 40.2, 
20.7, 18.6, 13.7; HRMS: Found (CI): [M+H]+ 189.128098, C13H17O requires 189.12794 
 
3-(p-Tolyl) Propiolaldehyde (78)97 
 
General Procedure F: Propargylic alcohol formation 
Orange oil, 2.5 g, 89%; νmax (film/cm
-1); 2855 (C-H), 2181 (C≡C), 1651 (C=O), 1508 (Ar); 1H 
NMR (600 MHz, CDCl3) δ 9.40 (1H, s, CHO), 7.50 (2H, d, J = 8.1, 2 × ArH), 7.20 (2H, d, J = 8.1, 
2 × ArH), 2.39 (3H, s, CH3); 
13C NMR (150 MHz, CDCl3) δ 177.0, 142.3, 133.5, 129.7, 116.4, 
96.1, 88.6, 21.9; LRMS: (EI): 144 ([M]+, 100), 115 (80) 
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Ethyl 3-hydroxy-5-(p-tolyl)pent-4-ynoate (70d) 
 
LiHMDS (1M in THF, 2 eq.) was added dropwise to a stirred solution of EtOAc (1 eq.) in dry 
THF (1 mLmmol-1) at -78 ˚C under an argon atmosphere. After 1 h 3-(p-
tolyl)propiolaldehyde 78 (1 eq.) was added and the resulting solution was stirred for 15 
min. The reaction was quenched with saturated NH4Cl solution and the organic phase 
extracted with Et2O. The combined organic phases were washed with brine, dried (MgSO4) 
and concentrated under reduced pressure. The residue was purified by column 
chromatography to give propargylic alcohol 70d.  
Orange oil, 71%; νmax (film/cm
-1) 3438 (O-H), 2982 (C-H), 1734 (C=O), 1510 (Ar), 1213, 1097; 
1H NMR (600 MHz, CDCl3) δ 7.31 (2H, d, J = 8.3, 2 × ArH), 7.10 (2H, d, J = 8.3, 2 × ArH), 4.98 
(1H, br. d, J = 5.6, OCH), 4.21 (2H, m, OCH2), 2.83 (2H, m, CHCH2), 2.33 (3H, s, ArCH3), 1.28 
(3H, t, J = 7.2, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 171.5, 138.8, 131.8, 129.2, 119.3, 87.5, 
85.3, 61.2, 59.4, 42.2, 21.6, 14.3; HRMS: Found (CI): [M+H]+ 233.11731, C14H17O3 requires 
233.11777 
 
5-Phenyl-1-(p-tolyl)pent-1-yn-3-ol (70f) 
 
General Procedure F: Propargylic alcohol formation 
Yellow solid, 93%; Mp 64 – 65 °C; νmax (film/cm
-1)  3383 (O-H), 3061 (C-H), 2923 (C-H), 2227 
(C≡C), 1509 (Ar); 1H NMR (600 MHz, CDCl3) δ 7.35 - 7.39 (2H, m, 2 × ArH), 7.30 - 7.34 (2H, 
m, 2 × ArH), 7.25 - 7.29 (2H, m, 2 × ArH), 7.21 - 7.25 (1H, m, 1 × ArH), 7.14 (2H, d, J = 7.9, 2 × 
ArH), 4.59 - 4.65 (1H, m, CHOH), 2.89 (2H, t, J = 7.5, PhCH2), 2.37 (3H, s, ArCH3), 2.11 - 2.20 
(2H, m, CHCH2); 
13C NMR (150 MHz, CDCl3) δ 141.5, 138.7, 131.8, 129.2, 128.7, 128.6, 126.1, 
Chapter 4  Experimental  
142 
 
119.6, 89.3, 85.5, 62.4, 39.5, 31.7, 21.6; HRMS: Found (CI): [M]+ 250.135335, C18H18O 
requires 250.13577 
 
4-Methyl-1-(p-tolyl)pent-1-yn-3-ol (70g) 
 
General Procedure F: Propargylic alcohol formation 
Yellow oil, 76%; νmax (film/cm
-1) 3351 (O-H), 2961 (C-H), 2872 (C-H), 2225 (C≡C), 1509 (Ar); 
1H NMR (600 MHz, CDCl3) δ 7.33 (2 H, d, J = 7.9, 2 × ArH), 7.11 (2H, d, J = 7.9, 2 × ArH), 4.39 
(1H, d, J = 5.3, CHOH), 2.34 (3H, s, ArCH3), 2.17 (1H, br. s, OH), 1.97 (1H, sx, J = 6.8), 1.08 
(3H, d, J = 6.8, CHCH3CH3), 1.05 (3H, d, J = 6.8, CHCH3CH3); 
13C NMR (150 MHz, CDCl3) δ 
138.6, 131.7, 129.2, 119.8, 88.3, 85.8, 68.5, 34.8, 21.6, 18.4, 17.7; HRMS: Found (EI): [M-H]+ 
187.112643, C13H15O requires 187.11229 
 
1-(p-Tolyl)oct-1-yn-3-ol (70h) 
 
General Procedure F: Propargylic alcohol formation 
Yellow oil,  75%; νmax (film/cm
-1)  3337 (O-H), 2954 (C-H), 2927 (C-H), 2859 (C-H), 1509 (Ar); 
1H NMR (500 MHz, CDCl3) δ 7.32 (2H, d, J = 8.1, 2 × ArH), 7.11 (2H, d, J = 8.1, 2 × ArH), 4.58 
(1H, t, J = 6.6, CHOH), 2.34 (3H, s, ArCH3), 1.75 - 1.82 (2H, m, CHCH2), 1.48 - 1.56 (2H, m, 
CHCH2CH2), 1.31 - 1.38 (4H, m, CH2CH2CH3), 0.91 (3H, t, J = 7.3, CH2CH3); 
13C NMR (125MHz, 
CDCl3) δ 138.5, 131.6, 129.1, 119.7, 89.7, 85.0, 63.1, 38.0, 31.6, 25.0, 22.6, 21.5, 14.1; 
HRMS: Found (EI): [M]+ 216.151670, C15H20O requires 216.15142 
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1-Ethoxyoct-1-yn-3-ol (70i) 
 
General Procedure F: Propargylic alcohol formation 
Colourless oil, 49%; νmax (film/cm
-1) 3379 (O-H), 2955 (C-H), 2930 (C-H), 2859 (C-H), 2262 
(C≡C); 1H NMR (600 MHz, CDCl3) δ 4.38 (1H, m, CHOH), 4.08 (2H, q, J = 7.2, OCH2CH3), 1.74 
(1H, br. s, OH), 1.57 - 1.69 (2H, m, CHCH2CH2), 1.42 (2H, sx, J =7.5, CHCH2CH2), 1.36 (3H, t, J 
= 7.2, OCH2CH3), 1.26 - 1.34 (4H, m, CH2CH2CH3), 0.88 (3H, t, J = 6.8, CH2CH2CH3); 
13C NMR 
(150 MHz, CDCl3) δ 93.8, 74.7, 62.6, 39.8, 38.8, 31.6, 25.1, 22.7, 14.5, 14.1; HRMS: Found 
(CI): [M+H]+ 171.137987, C10H19O2 requires 171.13850 
 
3-Ethyl-1-(p-tolyl)pent-1-yn-3-ol (70j) 
 
General Procedure F: Propargylic alcohol formation 
Yellow oil, 92%; νmax (film/cm
-1) 3384 (O-H), 2969 (C-H), 2937 (C-H), 2226 (C≡C), 1509 (Ar), 
1459 (Ar); 1H NMR (600 MHz, CDCl3) δ 7.33 (2H, d, J = 7.9, 2 × ArH), 7.10 (2H, d, J = 7.9, 2 × 
ArH), 2.39 (1H, s, OH), 2.34 (3H, s, ArCH3), 1.78 (4H,  2 × dq,  J = 14.3, 7.5, 2 × CH2), 1.12 (6H, 
t, J = 7.5, 2 × CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 138.3, 131.7, 129.1, 120.0, 91.2, 84.7, 
72.7, 34.6, 21.6, 8.9; HRMS: Found (CI): [M]+ 202.136131, C14H18O requires 202.13577 
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1-(4-Bromophenyl)-3-phenylprop-2-yn-1-ol (70k) 
 
General Procedure F: Propargylic alcohol formation 
Yellow solid, 81%; Mp 75 – 77 °C; νmax (film/cm
-1) 3452 (O-H), 1590 (Ar), 1487 (Ar), 1370, 
1011, 905; 1H NMR (600 MHz, CDCl3) δ 7.53 (2H, d, J = 8.6, 2 × ArH), 7.49 (2H, d, J = 8.6, 2 × 
ArH), 7.46 (2H, dd, J = 7.4, 1.8, 2 × ArH), 7.31 - 7.35 (3H, m, 3 × ArH), 5.65 (1H, s, OCH), 2.34 
(1H, br. s, OH); 13C NMR (150 MHz, CDCl3) δ 139.7, 131.88, 131.87, 128.9, 128.6, 128.5, 
122.6, 122.2, 88.2, 87.1, 64.6; HRMS: Found (EI): [M]+ 285.99857, C15H11OBr requires 
285.99878 
 
1-Phenyl-4-(p-tolyl)but-3-yn-2-ol (70m) 
 
General Procedure F: Propargylic alcohol formation 
Yellow solid, 40%, Mp 40 – 43 °C; νmax (film/cm
-1) 3410 (O-H), 2939 (C-H), 2893 (C-H), 2226 
(C≡C), 1509 (Ar), 1499 (Ar), 1337; 1H NMR (600 MHz, CDCl3) δ 7.37 - 7.39 (3H, m, 3 × ArH), 
7.34 - 7.37 (2H, m, 2 × ArH), 7.30 - 7.34 (1H, m, 1 × ArH), 7.15 (2H, d, J = 7.9, 2 × ArH), 4.83 
(1H, t, J = 6.3, CHOH), 3.14 (2H, dd, J = 6.3, 1.5, CHCH2), 2.41 (1H, br. s, OH), 2.39 (3H, s, 
ArCH3); 
13C NMR (150 MHz, CDCl3) δ 138.7, 136.9, 131.7, 130.1, 129.2, 128.5, 127.0, 119.7, 
89.1, 86.1, 63.9, 44.4, 21.7; HRMS: Found (CI): [M]+ 236.119176, C17H16O requires 
236.11957 
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Oct-1-yn-3-ol (70o) 
 
Hexanal (0.96 mL, 7.8 mmol) was added dropwise to stirring 0.5 M ethynyl MgBr (22 mL, 11 
mmol) at -20 °C. After 1 h, the solution stirred at RT for a further 1 h before addition of 
saturated NH4Cl (25 mL). The product was extracted with Et2O (3 × 20 mL) and the 
combined organic fractions were washed with brine (20 mL), dried (MgSO4) and filtered. 
The solvent was removed under reduced pressure and the residue was purified by column 
chromatography (EtOAc/petrol) to give the propargylic alcohol. 
Orange oil, 37%; νmax (film/cm
-1) 3362 (O-H), 2920 (O-H), 2205 (C≡C), 1509 (C=C); 1H NMR 
(600 MHz, CDCl3) δ 4.35 (1H, td, J = 6.6, 2.0, CHOH), 2.44 (1H, d, J = 2.0, C≡CH), 1.65 - 1.74 
(2H, m, CHCH2), 1.40 - 1.49 (2H, m, CHCH2CH2), 1.26 - 1.36 (4H, m, CH2CH2CH3), 0.88 (3H, t, J 
= 6.9, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 85.2, 72.8, 62.4, 37.7, 31.5, 24.7, 22.6, 14.0; 
LRMS: (EI): 127 ([M+H]+, 30), 99 (50), 83 (100) 
 
1-(p-Tolyl)hept-2-yn-1-ol (70p) 
 
General Procedure F: Propargylic alcohol formation 
Yellow oil, 79%; νmax (film/cm
-1) 3369 (O-H), 2957 (C-H), 2931 (C-H), 2203 (C≡C), 1604 (Ar), 
1512 (Ar), 1269; 1H NMR (600 MHz, CDCl3) δ 7.43 (2H, d, J = 8.1, 2 × ArH), 7.18 (2H, d, J = 
8.1, 2 × ArH), 5.41 (1H, s, CHOH), 2.36 (3H, s, ArCH3), 2.28 (2H, td, J = 7.3, C≡CCH2), 2.22 (1H, 
br. s, OH), 1.53 (2H, sx, J = 7.3, CH2CH2CH3), 1.43 (2H, sx, J = 7.3, CH2CH3), 0.92 (3H, t, J = 7.3, 
CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 138.6, 138.1, 129.3, 126.7, 87.6, 80.2, 64.8, 30.8, 
22.1, 21.3, 18.7, 13.8; HRMS: Found (EI): [M]+ 202.13514, C14H18O requires 202.13577 
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Dec-5-yn-4-ol (70q) 
 
General Procedure F: Propargylic alcohol formation 
Colourless oil, 64%; νmax (film/cm
-1) 3345 (O-H), 2958 (C-H), 2933 (C-H), 2873 (C-H), 2223 
(C≡C); 1H NMR (600 MHz, CDCl3) δ 4.31 - 4.37 (1H, m, CHOH), 2.19 (2H, td, J = 7.2, 1.9, 
C≡CH2), 1.85 (1H, d, J = 4.9, OH), 1.57 - 1.69 (2H, m, C≡CCH2CH2), 1.46 (4H, sx, J =7.5, 2 × 
CH2), 1.39 (2H, sx, J = 7.2, CHCH2CH2CH3), 0.93 (3H, t, J = 7.5, OHCH(CH2)2CH3), 0.89 (3H, t, J 
=7.2 CH(CH2)3CH3); 
13C NMR (150 MHz, CDCl3) δ 85.5, 81.4, 62.6, 40.4, 30.9, 22.0, 18.6, 18.4, 
13.9, 13.7; LRMS: (CI): 155 ([M]+, 100) 
 
1-(p-Tolyl)hex-5-en-1-yn-3-ol (70r) 
 
Propargyl aldehyde 78 (288 mg, 2.0 mmol) was added dropwise to a stirring solution of 1 M 
allyl MgBr (3 mL, 3 mmol) at 0 °C. After 2 h, water was added (5 mL) and the product was 
extracted with Et2O (3 × 5 mL) before the combined organic fractions were dried (MgSO4), 
and filtered. The solvent was removed under reduced pressure and the residue purified by 
column chromatography (EtOAc/petrol) to give alkene 70r.  
Orange oil, 37%; νmax (film/cm
-1) 3362 (O-H), 2920 (O-H), 2205 (C≡C), 1509 (C=C); 1H NMR 
(600 MHz, CDCl3) δ 7.32 (2H, d, J = 7.9, 2 × ArH), 7.11 (2H, d, J = 7.9, 2 × ArH), 5.96 (1H, ddt, 
J = 17.2, 10.5, 7.1, CH2CH=CHH), 5.24 (1H, d, J = 17.2, CH2CH=CHH), 5.21 (1H, d, J = 10.5, 
CH2CH=CHH), 4.65 (1H, t, J = 6.0, CHOH), 2.55 - 2.59 (2H, m, CH2) , 2.34 (3H, s, CH3); 
13C 
NMR (150 MHz, CDCl3) δ 138.7, 133.2, 131.7, 129.2, 119.5, 119.2, 88.8, 85.5, 62.2, 42.4, 
21.6; HRMS: Found (EI): [M]+ 186.104226, C13H14O requires 186.10447  
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1-Ethoxy-5-phenylpent-1-yn-3-ol (70t) 
 
General Procedure F: Propargylic alcohol formation 
Yellow oil, 1.025 g, 59%;  νmax (film/cm
-1) 3372 (O-H), 2931 (C-H), 2260 (C≡C), 1495 (Ar), 
1231; 1H NMR (600 MHz, CDCl3) δ 7.29 (2H, t, J = 7.5, 2 × ArH), 7.18 - 7.24 (3H, m, 3 × ArH), 
4.42 (1H, t, J = 6.4, CHOH), 4.11 (2H, q, J = 7.1, OCH2), 2.79 (2H, m, PhCH2), 1.93 - 2.05 (2H, 
m, CH2CH), 1.39 (3H, t, J = 7.1, CH3); 
13C NMR (150 MHz, CDCl3) δ 141.8, 128.6, 128.5, 126.0, 
94.2, 74.8, 61.9, 40.3, 39.5, 31.8, 14.5; HRMS: Found (CI): [M+H]+ 205.122313, C13H17O2 
requires 205.12285 
 
1,5-Di-p-tolylpenta-1,4-diyn-3-ol (70u) 
 
General Procedure F: Propargylic alcohol formation 
Brown solid, 45%; Mp 90 – 92 °C, [82 - 84 °C]98; νmax (film/cm
-1) 3326 (O-H), 2973 (C-H), 
2881 (C-H), 1379 (Ar), 1087, 1045; 1H NMR (500 MHz, CDCl3) δ 7.38 (4H, d, J = 8.1, 4 × ArH), 
7.13 (4H, d, J = 8.3, 4 × ArH), 5.55 - 5.58 (1H, m, CH), 2.35 (6H, s, 2 × CH3); 
13C NMR 
(125MHz, CDCl3) δ 139.2, 131.9, 129.2, 119.0, 85.5, 84.8, 53.5, 21.7; LRMS: (CI): 261 
([M+H]+, 90), 143 ([M-OH] +, 40), 145 (M-tolylacetylene]+ ,100) 
 
General Procedure G: Diiodohydration 
N-Iodosuccinimide (248 mg, 1.1 mmol) was added to a stirring solution of propargylic 
alcohol (0.5 mmol) and Ph3PAuNTf2 (2 mol%) in MeCN/H2O (2 mL, 10:1). Once the reaction 
was complete (TLC), the solvent was removed under reduced pressure before the residue 
was purified by column chromatography (EtOAc/Petrol) to give the diiodohydroxyketone. 
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3-Hydroxy-2,2-diiodo-1-(p-tolyl)hexan-1-one (76a) 
 
General Procedure G: Diiodohydration 
Yellow solid, 71%; Mp 88 – 90 °C; νmax (film/cm
-1) 3507 (O-H), 2955 (C-H), 1642 (C=O), 1601 
(Ar), 1379, 1230; 1H NMR (600 MHz, CDCl3) δ 8.38 (2H, d, J = 8.3, 2 × ArH), 7.24 (2H, d, J = 
8.3, 2 × ArH), 3.68 (1H, br. s, OH), 3.37 (1H, ddd, J = 9.4, 4.4, 1.5, CH), 2.45 (3H, s, ArCH3), 
2.15 (1H, m, CH(OH)CHH), 1.78 (1H, dtd, J = 13.9, 9.4, 5.5, CH(OH)CHH), 1.68 - 1.75 (1H, m, 
CH3CHH), 1.51 – 1.59 (1H, m, CH3CHH), 1.02 (3H, t, J = 7.5, CH2CH3); 
13C NMR (150 MHz, 
CDCl3) δ 191.9, 144.9, 132.0, 130.4, 128.6, 78.7, 39.0, 25.0, 21.9, 19.6, 14.2; HRMS: Found 
(CI): [M+H]+ 458.93132, C13H17O2I2 requires 458.93179; anal. cald. For C13H17O2I2 C, 34.09; H, 
3.52; Found: C, 33.33; H, 3.42 
 
3-Hydroxy-2,2-diiodo-1-(o-tolyl)hexan-1-one (76b) 
   
General Procedure G: Diiodohydration 
Brown oil, 71%; νmax (film/cm
-1) 3470 (O-H), 2958 (C-H), 1662 (C=O), 1598 (Ar), 1230; 1H 
NMR (500 MHz, CDCl3) δ 8.21 (1H, d, J = 7.7, ArH), 7.36 (1H, t, J = 7.7, ArH), 7.25 (1H, d, J = 
7.7, ArH), 7.21 (1H, t, J = 7.7, ArH), 3.45 – 3.49 (1H, m, CH), 2.92 (1H, br. s, OH), 2.33 (3H, s, 
ArCH3), 2.11 - 2.21 (1H, m, CH(OH)CHH), 1.64 - 1.75 (2H, m, CH(OH)CHH and CH3CHH), 1.48 
- 1.58 (1H, m, CH3CHH), 1.01 (3H, t, J = 7.3, CH2CH3);  
13C NMR (125MHz, CDCl3) δ 198.1, 
137.23, 137.17, 131.1, 130.7, 128.8, 125.1, 78.4, 39.1, 29.3, 20.6, 19.5, 14.0; HRMS: Found 
(CI): [M+H]+ 458.93219, C13H17O2I2 requires 458.93179 
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3-Hydroxy-2,2-diiodo-1-phenylpropan-1-one (76c) 
  
General Procedure G: Diiodohydration 
Brown oil, 68%; νmax (film/cm
-1) 3414 (O-H), 2915 (C-H), 1649 (C=O), 1445 (Ar), 1229; 1H 
NMR (500 MHz, CDCl3) δ 8.48 (2H, d, J = 8.5, 2 × ArH), 7.57 (1H, t, J = 7.4, ArH), 7.46 (2H, t, J 
= 7.9, 2 × ArH), 4.21 (2H, d, J = 7.7, CH2), 3.42 (1H, t, J = 7.7, OH); 
13C NMR (125MHz, CDCl3) 
δ 191.5, 134.0, 131.6, 130.4, 128.0, 76.0, 10.0; HRMS: Found (CI): [M+H]+ 402.8692, 
C9H9O2I2 requires 486.8684 
 
Ethyl 3-hydroxy-4,4-diiodo-5-oxo-5-(p-tolyl)pentanoate (76d) 
 
General Procedure G: Diiodohydration 
Brown oil, 78%; νmax (film/cm
-1) 3503 (O-H), 2978 (C-H), 1723 (C=O), 1648 (C=O), 1602 (Ar), 
1372, 1182; 1H NMR (600 MHz, CDCl3) δ 8.37 (2 H, d, J = 8.5, 2 × ArH), 7.25 (1H, d, J = 8.5, 2 
× ArH), 4.22 (2H, q, J = 7.2, OCH2), 4.10 (1H, ddd, J = 9.5, 3.7, 1.9, CHOH), 3.94 (1H, dd, J = 
4.1, 1.9, OH), 3.26 (1H, d, J = 16.0, CHOHCHH), 2.87 (1H, dd, J = 16.0, 9.5, CHOHCHH), 2.45 
(3H, s, ArCH3), 1.31 (3H, t,  J = 7.2, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 191.1, 171.0, 
145.1, 131.9, 130.0, 128.7, 75.9, 61.2, 42.7, 21.9, 19.6, 14.3; HRMS: Found (CI): [M-H]+ 
502.92162, C14H17O4l2 requires 502.921095; 
 
Ethyl 3-hydroxy-4,4-diiodo-5-oxo-5-(p-tolyl)pentanoate (R-76d) 
Determination of the enantiomeric ratios of alcohols obtained with the Mosher’s esters 
analysis: A solution of alcohol (1 eq.) and (R) or (S)-MTPA (3 eq.) in DCM (0.2M) was stirred 
at RT. EDCl.HCl (3 eq.) was added, followed by DMAP (3.3 eq.) and the resulting solution 
was stirred at RT for 24 h. The mixture was partitioned between water and DCM; the 
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phases were separated and the organic layer was dried (MgSO4), filtered and solvent 
removed under reduced pressure. The crude product was analysed by 1H NMR. The 
enantiomeric ratio was determined from the integration of the peaks of the two 
diastereoisomers. 
92%,   
20
D]   15.8, (c 0.26, CHCl3) 94:6 er, (R). The enantiomeric purity was determined by 
integration of the peaks at 8.24 and 8.21 ppm, indicating a diastereomeric ratio of 94:6 
 
3-Hydroxy-2,2-diiodo-1-(4-methoxyphenyl)hexan-1-one (70e) 
 
General Procedure G: Diiodohydration 
Brown oil, 58%; νmax (film/cm
-1)  3253 (O-H), 2960 (C-H), 1716 (C=O), 1656, 1595 (Ar), 1259, 
1173; 1H NMR (600 MHz, CDCl3) δ 8.49 (2H, d, J = 9.0, 2 × ArH), 6.89 (2H, d, J = 9.0, 2 × ArH), 
3.88 (3H, s, OCH3), 3.84 (1H, br. s, OH), 3.34 (1H, d, J = 9.4, CH), 2.14 (1H, m, CH(OH)CHH), 
1.78 (1H, dtd, J = 14.3, 9.4, 4.9, CH(OH)CHH), 1.67 - 1.75 (1H, m, CH3CHH), 1.50 – 1.59 (1H, 
m, CH3CHH), 1.01 (3H, t, J = 7.5, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 190.7, 163.8, 134.5, 
125.4, 113.1, 78.8, 55.7, 39.0, 25.5, 19.7, 14.2; HRMS: Found (CI): [M+H]+ 474.92581, 
C13H17O3I2 requires 474.92671 
 
3-Hydroxy-2,2-diiodo-5-phenyl-1-(p-tolyl)pentan-1-one (70f) 
 
General Procedure G: Diiodohydration 
Brown oil, 63%; νmax (film/cm
-1) 3504 (O-H), 2959 (C-H), 1637 (C=O), 1601 (Ar), 1228; 1H 
NMR (600 MHz, CDCl3) δ 8.37 (2H, d, J = 8.7, 2 × ArH), 7.27 - 7.34 (4H, m, 4 × ArH), 7.19 - 
7.25 (3H, m, 3 × ArH), 3.79 (1H, br. s, OH), 3.37 (1H, dd, J = 9.4, 3.0, CH), 3.04 (1H, ddd, J = 
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13.8, 9.4, 4.8, C(OH)HCHH), 2.83 (1H, ddd, J = 13.8, 9.4, 7.5, C(OH)HCHH), 2.55 (2H, td, J = 
11.3, 8.7, C(OH)HCH2CHH), 2.45 (3H, s, ArCH3), 2.13 (1H, dtd, J =13.8, 9.4, 4.8, 
C(OH)HCH2CHH); 
13C NMR (150 MHz, CDCl3) δ 191.7, 145.0, 141.7, 132.0, 130.2, 128.8, 
128.64, 128.56, 126.1, 78.1, 38.6, 32.4, 24.3, 21.9; HRMS: Found (CI): [M+H]+ 520.94711, 
C18H19O2I2 requires 520.94744 
 
3-Hydroxy-2,2-diiodo-4-methyl-1-(p-tolyl)pentan-1-one (70g) 
 
General Procedure G: Diiodohydration 
Brown oil, 60%; νmax (film/cm
-1) 3527 (O-H), 2961 (C-H), 2925 (C-H), 1646 (C=O), 1603 (Ar), 
1229, 1182; 1H NMR (600 MHz, CDCl3) δ 8.29 (2H, d, J = 8.3, 2 × ArH), 7.23 (2H, d, J = 8.3, 2 × 
ArH), 3.52 (1H, dd, J = 5.8, 3.8, CHOH), 3.43 (1H, d, J = 5.8, OH), 2.44 (3H, s, ArCH3), 2.26 
(1H, sptd, J = 6.8, 3.8, CH(CH3)2), 1.18 (3H, d, J = 6.8, CH(CH3)(CH3)),  1.08 (3H, d, J = 6.8, 
CH(CH3)(CH3)); 
13C NMR (150 MHz, CDCl3) δ 192.2, 144.5, 131.8, 130.7, 128.8, 81.4, 34.8, 
25.4, 23.7, 21.8, 18.6; HRMS: Found (APCI): [M+H]+ 458.9300, C13H17O2I2 requires 458.9312 
 
3-Hydroxy-2,2-diiodo-1-(p-tolyl)octan-1-one (70h) 
  
General Procedure G: Diiodohydration 
Brown oil, 55%; νmax (film/cm
-1) 3534 (O-H), 2953 (C-H), 1645 (C=O), 1603 (Ar), 1230, 1183; 
1H NMR (600 MHz, CDCl3) δ 8.38 (2H, d, J = 8.5, 2 × ArH), 7.24 (2H, d, J = 8.5, 2 × ArH), 3.69 
(1H, br. s, OH), 3.35 (1H, d, J = 9.4, CH), 2.45 (3H, s, ArCH3), 2.14 - 2.22 (1H, m, C(OH)HCHH), 
1.78 (1H, dtd, J = 13.9, 9.2, 4.9, C(OH)HCHH), 1.65 - 1.73 (1H, m, C(OH)HCH2CHH), 1.49 - 
1.57 (1H, m, C(OH)HCH2HH), 1.32 - 1.43 (4H, m, CH3CH2CH2), 0.92 (3H, t,  J = 7.0, CH3CH2); 
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13C NMR (150 MHz, CDCl3) δ 191.9, 144.9, 132.0, 130.4, 128.6, 79.0, 36.9, 31.8, 26.1, 25.6, 
22.8, 21.9, 14.2; HRMS: Found (CI): [M+H]+ 486.96200, C15H21O2I2 requires 486.96309 
 
Ethyl 3-hydroxy-2,2-diiodooctanoate (70i) 
 
General Procedure G: Diiodohydration 
Brown oil, 73%; νmax (film/cm
-1) 3479 (O-H), 2927 (C-H), 1705 (C=O), 1462 (Ar), 1239; 1H 
NMR (600 MHz, CDCl3) δ 4.33 (2H, q, J = 7.2, OCH2), 3.13 (1H, d, J = 9.0, CH), 1.96 - 2.05 (1H, 
m, OH), 1.58 - 1.67 (2H, m, C(OH)HCH2), 1.48 (1H, m, C(OH)HCH2CHH),  1.35 (3H, t, J = 7.2, 
OCH2CH3), 1.29 - 1.40 (5H, m, C(OH)HCH2CHH and CH3CH2CH2), 0.91 (3H, dt, J = 6.7, 
CH2CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 169.2, 78.7, 64.0, 36.4, 31.7, 25.9, 22.7, 14.2, 
13.6, 12.9; HRMS: Found (CI): [M+H]+ 440.94238, C10H19O3I2 requires 440.94236 
 
N-((1Z,2Z)-2-Iodo-1-(p-tolyl)hex-2-en-1-ylidene)acetamide (77) 
 
N-iodosuccinimide (248 mg, 1.1 mmol) was added to a stirring solution of propargylic 
alcohol (0.5 mmol) in MeCN (2 mL) and Ph3PAuNTf2 (2 mol%). Once reaction was complete 
(TLC), the solvent was removed under reduced before the residue was purified by column 
chromatography (EtOAc/Petrol) to give the imine as a orange oil.  
Orange oil, 10%; νmax (film/cm
-1) 2960 (C-H), 2931 (C-H), 1701 (C=O), 1619 (C=N),  1605 
(C=C), 1458 (Ar), 1206, 1179; 1H NMR (600 MHz, CDCl3) δ 7.47 (2H, d,  J = 8.1, 2 × ArH), 7.21 
(2H, d, J = 8.1, 2 × ArH), 6.12 (1H, t, J = 7.0, CH), 2.40 (3H, s, ArCH3), 2.34 (2H, q, J = 7.0, 
CHCH2), 2.09 (3H, s, COCH3), 1.49 - 1.54 (2H, m, CH2CH3), 0.97 (3H, t, J = 7.3, CH2CH3); 
13C 
NMR (150 MHz, CDCl3) δ 185.0, 162.3, 149.5, 141.8, 131.3, 129.3, 128.9, 99.5, 39.1, 25.1, 
21.6, 21.4, 13.9; HRMS: Found (CI): [M+H]+ 356.049974, C15H19INO requires 356.05058 
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Ethyl 3-oxo-5-(p-tolyl)pent-4-ynoate (80) 
 
Ethyl diazoacetate (1.0 mL, 9.6 mmol) in THF (10 mL) was added dropwise to a suspension 
of NaH (387 mg, 9.6 mmol) in THF (20 mL) at 0 °C. After 15 min the stirring was continued 
at RT for 1 h before aldehyde 78 (752 mg, 5.2 mmol) in THF (10 mL) was added dropwise 
over 10 min. After 3 h, the solution was filtered through a sinter, the solvent removed 
under reduced pressure and the residue purified by flash chromatography (EtOAc/petrol) 
to give the diazo-compound 79. This product was stable but mass spectrometry data could 
not be obtained. The oil 79 dissolved in DCM (5 mL) was added dropwise to a solution of 
Rh2(OAc)4 in DCM (10 mL) and stirred for 1 h before the solvent was removed under 
reduced pressure. The residue was purified by flash chromatography (EtOAc/petrol) to give 
the product. 
Yellow solid, 574 mg, 77% over 2 steps; Mp 77 – 79 °C; νmax (film/cm
-1) 2982 (C-H), 2202 
(C≡C), 1740 (C=O), 1670 (Ar), 1602 (Ar); 1H NMR (600 MHz, CDCl3) δ 11.97 (1H, =CH, major), 
7.48 (2H, d, J = 8.1,  2 × ArH, minor), 7.42 (2H, d, J = 7.9, 2 × ArH, major), 7.20 (2H, d, J = 8.1, 
minor), 7.17 (2H, d, J = 7.9, major), 5.43 (1H, s, OH, major), 4.21 - 4.27 (4H, m, OCH2, major 
and minor), 3.68 (2H, s, COCH2CO, minor), 2.39 (3H, s, ArCH3, minor), 2.37 (3H, s, ArCH3, 
major), 1.30 (3H, t, J = 7.2, CH2CH3, major), 1.31 (3H, t, J = 7.2, CH2CH3, minor); 
13C NMR 
(150 MHz, CDCl3) δ 178.9, 172.4, 166.4, 155.6, 142.2, 140.5, 133.4, 132.3, 129.6, 129.4, 
117.8, 116.4, 97.0, 94.0, 87.4, 83.1, 61.8, 60.7, 51.5, 21.9, 21.9, 21.8, 14.3, 14.2; HRMS: 
Found (CI):  [M+H]+ 231.101994, C14H15O3 requires 231.10212 
 
(R)-Ethyl 3-hydroxy-5-(p-tolyl)pent-4-ynoate, ((R)-70d) 
 
(R,R)-Teth-TsDPEN-RuCl (0.6 mg, 1.0 × 10–3 mmol) and HCO2H/Et3N 5/2 azeotropic mixture 
(168 mg) was added into a flask, and Ethyl 3-oxo-5-(p-tolyl)pent-4-ynoate 80 (0.2 mmol) in 
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degassed dichloromethane (1 cm3) was injected under a nitrogen atmosphere. The mixture 
was stirred at rt until reaction was complete and then the solution was concentrated and 
the residue purified by column chromatography (EtOAc/petrol) to give the chiral alcohol. 
Orange oil, 66%;   
20
D] + 8.1, (c 1.0, CHCl3) 94:6 er, (R) The enantiomeric ratios of the 
alcohol was determined by Mosher’s esters analysis as described above for R-76d. 
 
3-Hydroxy-1-(p-tolyl)hexan-1-one (92) 
 
N-Iodosuccinimide (113 mg, 0.5 mmol) was added to a stirring solution of propargylic 
alcohol (47 mg, 0.25 mmol) and Ph3PAuNTf2 (2 mol%) in MeCN/H2O (10:1, 2mL). Once the 
reaction was complete (TLC), MgSO4 (200 mg) was added followed by AcOH (0.5 mL) and 
zinc powder (60 mg, 1 mmol) and the solution stirred for 2 h before the solvent was 
removed under reduced pressure. The residue was purified by flash chromatography 
(EtOAc/petrol) to give the hydroxyketone.  
Yellow oil, 14 mg, 27% over 2 steps; νmax (film/cm
-1) 3457 (O-H), 2958 (C-H), 1737 (C=O), 
1672 (Ar), 1607 (Ar); 1H NMR (600 MHz, CDCl3) δ 7.85 (2H, d, J = 8.3, 2 × ArH), 7.27 (2H, d, J 
= 8.3, 2 × ArH), 4.19 - 4.25 (1 H, m, OCH), 3.31 (1H, br. s, OH), 3.15 (1H, dd, J = 17.5, 2.4, 
COCHH), 3.00 (1H, dd, J = 17.5, 9.2, COCHH), 2.41 (3H, s, ArCH3), 1.57 - 1.65 (1H, m, 
CHCHH), 1.39 - 1.56 (3H, m, CHCHH and CH2CH3), 0.93 - 0.98 (3H, t, J = 7.2, CH2CH3); 
13C 
NMR (150 MHz, CDCl3) δ 200.9, 144.6, 134.4, 129.5, 128.3, 67.6, 44.6, 44.9, 38.7, 21.8, 8.9, 
14.2; HRMS: Found (CI):  [M]+ 206.129623, C13H18O2 requires 206. 13013 
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3-Hydroxy-1-(p-tolyl)hexane-1,2-dione (93) 
 
N-Iodosuccinimide (113 mg, 0.5 mmol) was added to a stirring solution of propargylic 
alcohol (47 mg, 0.25 mmol) and Ph3PAuNTf2 (2 mol%) in MeCN/H2O (10:1, 2mL). Once the 
reaction was complete (TLC), NaOMe (54 mg, 1 mmol) was added and the solution stirred 
for 1 h before the solvent was removed under reduced pressure. The residue was purified 
by flash chromatography (EtOAc/petrol) to give the dione.  
Yellow oil, 17 mg, 32% over 2 steps; νmax (film/cm
-1) 3457 (O-H), 2962 (C-H), 1721 (C=O), 
1738  (C=O), 1666 (Ar), 1604 (Ar); 1H NMR (600 MHz, CDCl3) δ 7.87 (2H, d, J = 8.3,  2 × ArH), 
7.32 (2H, d, J = 8.3, 2 × ArH), 4.93 (1H, dd, J = 8.3, 3.8. OCH), 3.05 (1H, br. s, OH), 2.45 (3H, s, 
ArCH3), 1.77 (1H, m, CHCHH), 1.48 - 1.60 (3H, m, CHCHH and CH2CH3), 0.91 (3H, t, J = 7.3, 
CH2CH3); 
13C NMR (150 MHz, CDCl3) 204.3, 192.1, 146.8, 130.3, 129.9, 129.7, 74.2, 34.9, 
22.1, 18.7, 13.9; HRMS: Found (CI):  [M]+ 220.109258, C13H16O3 requires 220.10940 
 
General Procedure H: Dichlorohydration 
Trichloroisocyanuric acid (116 mg, 0.5 mmol) was added to a stirring solution of propargylic 
alcohol (0.5 mmol) in MeCN/H2O (2 mL, 10:1). Once the reaction was complete (TLC), the 
solvent was removed under reduced pressure before the residue was purified by column 
chromatography (EtOAc/Petrol) to give the dichlorohydroxyketone. 
 
3-Hydroxy-2,2-dichloro-1-(p-tolyl)hexan-1-one (94a) 
 
General Procedure H: Dichlorohydration 
White solid, 70%; Mp 64 – 65 °C; νmax (film/cm
-1) 3357 (O-H), 2962 (C-H), 1676 (C=O), 1606 
(Ar), 1257, 1187; 1H NMR (600 MHz, CDCl3) δ 8.20 (2H, d, J = 8.1, 2 × ArH), 7.27 (2H, d, J = 
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8.1, 2 × ArH), 4.39 (1H, d, J = 9.4, CH), 3.26 (1H, br. s, OH), 2.43 (3H, s, ArCH3), 1.90 - 2.00 
(1H, m, C(OH)HCHH), 1.67 - 1.79 (2H, m, C(OH)HCHH and C(OH)HCH2HH), 1.44 - 1.55 (1H, 
m, C(OH)HCH2HH), 1.01 (3H, t,  J = 7.3, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 189.9, 145.4, 
131.5, 129.1, 129.0, 88.1, 76.7, 32.6, 21.9, 19.4, 14.1; HRMS: Found (APCI): [M+H]+ 
275.0598, C13H17O2Cl2 requires 275.0600. 
 
3-Hydroxy-2,2-dichloro-1-(o-tolyl)hexan-1-one (94b) 
   
General Procedure H: Dichlorohydration 
Colourless oil, 61%; νmax (film/cm
-1) 3444 (O-H), 2961 (C-H), 1705 (C=O), 1238; 1H NMR (600 
MHz, CDCl3) δ 7.89 (1H, d, J = 7.7, ArH), 7.39 (1H, t, J = 7.7, ArH), 7.25 (2H, m, 2 × ArH), 4.47 
(1H, m, CH), 2.63 (1H, d, J = 6.4, OH), 2.37 (3H, s, ArCH3), 1.91 – 1.99 (1H, m, CH(OH)CHH), 
1.64 - 1.75 (2H, m, CH(OH)CHH and CH3CHH), 1.44 - 1.54 (1H, m, CH3CHH), 1.00 (3H, t, J = 
7.5, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 195.6, 137.9, 135.3, 131.4, 131.2, 127.9, 125.0, 
90.3, 76.5, 33.2, 20.5, 19.3, 14.0; HRMS: Found (ES+): [M+Na]+ 297.0475, C13H16O2Cl2Na 
requires 297.0425. 
 
3-Hydroxy-2,2-dichloro-1-phenylpropan-1-one (94c) 
  
General Procedure H: Dichlorohydration 
Colourless oil, 71%; νmax (film/cm
-1) 3397 (O-H), 1683 (C=O), 1596 (Ar), 1580 (Ar), 1259; 1H 
NMR (500 MHz, CDCl3) δ 8.32 (2H, d, J = 8.5, 2 × ArH), 7.62 (1H, t, J = 7.4, ArH), 7.49 (2H, t, J 
= 7.7, 2 × ArH), 4.27 (2H, d, J = 7.7, CH2); 
13C NMR (125MHz, CDCl3) δ 189.3, 134.3, 131.3, 
131.2, 128.4, 70.7, 63.7; HRMS: Found (ES+): [M+H]+ 218.9995, C9H9O2Cl2 requires 218.9980 
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Ethyl 4,4-dichloro-3-hydroxy-5-oxo-5-(p-tolyl)pentanoate (94d) 
 
General Procedure H: Dichlorohydration 
Colourless oil, 80%; νmax (film/cm
-1) 3496 (O-H), 2982 (C-H), 1732 (C=O), 1680 (C=O), 1569 
(Ar); 1H NMR (600 MHz, CDCl3) δ 8.19 (2H, d, J = 8.5, 2 × ArH), 7.28 (2H, d, J = 8.5, 2 × ArH), 
5.02 (1H, dt, J = 9.7, 2.5, CHOH), 4.22 (2H, q, J = 7.2, CH2CH3), 3.58 (1H, br. s, OH), 3.06 (1H, 
dd, J = 16.0, 2.5, CHOHCHH), 2.83 (1H, dd, J = 16.0, 9.7, CHOHCHH), 2.44 (3H, s, ArCH3), 1.30 
(3H, t, J = 7.2, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 189.0, 171.1, 145.6, 131.5, 129.1, 
128.8, 86.5, 73.8, 61.2, 36.8, 21.9, 14.3; HRMS: Found (APCI): [M+H]+ 319.0496, C14H17Cl2O4 
requires 319.0498 
 
Ethyl (R)-3-hydroxy-4,4-dichloro-5-oxo-5-(p-tolyl)pentanoate ((R)-94d) 
 
80%,   
20
D]   18.5 (c 1.0, CHCl3) 92:8 er, (R). The enantiomeric ratio was determined by 
Mosher’s esters analysis as described above for R-76d. The enantiomeric purity was 
determined by integration of the peaks at 2.92 and 2.81 ppm, indicating a diastereomeric 
ratio of 92:8 
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3-Hydroxy-2,2-dichloro-1-(4-methoxyphenyl)hexan-1-one (94e) 
 
General Procedure H: Dichlorohydration 
White solid, 68%; Mp 78 – 80 °C; νmax (film/cm
-1) 3516 (O-H), 2960 (C-H), 1665 (C=O), 1596 
(Ar), 1253, 1179; 1H NMR (600 MHz, CDCl3) δ 8.32 (2H, d, J = 9.0, 2 × ArH), 6.95 (2H, d, J = 
9.0, 2 × ArH), 4.37 (1H, d, J = 9.4, CH), 3.90 (3H, s, OCH3), 3.34 (1H, br. s, OH), 1.91 – 2.00 
(1H, m, CH(OH)CHH), 1.68 - 1.80 (2H, m, C(OH)HCHH and C(OH)HCH2CHH), 1.44 – 1.54 (1H, 
m, C(OH)HCH2CHH), 1.01 (3H, t, J = 7.5, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 188.9, 164.3, 
134.0, 124.2, 113.6, 88.0, 76.7, 55.7, 32.5, 19.4, 14.1; HRMS: Found (ES+): [M+H]+ 
291.0579, C13H17O3Cl2 requires 291.0555. 
 
3-Hydroxy-2,2-dichloro-5-phenyl-1-(p-tolyl)pentan-1-one (94f) 
 
General Procedure H: Dichlorohydration 
Yellow oil, 79%; νmax (film/cm
-1) 3433 (O-H), 2969 (C-H), 1675 (C=O), 1604 (ArH), 1256, 
1187; 1H NMR (600 MHz, CDCl3) δ 8.20 (2H, d, J = 8.3, 2 × ArH), 7.19 - 7.36 (7H, m, 7 × ArH), 
4.40 (1H, br. d, J = 10.2, CH), 3.40 (1H, d, J = 1.9, OH), 3.06 (1H, ddd, J = 13.7, 9.6, 4.6, 
C(OH)HCHH), 2.79 (1H, ddd, J = 13.7, 9.1, 7.7, C(OH)HCHH), 2.44 (3H, s, ArCH3), 2.34 (1H, 
ddd, J = 14.1, 9.1, 7.7, C(OH)HCH2CHH), 2.11 (1H, ddd, J = 14.1, 9.6, 4.6, C(OH)HCH2CHH); 
13C NMR (150 MHz, CDCl3) δ 189.8, 145.5, 141.6, 131.5, 129.2, 129.0, 128.7, 128.6, 128.2, 
87.8, 76.1, 32.16, 32.11, 21.9; HRMS: Found (ES+): [M+H]+ 337.0771, C18H19O2Cl2 requires 
337.0762 
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2,2-Dichloro-3-hydroxy-4-methyl-1-(p-tolyl)pentan-1-one (94g) 
 
General Procedure H: Dichlorohydration 
Colourless oil, 60%; νmax (film/cm
-1) 3545 (O-H), 2964 (C-H), 1674 (C=O), 1605 (Ar), 1238, 
1186; 1H NMR (600 MHz, CDCl3) δ 8.16 (2H, d, J = 8.3, 2 × ArH), 7.27 (2H, d, J = 8.3, 2 × ArH), 
4.30 (1H, d, J = 3.4, CHOH), 3.10 (1H, br. s, OH), 2.43 (3H, s, ArCH3), 2.38 (1H, sptd, J = 6.8, 
3.4, CH(CH3)2), 1.14 (3H, d, J = 6.8, CH(CH3)(CH3)), 1.12 (3H, d, J = 6.8, CH(CH3)(CH3)); 
13C 
NMR (150 MHz, CDCl3) δ 190.0, 145.1, 131.3, 129.4, 129.0, 88.8, 79.6, 30.0, 22.8, 21.9, 17.5; 
HRMS: Found (CI): [M+H]+ 275.06975, C13H17O2Cl2 requires 275.06056 
 
3-Hydroxy-2,2-dichloro-1-(p-tolyl)octan-1-one (94h) 
  
General Procedure H: Dichlorohydration 
Colourless oil, 60%; νmax (film/cm
-1) 3551 (O-H), 2957 (C-H), 2928 (C-H), 1674 (C=O), 1605 
(ArH), 1254, 1186; 1H NMR (500 MHz, CDCl3) δ 8.20 (2H, d, J = 8.2, 2 × ArH), 7.27 (2H, d, J = 
8.2, 2 × ArH), 4.37 (1H, dd, J = 9.7, 1.5, CH), 3.10 - 3.31 (1H, br. s, OH), 2.43 (3H, s, ArCH3), 
1.98 (1H, m, C(OH)HCHH), 1.65 - 1.78 (2H, m, C(OH)HCHH and C(OH)HCH2HH), 1.42 - 1.51 
(1H, m, C(OH)HCH2HH), 1.32 - 1.42 (4H, m, CH3CH2CH2), 0.92 (3H, t, J = 7.1, CH3CH2); 
13C 
NMR (125MHz, CDCl3) δ 189.9, 145.2, 131.4, 129.2, 129.0, 88.3, 76.9, 31.7, 30.5, 25.8, 22.7, 
21.8, 14.1; HRMS: Found (ES+): [M+H]+ 303.0894, C15H21O2Cl2 requires 303.0919 
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Ethyl 3-hydroxy-2,2-dichloro-octanoate (94i) 
 
General Procedure H: Dichlorohydration 
Colourless oil, 50%; νmax (film/cm
-1) 3431 (O-H), 2957 (C-H), 2931 (C-H), 1743 (C=O), 1250, 
1022; 1H NMR (600 MHz, CDCl3) δ 4.35 (2H, q, J = 7.2, OCH2), 4.17 – 4.23 (1H, m, CH), 2.56 
(1H, d, J = 6.0, OH), 1.81 – 1.88 (1H, m, C(OH)HCHH), 1.56 - 1.66 (2H, m, C(OH)HCHH and 
C(OH)HCH2CHH), 1.89 – 1.46 (1H, m, C(OH)HCH2CHH), 1.27 – 1.38 (4H, m, CH3CH2CH2), 1.36  
(3H, t, J = 7.2, OCH2CH3), 0.90 (3H, t, J = 6.7, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 166.0, 
87.2, 77.4, 64.1, 31.6, 31.1, 25.7, 22.6, 14.1, 13.9; HRMS: Found (ES+): [M+H]+ 257.0708, 
C10H19O3Cl2 requires 257.0711 
 
3-Hydroxy-2,2-dichloro-3-ethyl-1-(p-tolyl)pentan-1-one (94j) 
 
General Procedure H: Dichlorohydration 
Colourless oil, 85%; νmax (film/cm
-1) 3532 (O-H), 2972 (C-H), 1671 (C=O), 1604 (Ar), 1235, 
1187; 1H NMR (600 MHz, CDCl3) δ 8.13 (2H, d, J = 8.3, 2 × ArH), 7.26 (2H, d, J = 8.3, 2 × ArH), 
4.05 (1H, br. s., CH), 2.43 (3H, s, ArCH3), 2.01 (4H, q, J = 7.5, 2 × CH2CH3), 1.07 (6H, t, J = 7.5, 
2 × CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 192.4, 144.9, 131.3, 130.5, 128.8, 92.0, 81.4, 29.0, 
21.9, 9.22; HRMS: Found (CI): [M+H]+ 289.075911, C14H19Cl2O2 requires 289.075911 
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3-(4-Bromophenyl)-2,2-dichloro-3-hydroxy-1-phenylpropan-1-one (94k) 
 
General Procedure H: Dichlorohydration 
Yellow solid, 38%; Mp 135 – 139 °C; νmax (film/cm
-1) 3567 (O-H), 1669 (C=O), 1592 (Ar), 
1283, 1010; 1H NMR (600 MHz, CDCl3) δ 8.30 (2H, d, J = 7.5, 2 × ArH), 7.63 (1H, t, J = 7.2, 
ArH), 7.52 - 7.55 (2H, m, 2 × ArH), 7.47 - 7.51 (4H, m, 4 × ArH), 5.54 (1H, d, J = 3.4, CH(OH)), 
3.82 (1H, br. s., OH); 13C NMR (150 MHz, CDCl3) δ 190.7, 134.7, 134.6, 134.4, 131.6, 131.5, 
130.8, 128.4, 123.3, 86.2, 77.5; HRMS: Found (CI): [M+H]+ 372.93860, C15H12O2Cl2Br 
requires 372.93977 
 
3-Hydroxy-2,2-dichloro-1,3-diphenylpropan-1-one (94l) 
 
General Procedure H: Dichlorohydration 
White solid, 32%; Mp 93 – 96 °C; νmax (film/cm
-1) 3537 (O-H), 1666 (C=O), 1240, 1059; 1H 
NMR (600 MHz, CDCl3) δ 8.30 (2H, d, J = 8.5, 2 × ArH), 7.60 - 7.64 (3H, m, 3 × ArH), 7.49 (2H, 
t, J = 7.8, 2 × ArH), 7.38 - 7.43 (3H, m, 3 × ArH), 5.59 (1H, d, J = 4.0, CHOH), 3.76 (1H, d, J = 
4.0, OH); 13C NMR (150 MHz, CDCl3) δ 190.9, 135.7, 134.1, 132.0, 131.3, 129.9, 129.0, 128.3, 
127.6, 86.7, 78.0; HRMS: Found (APCI): [M+H]+ 295.0286, C15H13Cl2O2 requires 295.0287 
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3-Hydroxy-2,2-dichloro-4-phenyl-1-(p-tolyl)butan-1-one (94m) 
 
White solid, 24%; Mp 85 – 88 °C; νmax (film/cm
-1) 3516 (O-H), 2934 (C-H), 1671 (C=O), 1603 
(Ar), 1258; 1H NMR (600 MHz, CDCl3) δ 8.23 (2H, d, J = 8.3, 2 × ArH), 7.32 - 7.38 (4H, m, 4 × 
ArH), 7.26 - 7.31 (3H, m, 3 × ArH), 4.61 (1H, dd, J = 9.8, 2.3, CH(OH)), 3.38 (1H, d, J = 13.9, 
CHCHH), 3.25 (1H, br. s, OH), 2.97 (1H, dd, J = 13.9, 9.8, CHCHH), 2.45 (3H, s, CH3); 
13C NMR 
(150 MHz, CDCl3) δ 189.6, 145.5, 138.3, 131.5, 129.7, 129.1, 129.0, 128.6, 126.8, 87.5, 78.3, 
37.2, 21.9; HRMS: Found (CI): [M+H]+ 323.06101, C17H17O2Cl2 requires 323.06056 
 
1-Hydroxy-2,2-dichloro-hexan-3-one (94n) 
 
General Procedure H: Dichlorohydration 
Colourless oil, 20%; νmax (film/cm
-1) 3547 (O-H), 2959 (C-H), 1675 (C=O); 1H NMR (600 MHz, 
CDCl3) δ 4.13 (2H, s, OCH2), 2.87 - 2.94 (2H, t, J = 7.3, COCH2), 2.74 (1H, br. s, OH), 1.70 (2H, 
sx, J = 7.3, CH2CH3), 0.97 (3H, t, J = 7.3, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 199.8, 85.9, 
69.3, 37.6, 17.8, 13.5; HRMS: Found (CI): [M+H]+ 185.0135412, C6H11Cl2O2 requires 
185.01361 
 
Ethyl 3-hydroxy-2,2-dichloro-5-phenylpentanoate (94t) 
 
General Procedure H: Dichlorohydration 
Colourless oil, 70%; νmax (film/cm
-1) 3473 (O-H), 2934 (C-H), 1741 (C=O), 1454 (Ar), 1392, 
1235; 1H NMR (600 MHz, CDCl3) δ 7.29 - 7.33 (2H, m, 2 × ArH), 7.20 - 7.25 (3H, m, 3 × ArH), 
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4.33 (2H, q, J = 7.2, OCH2), 4.22 (1H, m, CH(OH)), 2.98 (1H, ddd, J = 14.0, 9.3, 4.8, 
CH(OH)CHH), 2.72 - 2.78 (2H, m, CH(OH)CHH and OH), 2.16 - 2.22 (1H, m, ArCHH), 1.97 (1H, 
ddd, J = 14.0, 9.3, 4.8, ArCHH), 1.34 (3H, t, J = 7.2, CH3); 
13C NMR (150 MHz, CDCl3) δ 166.0, 
141.2, 128.7, 128.65, 128.62, 126.3, 86.7, 76.6, 64.2, 32.8, 32.0, 13.9; HRMS: Found (CI): 
[M+H]+ 291.05567, C13H17O3Cl2 requires 291.05547 
 
3-Hydroxy-2,2,4,4-tetrachloro-1,5-di-p-tolylpentane-1,5-dione (94u) 
 
General Procedure H: Dichlorohydration 
White solid, 46%; Mp 145 – 148 °C; νmax (film/cm
-1) 3443 (O-H), 1679 (C=O), 1602 (Ar); 1H 
NMR (600 MHz, CDCl3) δ 8.02 (4H, d, J = 8.3, 4 × ArH), 7.26 (4H, d, J = 8.3, 4 × ArH), 5.99 
(1H, d, J = 9.4, OH), 4.17 (1H, d, J = 9.4, CH(OH)), 2.42 (6H, s, 2 × CH3); 
13C NMR (150 MHz, 
CDCl3) δ 188.9, 144.7, 130.9, 129.6, 129.1, 86.8, 77.7, 21.9; HRMS: Found (APCI): [M+H]
+ 
432.9920, C19H17Cl4O3 requires 432.9926 
 
(E)-N-Acetyl-2,2-dichloro-3-hydroxy-5-phenylpentanimidate (96) 
 
General Procedure H: Dichlorohydration 
Colourless oil, 27%; νmax (film/cm
-1) 1754 (C=O), 1620 (C=N), 1370, 1215; 1H NMR (600 MHz, 
CDCl3) δ 7.27 - 7.32 (2H, m, 2 × ArH), 7.18 - 7.23 (3H, m, 3 × ArH), 5.76 (1H, dd, J = 9.4, 2.4, 
OCH), 4.65 (2H, m, OCH2), 2.69 (2H, t, J = 8.1, PhCH2), 2.10 - 2.22 (2H, m, OCHCH2), 2.13 (3H, 
s, COCH3), 1.45 (3H, t, J = 7.1, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 170.1, 165.3, 140.8, 
128.6, 128.5, 126.3, 88.0, 76.3, 72.3, 33.0, 32.1, 20.9, 15.4; HRMS: Found (CI): [M+H]+ 
332.082067, C15H20NO3Cl2 requires 332.08202 
Chapter 4  Experimental  
164 
 
1-(3-Methoxyhex-1-yn-1-yl)-4-methylbenzene (97) 
 
Powdered KOH (225 mg, 4.0 mmol) was added to a stirring solution of methyl iodide (375 
μL, 6.0 mmol) and propargylic alcohol 70a (376 mg, 2.00 mmol) in DMSO (20 mL) under an 
argon atmosphere. After 2 h, the solution was put through a silica plug (petrol). Water (10 
mL) was added to the solution and the product was extracted with Et2O (3 × 10 mL), the 
combined organic fractions was dried (MgSO4) and filtered. The solvent was removed 
under reduced pressure and the residue purified by column chromatography 
(EtOAc/petrol) to give ether 97.  
Yellow oil, 71%; νmax (film/cm
-1) 2959 (C-H) 2932 (C-H), 1509 (Ar), 1089; 1H NMR (600 MHz, 
CDCl3) δ 7.33 (2H, d, J = 8.1, 2 × ArH), 7.11 (2H, d, J = 8.1, 2 × ArH), 4.16 (1H, t, J = 6.6, 
CHOCH3), 3.46 (3H, s, OCH3), 2.34 (3H, s, ArCH3), 1.71 - 1.83 (2H, m, CHCH2), 1.53 (2H, sx, J = 
7.4, CH2CH3), 0.96 (3H, t, J = 7.4, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 138.5, 131.7, 129.1, 
119.9, 87.5, 86.0, 71.7, 56.6, 37.9, 21.6, 18.7, 14.0; HRMS: Found (EI): [M]+ 202.134827, 
C14H18O requires 202.13577 
 
(Z)-2-Chloro-1-(p-tolyl)hex-2-en-1-one (98) 
 
General Procedure H: Dichlorohydration 
Yellow oil, 32%; νmax (film/cm
-1) 2961 (C-H) 2930 (C-H), 1663 (C=O), 1607 (Ar), 1269; 1H NMR 
(600 MHz, CDCl3) δ 7.62 (2H, d, J = 7.9, 2 × ArH), 7.26 (2H, d, J = 7.9, 2 × ArH), 6.64 (1H, t, J = 
7.4, CH), 2.45 (2H, q, J = 7.4, CHCH2), 2.42 (3H, s, ArCH3), 1.54 (2H, sx, J = 7.4, CH2CH3), 0.98 
(3H, t, J = 7.4, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 190.3, 144.6, 143.4, 134.2, 133.3, 
129.8, 129.2, 31.9, 21.8, 21.4, 14.1; HRMS: Found (EI): [M]+ 222.080149, C13H15ClO requires 
222.08114 
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5-Phenyl-1-(p-tolyl)pent-1-yn-3-one (103) 
 
Propargylic alcohol 70f (500 mg, 2.00 mmol) was added to a stirring solution of 2,3-
dichloro-1,4-dicyanobenzoquinone (DDQ) (5 mg, 0.02 mmol) and NaNO2 (14 mg, 0.02 
mmol) in DCM/AcOH (10:1, 10 mL). This solution was stirred for 48 h under an argon 
atmosphere before the solvent was removed under reduced pressure and the residue 
purified by column chromatography (EtOAc/petrol) to give the ketone 103.  
Yellow oil, 48%; νmax (film/cm
-1) 3028 (C-H), 2196 (C≡C), 1663 (C=O), 1604 (Ar), 1089; 1H 
NMR (600 MHz, CDCl3) δ 7.46 (2H, d, J = 7.9, 2 × ArH), 7.28 - 7.32 (2H, m, 2 × ArH), 7.18 - 
7.25 (5H, m, 5 × ArH), 3.04 - 3.08 (2H, m, COCH2), 2.98 - 3.03 (2H, m, PhCH2), 2.39 (3H, s, 
CH3); 
13C NMR (150 MHz, CDCl3) δ 187.1, 141.7, 140.5, 133.3, 129.6, 128.7, 128.5, 126.4, 
116.9, 92.0, 87.8, 47.1, 30.2, 21.9; HRMS: Found (EI): [M]+ 248.11920, C18H16O requires 
248.12012 
 
2,2-Dichloro-5-phenyl-1-(p-tolyl)pentane-1,3-dione (104) 
 
General Procedure H: Dichlorohydration 
Colourless oil, 55%; νmax (film/cm
-1) 3029 (C-H), 1747 (C=O), 1674 (C=O), 1604 (Ar), 1186; 1H 
NMR (600 MHz, CDCl3) δ 7.89 (2H, d, J = 8.5, 2 × ArH), 7.24 - 7.28 (2H, m, 2 × ArH), 7.23 (2H, 
d, J = 8.5, 2 × ArH), 7.17 - 7.21 (1H, m, ArH), 7.15 (2H, d, J = 7.2, 2 × ArH), 3.03 - 3.06 (2H, m, 
COCH2), 2.97 - 3.01 (2H, m, PhCH2), 2.42 (3H, s, CH3); 
13C NMR (150 MHz, CDCl3) δ 194.3, 
185.5, 145.9, 140.0, 130.8, 129.5, 128.7, 128.5, 128.3, 126.5, 86.9, 39.3, 30.6, 22.0; HRMS: 
Found (EI): [M]+ 334.05177, C18H16O2Cl2 requires 334.05274 
 
 
Chapter 4  Experimental  
166 
 
5-(p-Tolyl)pent-4-yn-2-ol (108d) 
 
n-Butyllithium (1.6M in hexane, 1.2 eq.) was added dropwise to a stirred solution of alkyne 
(1 eq.) in dry THF (1 mLmmol-1) at -78 ˚C under an argon atmosphere. After 1 h BF3OEt2 (2.5 
eq.) was added and stirred for 30 min before epoxide (2.5 eq.) was added and the resulting 
solution was stirred for 5 min at 0 ˚C and 1h at rt. The reaction was quenched with 
saturated NH4Cl solution and the organic phase extracted with Et2O. The combined organic 
phases were washed with brine, dried (MgSO4) and concentrated under reduced pressure. 
The residue was purified by column chromatography to give homopropargylic alcohol 108d. 
Yellow oil, 31%; νmax (film/cm
-1) 3353 (O-H), 2970 (C-H), 2922 (C-H), 1509 (Ar); 1H NMR (500 
MHz, CDCl3) δ 7.31 (2H, d, J = 8.1, 2 × ArH), 7.10 (2H, d, J = 8.1, 2 × ArH), 4.04 (1H, qdd, J = 
6.4, 6.4, 5.1, CH(OH)), 2.62 (1H, dd, J = 16.8, 5.2, CH(OH)CHH), 2.54 (1H, dd, J = 16.8, 6.4, 
CH(OH)CHH), 2.34 (3H, s, ArCH3), 1.32 (3H, d, J = 6.4, CHCH3); 
13C NMR (125MHz, CDCl3) δ 
138.1, 131.6, 129.1, 120.3, 85.4, 83.3, 66.7, 30.2, 22.5, 21.6; HRMS: Found (CI): [M+H]+ 
175.112819, C12H15O requires 175.11229 
 
2-Methyl-5-(p-tolyl)pent-4-yn-2-ol (108e) 
 
n-Butyllithium (1.6M in hexane, 1.2 eq.) was added dropwise to a stirred solution of alkyne 
(1 eq.) in dry THF (1 mLmmol-1) at -78 ˚C under an argon atmosphere. After 1 h BF3OEt2 (2.5 
eq.) was added and stirred for 30 min before epoxide (2.5 eq.) was added and the resulting 
solution was stirred for 5 min at 0 ˚C and 1 h at rt. The reaction was quenched with 
saturated NH4Cl solution and the organic phase extracted with Et2O. The combined organic 
phases were washed with brine, dried (MgSO4) and concentrated under reduced pressure. 
The residue was purified by column chromatography (EtOAc/petrol) to give 
homopropargylic alcohol 108e. 
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Pale yellow oil, 66%; νmax (film/cm
-1)  3393 (O-H), 2973 (C-H), 1509 (Ar), 1376, 1213; 1H NMR 
(600 MHz, CDCl3) δ 7.32 (2H, d, J = 8.0, 2 × ArH), 7.10 (2H, d, J = 8.0, 2 × ArH), 2.59 (2H, s, 
CH2), 2.34 (3H, s, ArCH3), 1.37 (6H, s, CH2C(CH3)(CH3)); 
13C NMR (150 MHz, CDCl3) δ 138.1, 
131.6, 129.1, 120.4, 85.6, 83.7, 70.4, 35.2, 28.8, 21.6; HRMS: Found (EI): [M]+ 188.120324, 
C13H16O requires 188.12012 
 
4-(p-Tolyl)but-3-yn-1-ol (108f)99 
  
Pd(PPh3)4 (0.01 eq.) and CuI (0.02 eq.) were added to the solution of iodotoluene (2.0 
equiv) and alkynol (1.0 eq.) in NEt3 (10 eq.) and THF (0.5M) under Ar. The reaction mixture 
was stirred at rt for 12 h. The mixture was filtered and the filtrate was concentrated under 
reduced pressure. The product was purified by column chromatography (EtOAc/petrol) to 
give alkynol 108f. 
Yellow oil, 846mg, 99%; νmax (film/cm
-1) 3298 (O-H), 2882 (C-H), 1508 (Ar), 1371; 1H NMR 
(500 MHz, CDCl3) δ 7.30 (2H, d, J = 8.1, 2 × ArH), 7.10 (2H, d, J = 8.1, 2 × ArH), 3.81 (2H, t, J = 
6.2, OCH2), 2.68 (2H, t, J = 6.2, CCH2), 2.34 (3H, s, CH3), 1.79 (1H, br. s, OH); 
13C NMR (125 
MHz, CDCl3) δ 138.1, 131.6, 129.1, 120.3, 85.5, 82.7, 61.3, 23.9, 21.5; LRMS: (EI): 160 ([M]
+, 
10), 129 ([M-EtOH] +, 100) 
 
5-(p-Tolyl)pent-4-yn-1-ol (108g)100 
  
Pd(PPh3)4 (0.01 eq.) and CuI (0.02 eq.) were added to the solution of iodotoluene (2.0 
equiv) and alkynol (1.0 eq.) in triethylamine (10 eq.) and THF (0.5M) under Ar. The reaction 
mixture was stirred at rt for 12 h. The mixture was filtered and the filtrate was 
concentrated under reduced pressure. The product was purified by column 
chromatography (EtOAc/petrol) to give alkynol 108g. 
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Orange solid, 880 mg, 95%; Mp 40 – 41 °C; νmax (film/cm
-1) 3324 (O-H), 2924 (C-H), 1509 
(Ar), 1045;  1H NMR (600 MHz, CDCl3) δ 7.28 (2H, d, J = 7.9, 2 × ArH), 7.09 (2H, d, J = 7.9, 2 × 
ArH), 3.82 (2H, t, J = 6.5, OCH2), 2.53 (2H, t, J = 6.5, CCH2), 2.33 (3H, s, ArCH3), 1.85 (2H, qn, J 
= 6.5, 2 OCH2CH2); 
13C NMR (150 MHz, CDCl3) δ 137.8, 131.5, 129.1, 120.7, 88.6, 81.3, 62.0, 
31.5, 21.5, 16.1; LRMS: (CI): 175 ([M+H]+, 90), 131 ([M-EtOH] +, 100)  
 
6-(p-Tolyl)hex-5-yn-1-ol (108h)101 
  
Pd(PPh3)4 (0.01 eq.) and CuI (0.02 eq.) were added to the solution of iodotoluene (2.0 
equiv) and alkynol (1.0 eq.) in triethylamine (10 eq.) and THF (0.5 mLmmol-1)  under Ar. The 
reaction mixture was stirred at rt for 12 h. The mixture was filtered and the filtrate was 
concentrated under reduced pressure. The product was purified by column 
chromatography (EtOAc/petrol) to give alkynol 108h. 
Orange oil, 968 mg, 95%; νmax (film/cm
-1) 3337 (O-H), 2937 (C-H), 1509 (Ar), 1058; 1H NMR 
(600 MHz, CDCl3) δ 7.28 (2H, d, J = 8.1, 2 × ArH), 7.08 (2H, d, J = 8.1, 2 × ArH), 3.71 (2H, t, J = 
6.4, OCH2), 2.44 (2H, t, J = 6.8, CCH2), 2.33 (3H, s, CH3), 1.72 - 1.77 (2H, m, CCH2CH2), 1.65 - 
1.71 (2H, m, OCH2CH2); 
13C NMR (150 MHz, CDCl3) δ 137.7, 131.5, 129.1, 120.9, 89.2, 81.1, 
62.6, 32.0, 25.2, 21.5, 19.3; HRMS: Found (EI): [M]+ 188.120621, C13H16O requires 
188.12012 
 
3,3-Dichloro-2-propyltetrahydrofuran-2-ol (109a) 
 
General Procedure H: Dichlorohydration 
Colourless oil, 53%; νmax (film/cm
-1) 3421 (O-H), 2967 (C-H), 1730 (C=O), 1046; 1H NMR (600 
MHz, CDCl3) δ 4.09 (1H, td, J = 8.8, 2.9, OCHH), 4.03 (1H, br. q, J = 8.8, OCHH), 3.01 (1H, dt, J 
= 13.2, 8.8, OCH2CHH), 2.75 (1 H, ddd, J = 13.2, 7.3, 2.9, OCH2CHH), 1.53 - 1.67 (4H, m, 
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CH3CH2CH2), 0.99 (3H, t, J = 7.3, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 106.6, 91.6, 64.4, 
43.9, 36.2, 16.6, 14.5; HRMS: Found (CI): [M-H2O]
+ 181.017931, C7H11Cl2O requires 
181.01870  
 
2-(Dichloromethyl)tetrahydrofuran-2-ol (109b) 
 
General Procedure H: Dichlorohydration 
White solid, 99%; Mp 66 – 68 °C; νmax (film/cm
-1) 3422 (O-H), 3010 (C-H), 1208, 1005; 1H 
NMR (600 MHz, CDCl3) δ 5.73 (1H, s, CHCl2), 4.16 - 4.22 (1H, m, OCHH), 4.02 (1H, m, OCHH), 
2.88 - 3.03 (1H, m, OH), 2.14 - 2.25 (3H, m, OCH2CH2, OCH2CH2CHH), 1.99 - 2.06 (1H, m, 
OCH2CH2CHH); 
13C NMR (150 MHz, CDCl3) δ 106.2, 76.3, 70.4, 34.9, 25.2; HRMS: Found (CI): 
[M+H]+ 170.99651, C5H9Cl2O2 requires 170.99796; anal. cald. For C5H9Cl2O2 C, 35.12; H, 4.72; 
Found: C, 33.33; H, 4.42 
 
2-(Dichloromethyl)tetrahydro-2H-pyran-2-ol (109c) 
 
General Procedure H: Dichlorohydration 
Colourless oil, 65%; νmax (film/cm
-1) 3432 (O-H), 2847 (C-H), 2881 (C-H), 1727 (C=O); 1H NMR 
(600 MHz, CDCl3) δ 5.57 (1H, s, CHCl2), 3.93 – 3.97 (1H, m, OCHH), 3.79 – 3.92 (1H, m, 
OCHH), 2.78 (1H, d, J = 2.7, OH), 1.95 (1H, dt, J = 13.3, 3.3, (C)CHH), 1.82 - 1.89 (1H, m, 
OCH2CH2CHH), 1.72 - 1.79 (1H, m, OCH2CH2CHH), 1.64 (1 H, ddd, J = 13.3, 4.8, 2.6, (C)CHH), 
1.53 - 1.62 (2H, m, OCH2CH2); 
13C NMR (150 MHz, CDCl3) δ 96.0, 78.2, 62.7, 30.2, 24.7, 19.0; 
HRMS: Found (ES-): [M-H]+ 182.9928, C6H9O2Cl2 requires 182.9980; 
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3,3-Dichloro-5-methyl-2-(p-tolyl)tetrahydrofuran-2-ol (109d) 
 
General Procedure H: Dichlorohydration 
Colourless oil, 79%; νmax (film/cm
-1) 3403 (O-H), 2977 (C-H), 1513 (Ar), 1184; 1H NMR (600 
MHz, CDCl3) δ 7.58 - 7.66 (2H, m, 2 × ArH), 7.16 - 7.22 (2H, m, 2 × ArH), 4.60 (1H, dqd,  J = 
9.5, 6.2, 5.8 OCH), 3.00 (1H, dd, J = 12.9, 5.8, OCHCHH), 2.86 (1H, dd, J = 12.9, 9.5, OCHCHH-
major), 2.38 (3H, s, ArCH3), 1.42 - 1.48 (3H, m, CHCH3); 
13C NMR (150 MHz, CDCl3) δ 139.4, 
134.9, 128.5, 127.4, 106.1, 91.8, 74.1, 51.8, 22.6, 21.4; HRMS: Found (CI): [M+H]+ 
261.043998, C12H15Cl2O2 requires 261.04491 
 
3,3-Dichloro-5,5-dimethyl-2-(p-tolyl)tetrahydrofuran-2-ol (109e) 
 
General Procedure H: Dichlorohydration 
White solid, 84%; Mp 77 – 79 °C; νmax (film/cm
-1) 3420 (O-H), 2988 (C-H), 1440 (Ar); 1H NMR 
(600 MHz, CDCl3) δ 7.63 (2H, d, J = 8.3, 2 × ArH), 7.19 (2H, d, J = 8.3, 2 × ArH), 3.10 (1H, d, J 
= 13.6, COCHH), 3.03 (1H, s, OH), 2.93 (1H, d,  J = 13.6, COCHH), 2.38 (3H, s, ArCH3), 1.56 
(3H, s, C(CH3)(CH3), 1.54 (3H, s, C(CH3)(CH3); 
13C NMR (150 MHz, CDCl3) δ 139.3, 135.2, 
128.5, 127.3, 106.8, 92.0, 80.8, 56.4, 32.2, 28.6, 21.4; HRMS: Found (CI): [M-H]+ 
275.059913, C13H17O2Cl2 requires 275.06056 
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3,3-Dichloro-2-(p-tolyl)tetrahydrofuran-2-ol (109f) 
 
General Procedure H: Dichlorohydration 
White solid, 89%; Mp 115 – 118 °C; νmax (film/cm
-1) 3357 (O-H), 1441 (Ar), 1268; 1H NMR 
(400 MHz, CDCl3) δ 7.64 (2H, d, J = 8.3, 2 × ArH), 7.22 (2H, d, J = 8.3, 2 × ArH), 4.23 (1H, ddd, 
J = 9.4, 8.3, 7.1, OCHH), 4.12 (1H, ddd, J = 9.4, 8.3, 2.2, OCHH), 3.60 (1H, s, OH), 3.19 (1H, dt, 
J = 13.1, 9.4, OCH2CHH), 2.90 (1 H, ddd, J =13.1, 7.1, 2.2, OCH2CHH), 2.41 (3H, s, ArCH3); 
13C 
NMR (150 MHz, CDCl3) δ 139.5, 134.4, 128.6, 127.4, 105.9, 91.2, 64.6, 44.5, 21.4; HRMS: 
Found (EI): [M]+ 246.021313, C11H12Cl2O2 requires 246.02143; anal. cald. For C11H12Cl2O2 C, 
53.47; H, 4.89; Found: C, 53.93; H, 4.94 
 
3,3-Dichloro-2-(p-tolyl)tetrahydro-2H-pyran-2-ol (109g) 
 
General Procedure H: Dichlorohydration 
White solid, 57%; Mp 97 – 99 °C; νmax (film/cm
-1) 3411 (O-H), 2971 (C-H), 1617 (C=O), 1388, 
1074; 1H NMR (600 MHz, CDCl3) δ 7.66 (2H, d, J = 8.1, 2 × ArH), 7.19 (2H, d, J = 8.1, 2 × ArH), 
4.23 (1H, ddd, J = 13.6, 11.4, 3.0, OCHH), 3.86 (1 H, dd, J = 11.4, 5.5, OCHH), 2.95 (1H, td, J = 
13.6, 4.3, OCH2CHH), 2.85 (1H, s, OH), 2.55 (1H, d, J = 13.6, OCH2CHH), 2.30 - 2.39 (4H, m, 
ArCH3, OCH2CH2CHH), 1.63 - 1.69 (1H, m, OCH2CH2CHH); 
13C NMR (150 MHz, CDCl3) δ 139.2, 
136.5, 128.6, 128.0, 98.8, 91.0, 60.3, 40.4, 23.9, 21.4; HRMS: Found (CI): [M+H]+ 
261.044010, C12H15Cl2O2 requires 261.04491 
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6-Hydroxy-2,2-dichloro-1-(p-tolyl)hexan-1-one (109h) 
 
General Procedure H: Dichlorohydration 
Colourless oil, 72%; νmax (film/cm
-1) 3345 (O-H), 2941 (C-H), 2873 (C-H), 1685 (C=O), 1606, 
1253;  1H NMR (600 MHz, CDCl3) δ 8.19 (2H, d, J =8.3, 2 × ArH), 7.26 (2H, d, J = 8.3, 2 × ArH), 
3.72 (2H, t, J = 6.4, OCH2), 2.50 - 2.55 (2H, m, Cl2CCH2), 2.43 (3H, s, CH3), 1.76 - 1.83 (2H, m, 
Cl2CCH2), 1.67 – 1.72 (2H, m, CH2OCH2CH2); 
13C NMR (150 MHz, CDCl3) δ 188.2, 144.7, 
131.3, 129.2, 128.9, 87.4, 62.6, 44.2, 32.1, 21.9, 21.4; HRMS: Found (CI): [M-H]+ 
275.060120, C13H17O2Cl2 requires 275.06056 
 
1-(But-3-en-1-yn-1-yl)-4-methylbenzene (114a)102 
 
Vinyl bromide (1M in THF, 15 mL, 15mmol) was added in one portion to a stirring solution 
of tolylacetylene (1.16 g, 10 mmol) and diisopropylamine (5 mL), followed by the addition 
of Pd(PPh3)4 (184 mg) and CuI (92 mg). After 18 h, water (40 mL) was added and the 
product was extracted with Et2O (3 × 20 mL), the combine organic fractions were dried 
(MgSO4), filtered and solvent was removed under reduced pressure before purification by 
flash chromatography (petrol) to give eneyne 114a.  
Colourless oil, 990 mg, 70%; νmax (film/cm
-1) 3030 (C-H), 1601 (C=C), 1507 (Ar); 1H NMR (600 
MHz, CDCl3) δ 7.34 (2H, d, J = 8.1, 2 × ArH), 7.13 (2H, d, J = 8.1, 2 × ArH), 6.02 (1H, dd, J = 
17.7, 11.2, CHH), 5.72 (1H, dd, J = 17.7, 2.1, CHH), 5.52 (1H, dd, J = 11.2, 2.1, CH), 2.35 (3H, 
s, CH3); 
13C NMR (150 MHz, CDCl3) δ 138.6, 131.6, 129.2, 126.6, 120.1, 117.4, 90.3, 87.6, 
21.6; LRMS: (EI): 142 ([M-H]+, 50), 115 (100), 63 (40) 
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1-Methyl-4-(pent-4-en-1-yn-1-yl)benzene (114b)103 
 
Allyl bromide (1.3 mL, 15 mmol) was added to stirring solution of tolylacetylene (1.16 g, 10 
mmol), K2CO3 (2.4 g, 17 mmol), CuI (190 mg) in anhydrous DMF (10 mL). After 18 h, water 
(40 mL) was added and the product was extracted with Et2O (3 × 20 mL), the combined 
organic fractions were dried (MgSO4), filtered and solvent was removed under reduced 
pressure before purification by flash chromatography (petrol) to give eneyne 114b.  
Colourless oil, 890 mg, 57%; νmax (film/cm
-1) 2981 (C-H), 1641 (C=C), 1509 (Ar); 1H NMR (600 
MHz, CDCl3) δ 7.32 (2H, d, J = 8.0, 2 × ArH), 7.10 (2H, d, J = 8.0, 2 × ArH), 5.90 (1H, ddt, J = 
16.9, 10.0, 5.3, CH), 5.41 (1H, dtd, J = 16.9, 1.9, 1.7, =CHH), 5.16 (1H, dtd, J = 10.0, 1.9, 1.7, 
=CHH), 3.19 (2H, ddd, J = 5.3, 1.9, 1.7, CCH2), 2.34 (3H, s, CH3); 
13C NMR (150 MHz, CDCl3) δ 
137.9, 132.7, 131.6, 129.1, 120.7, 116.7, 116.3, 85.8, 83.0, 23.9, 21.6; LRMS: (EI): 156 ([M]+, 
50), 141 (70), 128 (70), 115 (100); HRMS: Found (EI): [M]+ 156.09357, C11H12 requires 
156.09390 
 
4-(p-Tolyl)but-3-yne-1,2-diol (115a) 
 
K2OsO4.H2O (94 mg) was added to a stirring solution of alkene 114a (710 mg, 5.0 mmol), N-
methylmorpholine oxide (NMO) (892 mg, 7.5 mmol) in DCM/H2O (40:5, 20 mL). After 18 h, 
saturated Na2S2O3 solution (15 mL) was added and the product was extracted with DCM (3 
× 20 mL) before the combined organic fractions were washed with brine and dried (MgSO4) 
and filtered. The solvent was removed under reduced pressure before the residue was 
purified by flash chromatography (EtOAc/petrol) to give diol 115a.  
White solid, 385 mg, 44%; Mp 90 – 91 °C; νmax (film/cm
-1) 3208 (O-H), 2921 (C-H), 1509 (Ar); 
1H NMR (600 MHz, CDCl3) δ 7.33 (2H, d, J = 8.0, 2 × ArH), 7.12 (2H, d, J = 8.0, 2 × ArH), 4.68 
(1H, dd, J = 6.8, 3.8, OCH), 3.83 (1H, dd, J = 11.4, 3.8, OCHH), 3.78 (1H, dd, J = 11.4, 6.8, 
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CHH), 2.35 (3H, s, CH3), 2.24 (2H, br. s, 2 × OH); 
13C NMR (150 MHz, CDCl3) δ 139.1, 131.8, 
129.2, 119.0, 86.6, 85.8, 66.7, 63.9, 21.6; LRMS: (EI): 176 ([M]+, 30), 145 (100), 115 (30); 
HRMS: Found (EI): [M]+ 176.08311, C11H12O2 requires 176.08373 
 
5-(p-Tolyl)pent-4-yne-1,2-diol (115b) 
 
K2OsO4.H2O (94 mg) was added to a stirring solution of alkene 114b (950 mg, 5 mmol), N-
methylmorpholine oxide (NMO) (892 mg, 7.5 mmol) in DCM/H2O (40:5, 20 mL). After 18 h, 
saturated Na2S2O3 solution (15 mL) was added and the product was extracted with DCM (3 
× 20 mL) before the combined organic fractions were washed with brine and dried (MgSO4) 
and filtered. The solvent was removed under reduced pressure before the residue was 
purified by flash chromatography (EtOAc/petrol) to give diol 115b.  
White solid, 543 mg, 57%; Mp 59 – 62 °C; νmax (film/cm
-1) 3298 (O-H), 2916 (C-H), 1508 (Ar); 
1H NMR (600 MHz, CDCl3) δ 7.29 (2H, d, J = 8.0, 2 × ArH), 7.10 (2H, d, J = 8.0, 2 × ArH), 3.96 
(1H, dddd, J = 6.5, 6.5, 6.1, 3.5, OCH), 3.81 (1H, dd, J = 11.3, 3.5, OCHH), 3.66 (1H, dd, J = 
11.3, 6.5, OCHH), 2.68 (1H, dd, J = 16.8, 6.5, CCHH), 2.64 (1H, dd, J = 16.8, 6.1, CCHH), 2.34 
(3H, s, CH3); 
13C NMR (150 MHz, CDCl3) δ 138.3, 131.6, 129.2, 120.1, 84.5, 83.4, 70.5, 65.8, 
24.6, 21.6; LRMS: (EI): 176 ([M]+, 40), 129 (100), 115 (60); HRMS: Found (EI): [M]+ 
190.098911, C12H14O2 requires 190.09938 
 
5-(p-Tolyl)pent-4-yne-1,3-diol (115c) 
  
LiBH4 (2 eq.) was added to a stirring solution of ester 70d (150 mg, 0.64 mmol) in Et2O (2 
mL) at 0 °C. After 2 h the solvent was removed under reduced pressure before the residue 
was purified by column chromatography (EtOAc/petrol) to give diol 115c.  
Chapter 4  Experimental  
175 
 
Yellow oil, 102 mg, 0.54 mmol, 84%; νmax (film/cm
-1) 3325 (O-H), 2921 (C-H), 1509 (Ar), 
1421; 1H NMR (600 MHz, CDCl3) δ 7.32 (2H, d, J = 7.9, 2 × ArH), 7.11 (2H, d, J = 7.9, 2 × ArH), 
4.87 (1H, dd, J = 6.8, 4.5, OCH), 4.07 (1H, ddd, J = 11.0, 7.4, 4.0, OCHH), 3.92 (1H, ddd, J = 
11.0, 6.8, 4.0, CHH), 2.34 (3H, s, CH3), 2.07 - 2.14 (1H, m, OCH2CHH), 2.00 - 2.06 (1H, m, 
OCH2CHH); 
13C NMR (150 MHz, CDCl3) δ 138.8, 131.7, 129.2, 119.4, 88.7, 85.6, 62.4, 60.7, 
39.1, 21.6; HRMS: Found (CI): [M]+ 190.098631, C12H14O2 requires 190.09938 
 
3,3-Dichloro-2-(p-tolyl)tetrahydrofuran-2,4-diol (116a) 
 
General Procedure H: Dichlorohydration 
White solid, 92%; Mp 126 – 128 °C; νmax (film/cm
-1) 3456 (O-H), 3402 (O-H), 3336 (O-H), 
3120 (C-H), 1512 (Ar), 1421 (Ar); 1H NMR (600 MHz, CDCl3) δ 7.61 (2H, d, J = 8.3, 2 × ArH), 
7.21 (2H, d, J = 8.3, 2 × ArH), 4.62 (1H, dd, J = 10.1, 5.1, OCHH), 4.54 - 4.57 (1H, m, OCH), 
4.26 (1H, dd, J = 10.1, 0.9, OCHH), 4.06 (1H, s, OH), 3.54 (1H, br. d, J = 7.3, OH), 2.38 (3H, s, 
CH3); 
13C NMR (150 MHz, CDCl3) δ 139.6, 133.4, 128.6, 127.5, 106.1, 92.7, 79.8, 72.5, 21.4; 
HRMS: Found (CI): [M+H]+ 263.024050, C11H13Cl2O3 requires 263.02417 
 
3,3-Dichloro-5-(hydroxymethyl)-2-(p-tolyl)tetrahydrofuran-2-ol (116b) 
 
General Procedure H: Dichlorohydration 
White solid, 91%; Mp 71 – 75 °C; νmax (film/cm
-1) 3030 (O-H), 3008 (C-H), 2920 (C-H), 1602 
(C=O), 1508 (Ar), 1410 (C-H); 1H NMR (600 MHz, CDCl3) δ 7.61 (2H, d, J = 8.1, 2 × ArH), 7.19 
(2H, d, J = 8.1, 2 × ArH),  4.58 (1H, dddd, J = 9.3, 6.4, 3.1, 3.1, OCH), 3.88 (1H, ddd, J = 6.0, 
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6.0, 2.9, OCHH), 3.54 (1H, ddd, J = 6.0, 6.0, 3.1, OCHH), 3.06 - 3.11 (1H, m, CCl2CHH), 2.84 
(1H, ddd, J = 6.7, 6.6, 2.2, CCl2CHH), 2.38 (3H, s, CH3); 
13C NMR (150 MHz, CDCl3) δ 139.3, 
133.9, 128.5, 127.3, 105.7, 91.9, 76.3, 62.7, 44.6, 21.4; HRMS: Found (CI): [M+H]+ 
258.029542, C12H13Cl2O2 requires 259.02926 
 
3,3-Dichloro-2-(p-tolyl)tetrahydro-2H-pyran-2,4-diol (116c) 
 
General Procedure H: Dichlorohydration 
White solid, 53%; Mp 122 – 126 °C; νmax (film/cm
-1) 3533 (O-H), 3391 (O-H), 3297 (O-H), 
2953 (C-H), 1461 (Ar), 1435 (Ar); 1H NMR (600 MHz, CDCl3) δ 7.67 (2H, d, J = 8.3, 2 × ArH), 
7.21 (2H, d, J = 8.3, 2 × ArH), 4.53 - 4.59 (1H, m, OCH), 4.20 - 4.28 (1H, m, OCHH), 3.89 - 3.95 
(1H, m, OCHH), 2.38 (3H, s, CH3), 2.13 - 2.22 (1H, m, OCH2CHH), 1.97 - 2.02 (1H, m, 
OCH2CHH); 
13C NMR (150 MHz, CDCl3) δ 139.5, 136.0, 128.5, 128.2, 100.5, 96.2, 73.1, 58.9, 
31.6, 21.4; HRMS: Found (APCI): [M+H]+ 277.0393, C12H15Cl2O3 requires 277.0393 
 
2,2-Dichloro-1-phenylpropane-1,3-diol (117c) 
 
 NaBH4 (1.2 eq.) was added to a stirring solution of ketone 94c in MeOH (0.5 mL) at 0 °C. 
Once the reaction is complete (TLC), the reaction mixture was quenched with saturated 
NH4Cl solution and the organic phase extracted with EtOAc. The combined organic phases 
were dried (MgSO4) and concentrated under reduced pressure. The residue was purified by 
column chromatography to give diol 117c. 
White solid, 93%; Mp 104 – 105 °C; νmax (film/cm
-1) 3326 (O-H), 3203 (O-H), 1452 (Ar), 1110; 
1H NMR (600 MHz, CDCl3) δ 7.52 - 7.57 (2H, m, 2 × ArH), 7.36 - 7.41 (3H, m, 3 × ArH), 5.24 
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(1H, s, CHPh), 4.11 (1H, d, J = 12.4, CHH) , 3.89 (1H, d, J = 12.4, CHH), 3.01 (1H, br. s, OH), 
2.57 (1H, br. s, OH); 13C NMR (150 MHz, CDCl3) δ 136.6, 129.2, 128.6, 128.1, 95.4, 78.6, 
70.3; HRMS: Found (APCI): [M+NH4]
+ 238.0392, C9H14Cl2NO2 requires 238.0396; anal. cald. 
For C9H10Cl2O2 C, 48.90; H, 4.56; Found: C, 48.82; H, 4.56 
 
2,2-Dichloro-3-ethyl-1-(p-tolyl)pentane-1,3-diol (117j) 
 
NaBH4 (1.2 eq.) was added to a stirring solution of ketone 94j in MeOH (0.5 mL) at 0 °C. 
Once the reaction is complete (TLC), the reaction mixture was quenched with saturated 
NH4Cl solution and the organic phase extracted with EtOAc. The combined organic phases 
were dried (MgSO4) and concentrated under reduced pressure. The residue was purified by 
column chromatography to give diol 117j. 
White solid, 87%, Mp 68 – 70 °C;  νmax (film/cm
-1) 3335 (O-H), 2971 (C-H), 2943 (C-H), 1458 
(Ar), 1410 (Ar); 1H NMR (600 MHz, CDCl3) δ 7.48 (2H, d, J = 8.1, 2 × ArH), 7.17 (2H, d, J = 8.1, 
2 × ArH), 5.33 (1H, s, CH(OH)), 2.37 (3H, s, ArCH3), 2.02 - 2.19 (4H, m, 2 × CH2CH3), 1.16 (3H, 
t, J = 7.5, CH2CH3), 1.03 (3H, t, J = 7.5, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 138.6, 134.9, 
129.9, 128.2, 100.7, 83.4, 79.5, 28.4, 27.2, 21.4, 9.8, 8.6; HRMS: Found (CI): [M+H]+ 
291.091218, C14H21Cl2O2 requires 291.09186 
 
2,2-Dichloro-1-(p-tolyl)pentane-1,5-diol (118) 
 
NaBH4 (1.2 eq.) was added to a stirring solution of lactol 109f in MeOH (0.5 mL) at 0 °C. 
Once the reaction is complete (TLC), the reaction mixture was quenched with saturated 
NH4Cl solution and the organic phase extracted with EtOAc. The combined organic phases 
were dried (MgSO4) and concentrated under reduced pressure. The residue was purified by 
column chromatography to give diol 118. 
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White solid, 99%; Mp 74 – 77 °C; νmax (film/cm
-1) 3341 (O-H), 3178 (O-H), 2966 (C-H), 1452 
(ArH), 1048; 1H NMR (600 MHz, CDCl3) δ 7.40 (2H, d, J = 8.1, 2 × ArH), 7.17 (2H, d, J = 8.1, 2 
× ArH), 5.00 (1H, s, CH), 3.68 (2H, t, J = 6.0, CH2OH), 2.36 (3H, s, CH3), 2.25 (1H, ddd,  J = 
15.6, 7.9, 6.2, C(Cl)2CHH), 2.17 (1H, ddd, J = 15.6, 7.9, 6.2, CCl2CHH), 2.00 (2H, dt, J = 14.3, 
6.4, CH2CH2OH); 
13C NMR (150 MHz, CDCl3) δ 138.9. 133.7, 128.74, 128.73, 98.6, 81.9, 62.2, 
39.2, 28.2, 21.4; HRMS: Found (CI): [M]+ 262.051223, C12H16O2Cl2 requires 262.05274 
 
3,3-Dichloro-2-(p-tolyl)tetrahydro-2H-pyran (119) 
 
BF3.OEt2 (3 eq.) was added to stirring solution of HSiEt3 (2 eq.) and lactol 109f (1 eq.) in 
DCM (0.5 mL) at -78 °C and then warmed to rt over 15 mins. The solvent was then removed 
under reduced pressure and the residue was purified by column chromatography to give 
tetrahydropyran 119.  
White solid, 80%; Mp 78 – 79 °C; νmax (film/cm
-1) 2974 (C-H), 1515 (Ar), 1439 (Ar), 1185; 1H 
NMR (600 MHz, CDCl3) δ 7.42 (2H, d, J = 8.3, 2 × ArH), 7.17 (2H, d, J = 8.3, 2 × ArH), 4.54 
(1H, s, OCH), 4.21 (1H, dddd, J = 11.8, 4.9, 1.6, 1.5, OCHH), 3.65 (1H, ddd, J = 12.1, 11.8, 2.3, 
OCHH), 2.82 (1 H, dddd, J = 13.8, 4.2, 2.3, 2.1, OCH2CHH), 2.49 (1H, td, J = 13.2, 4.2, 
OCH2CHH), 2.36 (3H, s, ArCH3), 2.31 - 2.34 (1H, m, CCl2CHH), 1.67 - 1.71 (1H, m, CCl2CHH); 
13C NMR (150 MHz, CDCl3) δ 138.5, 132.9, 129.2, 128.2, 89.7, 87.1, 69.0, 45.5, 24.7, 21.4; 
HRMS: Found (EI): [M]+ 244.042276, C12H14OCl2 requires 244.04217 
 
(1S,3S)-2,2-Dichloro-1-(4-methoxyphenyl)hexane-1,3-diol (anti-120e) 
  
A solution of ketone 94e (1 eq.) in MeCN (0.5mL) was added dropwise to a sFtirring 
solution of tetramethylammonium triacetoxyborohydride (8 eq.) in anhydrous MeCN (1.5 
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mL) and glacial acetic acid (1.5 mL) at -40 °C. After 2 h, the reaction mixture was diluted 
with DCM (5 mL) and washed with saturated NaHCO3 then the aqueous phase was 
extracted with DCM. The combined organic phases were dried (MgSO4) and concentrated 
under reduced pressure. The residue was purified by column chromatography to give a 9:1 
mixture of diastereomers of diol anti-120e. 
Colourless oil, 71%; νmax (film/cm
-1) 3410 (O-H), 2960 (C-H), 1611, 1513 (Ar), 1247; 1H NMR 
(600 MHz, CDCl3) δ 7.47 (2H, d,  J = 8.9, 2 × ArH), 6.91 (2H, d, J = 8.9, 2 × ArH), 5.25 (1H, s, 
ArCHOH), 4.12 (1H, d, J = 9.8, CHOHCH2), 3.83 (3H, s, ArOCH3), 2.01 - 2.08 (1H, m, 
CHOHCHH), 1.63 - 1.71 (2H, m, CHOHCHH and CH3CHH), 1.43 - 1.47 (1H, m, CH3CHH), 0.99 
(3H, t, J = 7.2, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 160.0, 130.3, 129.3, 97.9, 78.5, 77.3, 
55.4, 34.3, 19.5, 14.0; HRMS: Found (CI): [M+H]+ 293.071013, C13H19O3Cl2 requires 293.7112 
 
General Procedure I: Dibromohydration 
Dibromoisocyanuric acid (215 mg, 0.75 mmol) was added to a stirring solution of 
propargylic alcohol (0.5 mmol) in MeCN/H2O (2 mL, 10:1). Once the reaction was complete 
(TLC), the solvent was removed under reduced pressure before the residue was purified by 
column chromatography (EtOAc/Petrol) to give the dibromohydroxyketone. 
 
2,2-Dibromo-3-hydroxy-1-phenylpropan-1-one (122c) 
 
General Procedure I: Dibromohydration 
Yellow oil, 63%; νmax (film/cm
-1) 3422 (O-H), 2918 (C-H), 1667 (C=O), 1446 (C=C); 1H NMR 
(600 MHz, CDCl3) δ 8.40 (2H, dd, J = 8.6, 1.2, 2 × ArH), 7.61 (1H, tt, J = 7.4, 1.2, ArH), 7.49 
(2H, dd, J = 8.6, 7.4, 2 × ArH), 4.35 (2H, s, CH2), 3.12 (1H, br. s, OH); 
13C NMR (150 MHz, 
CDCl3) δ 189.5, 134.3, 131.7, 131.4, 128.3, 72.1, 63.4; HRMS: Found (CI): [M+H]
+ 306.89622, 
C9H9Br2O2 requires 306.89693  
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Ethyl 4,4-dibromo-3-hydroxy-5-oxo-5-(p-tolyl)pentanoate (122d) 
 
General Procedure I: Dibromohydration 
Pale yellow oil, 63%; νmax (film/cm
-1) 3514 (O-H), 2980 (C-H), 1732 (C=O), 1666 (C=O) 1568 
(Ar); 1H NMR (600 MHz, CDCl3) δ 8.28 (2H, d, J = 8.2, 2 × ArH), 7.27 (2H, d, J = 8.2, 2 × ArH), 
4.88 (1H, dd, J = 9.6, 2.2, CHOH), 4.23 (2H, q, J = 7.2, CH2CH3), 3.71 (1H, br. s, OH), 3.18 (1H, 
dd, J = 16.0, 2.2, CHOHCHH), 2.88 (1H, dd, J = 16.0, 9.6, CHOHCHH), 2.44 (3H, s, ArCH3), 1.30 
(3H, t, J = 7.2, CH2CH3); 
13C NMR (150 MHz, CDCl3) δ 189.2, 171.1, 145.4, 131.7, 129.4, 
128.9, 74.4, 68.5, 61.2, 39.0, 21.9, 14.3; HRMS: Found (CI): [M+H]+  406.94910, C14H17Br2O4 
requires 406.94936 
 
2-(Dibromomethyl)tetrahydrofuran-2-ol (123b) 
 
General Procedure I: Dibromohydration 
White crystals, 43%; Mp 70 – 71 °C; νmax (film/cm
-1) 3354 (O-H), 3014 (C-H); 1H NMR (600 
MHz, CDCl3) δ 5.72 (1H, s, CH), 4.17 - 4.23 (1H, m, OCHH), 4.00 - 4.07 (1H, m, OCHH), 3.05 
(1H, br. s, OH), 2.19 - 2.29 (3H, m, OCH2CH2CHH), 2.01 - 2.10 (1H, m, OCH2CH2CHH); 
13C 
NMR (150 MHz, CDCl3) δ 105.6, 70.4, 51.6, 35.2, 25.6; HRMS: Found (ES): [M-H]
+ 256.8821, 
C5H7Br2O2 requires 256.8813 
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3,3-Dibromo-5,5-dimethyl-2-(p-tolyl)tetrahydrofuran-2-ol (123e) 
 
General Procedure I: Dibromohydration 
Yellow solid, 76%; Mp 65 – 67 °C; νmax (film/cm
-1) 3519 (O-H), 2970 (C-H); 1H NMR (600 
MHz, CDCl3) δ
 7.71 (2H, d, J = 8.2, 2 × ArH), 7.20 (2H, d, J = 8.2, 2 × ArH), 3.41 (1H, d, J = 
14.1, CHH), 3.18 (1H, d, J = 14.1, CHH), 2.97 (1H, s, OH), 2.38 (3H, s, ArCH3), 1.62 (3H, s, 
CCH3CH3), 1.52 (3H, s, CCH3CH3); 
13C NMR (150 MHz, CDCl3) δ 139.3, 136.3, 128.4, 127.2, 
106.8, 81.5, 68.2, 58.8, 32.6, 28.7, 21.4; HRMS: Found (CI): [M]+ 361.95116, C13H16Br2O2 
requires 361.95170 
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